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Abstract 
 
The production of therapeutic glycoproteins typically relies on the purification of the desired 
glycoprotein from engineered tissue culture systems. This process is costly and inefficient, 
and the isolated glycoproteins are adorned with an array of heterogeneous sugars.  
Expression of glycoproteins in cheaper non-mammalian host cells such as yeast produces 
large quantities of folded glycoproteins though the sugar chains are immunogenic to humans.  
This project initially aimed to develop a general strategy for the humanisation of yeast 
glycoproteins using the copper (I) mediated ligation between azide and acetylene functional 
groups, commonly known as “click” chemistry.  It required that azide and acetylene groups 
could be efficiently incorporated into (glyco)peptides and sugars respectively, and to this end 
propargylic glycosides of mannose, N-acetyl glucosamine, and N-acetyl lactosamine were 
successfully prepared. 
 
Two different glycoprotein remodelling methods were ultimately investigated. The first 
method explored a chemoenzymatic strategy developed in our group. A target glycoprotein, 
erythropoietin (EPO), was expressed in the presence of azide bearing mannose sugars in 
the hope that azide groups would be incorporated during glycoprotein biosynthesis.  
Subsequent elaboration of the azide functionality with propargyl N-acetyl lactosamine 
followed by enzymatic sialylation was expected to yield a glycoprotein with human-like sialyl 
lactosamine antennae.  However, upon purification from Pichia pastoris incorporation of 
azide could not be detected, limiting the strategy to in vitro glycoprotein remodelling. Several 
technological advances were made including optimisation of the final “click” reaction 
between the propargyl glycoside of N-acetyllactosamine and 4-azidomannose followed by 
enzymatic transfer of sialic acid.  While considerable effort was directed towards the key 
transfer of unnatural azidosugars, from nucleotide donors to potential substrates using an α-
1,2-mannosyltransferase, this step proved unreliable. 
 
The second method introduced azide groups into fully synthetic peptides using the amino 
acid azidohomoalanine (Aha).  Click chemistry with synthetic propargyl glycosides allowed 
further modification to homogeneous glycopeptide analogues which were shown to be 
compatible with native chemical ligation, a proven tool for glycoprotein synthesis and semi-
synthesis. Ultimately both methods may eventually facilitate glycoprotein synthesis and 
remodelling such that the biological activity and immunogenicity may be modulated to suit 
future therapeutic requirements. 
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                                          Chapter 1 
 
Introduction 
 
For many years glycoproteins have been a subject of interest for biochemists and biologists, 
partly due to the fact that glycoproteins were discovered to be abundant in living organisms 
and by the diverse functions of glycoproteins; glycoproteins appear in many biological 
process [1]. Glycoproteins are proteins that contain carbohydrates which are covalently 
attached to a polypeptide side-chain. The carbohydrate may be in the form of 
monosaccharides, disaccharides, oligosaccharides, or polysaccharides, and are sometimes 
referred to as glycans. The carbohydrates are attached to the protein in a co-translational or 
post-translational modification. This process is known as glycosylation [1 - 6].  
 
Many glycoproteins have different structural functions [1, 2]. For instance, in proteins that 
have segments extending extracellularly, this segment is often glycosylated and is known to 
play a role in cell-cell interaction. Glycoproteins are also found in gastrointestinal mucus 
secretions where they are used as protective agents and lubricants [3]. They also form 
connective tissues such as collagen and are abundantly found in the blood plasma where 
they serve many functions [4]. 
 
The carbohydrate content in glycoproteins can vary markedly; collagens contain 1% 
carbohydrate content, while certain mucins have 60% carbohydrate content [3, 5]. 50% of 
human proteins are glycosylated [7] therefore it is not surprising to envisage the importance 
of glycoproteins in the regulation of the human body. A few examples of these glycoproteins 
include antibodies (immunoglobulins) that interact directly with antigens, major 
histocompatibility complex molecules that interact with the T-cells as part of an adaptive 
immune response [8] and components of the zona pellucida which are important for sperm-
egg interaction [9]. The prevalence of glycoproteins in disease processes can be harnessed 
to address diagnostic requirements. For instance the presence of small integrin-binding 
ligand N-linked glycoproteins (SIBLINGs) is now a recognised biomarker used to detect 
malignant transformation and cancer progression [10]. Glycoproteins are also important in 
blood to carry blood group determinants. The carbohydrate portion of this glycoprotein is 
usually a small sugar component made up of individual monosaccharide units. This 
carbohydrate component may be a combination of up to seven of the many naturally 
occurring sugar molecules in mammals including glucose, glucosamine, galactose, 
galactosamine, mannose, fucose, and sialic acid [5]. Another important glycoprotein related 
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to blood is erythropoietin (EPO). Produced by the peritubular capillary endothelial cells in the 
kidney, EPO is a hormone that regulates red blood cell production [5, 11]. 
The importance of glycoproteins for the regulation of human body to function properly is 
evident; therefore glycosylation defects may result to a whole spectrum of diseases. 
Congenital muscular dystrophy (CMD) is a general muscle weakness disease and is caused 
by various different genetic errors [12]. Reduced glycosylation of alpha-dystroglycan (ADG) 
has been found to relate to CMD. ADG is a peripheral membrane protein that undergoes 
multiple and complex glycosylation steps to regulate its ability to effectively interact with 
extracellular matrix proteins, such as laminin and agrin [12]. In fact, reduced glycosylation of 
ADG is now referred to as dystroglycanopathies and mutations in six genes (POMT1, 
POMT2, POMGnT1, Fukutin, FKRP and LARGE) have been identified in patients with a 
dystroglycanopathy [12]. 
A further role for glycosylation of proteins may lie in protecting the associated protein and aid 
the glycoprotein to function. An example of this is where heavily glycosylated mucins give 
them considerable water holding capacity and make them resistant to proteolysis, which may 
be important in maintaining mucosal barriers [3, 5]. Glycosylation in general aids the 
functionality of the protein and the biological processes that it is involved in.    
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1.1 Structure and linkages of glycoproteins 
 
The biosynthesis of glycoproteins involves the addition of sugars to dolichol which are then 
transferred to a protein or by directly transferring sugars to a protein. The covalent bond 
between carbohydrate and protein is dependent on the amino acid which is glycosylated. 
Glycoproteins can be classified into a series of glycosylated forms. 
 
N-linked glycoproteins, by far one of the most common forms, is when the saccharide is 
linked to the nitrogen atom of the side chain amide group of an asparagine (Asn). This 
residue must be embedded in the consensus sequence Asn-X-Ser/Thr though this sequence, 
in itself, is not sufficient for glycosylation; [13, 14] where the X represents any amino acid 
except proline. 
 
O-linked glycoproteins are when the hydroxyl group of a serine or threonine, residue in a 
proline-rich region are involved in the linkage; [13, 15, 16]. This type of glycosylation is one 
of the most common forms. 
 
C-linked glycoproteins are defined by a C-C linkage between the carbohydrate moiety and 
the peptide; examples include tryptophan indole bound to monosaccharides [14, 17] and of 
the amino terminal isoleucine backbone bound to methyl deoxy-fructose [13, 17]. C-
glycosylation is not a typical process therefore is redundant. 
 
P-linked glycoproteins are when either a phosphonamide or a phosphodiester hinge is 
joined to various amino acids or glycopeptides; [14, 18]. An example where P-glycosylation 
is found is in the glycosylphosphatidylinositol (GPI) anchor. 
 
S-linked glycoproteins is when the carbohydrate is joined through a thioglycosidic linkage to 
the side chain of a cysteine (Cys), [14, 19-21] or through a thiazolidine linkage [20, 21]. 
 
The most common glycoproteins belong to the first two groups, the biosynthesis of which will 
be the focus of this chapter. 
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1.2 Biosynthesis of N-linked glycoproteins 
 
N-glycosylation is a co-translational process which occurs in the endoplasmic reticulum (ER) 
an important organelle in mammalian cells. The oligosaccharide chain starts to assemble by 
the addition of two N-acetylglucosamine (GlcNAc) and five mannose residues, one by one 
on to a dolichol phosphate lipid anchor at the cytosolic surface of the rough (ER) [22, 23]. 
Next, the glycolipid flips into the lumenal side of the ER (Figure 1.0) and another four 
mannose and three glucose units are transferred before the polypeptide is conjugated. 
Three glucose residues and one terminal mannose are trimmed off by three different 
enzyme α-1,2-glucosidase I, α-1,3-glucosidase II, and α-1,2-mannosidase (Figure 1.1) [23]. 
The removal of the two glucose molecules by the sequential action of glucosidase I and 
glucosidase II produces a monoglucosylated species that is recognised by the chaperones 
calnexin and calreticulin [24, 25]. Calnexin and calreticulin are lectins that form complexes 
with the glycoprotein and ensure correct folding of the glycoprotein [24, 25]. This is 
controlled upon removal of the last glucose by glucosidase II, and reformed by 
glucosyltransferases activity. Calnexin and calreticulin each consist of a globular domain, 
which contains the sugar-binding site, and an extended arm (the P-domain), the tip of which 
weakly associates with ERp57 (oxidoreductase), a member of the protein disulphide 
isomerase (PDI) superfamily. Once the glycoprotein has acquired its native conformation, 
glucosidase II hydrolyses the remaining glucose residue and the glycoprotein releases from 
the lectin anchor for transport to the Golgi [26].  
 
Figure 1.0 Biosynthesis of N-linked glycoproteins [22, 23]. 
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Figure 1.1 Continued biosynthesis of N-linked glycoproteins: three glucose units are 
received by the glycolipid before the glycan is conjugated to the polypeptide by 
oligosaccharyltransferase. The removal of one mannose and two glucose results in a 
monoglucosylated species that is recognised by the chaperones calnexin and calreticulin. 
Hydrolysis of the remaining glucose residue releases the glycoprotein from the calnexin and 
calreticulin cycle and ready for transport to the Golgi [22-26]. 
 
Transport of the glycoproteins via membranous vesicles to the Golgi apparatus allows 
further glycosylation/deglycosylation. A variety of processing enzymes in the cisternae of the 
Golgi stack are responsible for this process. The Golgi stack can be divided into the cis, 
medial and trans and each plays an important role in glycoprotein maturation. The cis 
apparatus cleaves three mannose units with mannosidase, and N-acetylglucosamine 
transferase 1 (GlcNAcT I) adds an N-acetylglucosamine (GlcNAc) unit. In the medial 
cisternae, two mannose units are removed by mannosidase II, and two GlcNAc are added 
by GlcNAcT II, and one fucose residue is added by fucosyltransferase [27]. Finally, in the 
medial and trans Golgi, other glycosyltransferases add GlcNAc, galactose, and/or sialic acid 
residues [28]. This results in four groups of heterogeneous glycoprotein, the carbohydrate 
component is classified as either: high-mannose, complex, hybrid or poly-N-
acetyllactosamine N-linked oligosaccharides (Figure 1.2). 
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Figure 1.2 Example of high mannose, complex and hybrid oligosaccharides containing the 
conserved core pentasaccharide. 
 
It is important to note that all of the N-linked oligosaccharides feature the same common 
core pentasaccharide [29]. However it is the different arrangement of monosaccharide units 
on the core pentasaccharide which determines the characteristic of each species [30, 31]. 
 
 
1.3 O-linked glycoproteins 
 
O-linked glycoproteins occur when the carbohydrates are attached to a hydroxyl group of 
serine, threonine, or hydroxylysine (hLys) of a polypeptide backbone [32]. Unlike N-linked 
glycosylation, O-linked glycosylation is a „true post-translational‟ event in that it does not 
require an oligosaccharide precursor which is transferred to a protein. The most common 
type of O-linked glycosylation is the attachment of GalNAc to the protein backbone [33]. This 
is commonly known as mucin-type O-glycosylation and generally produces highly 
heterogeneous glycans, usually shorter in length compared to N-linked glycans [33].  
 
The β-O-GlcNAc modification has been recently shown to be related to phosphorylation 
states and dynamic processes related to cell signalling events. Furthermore β-O-GlcNAc 
O
O
HO
NHAc
OH
O
O
HO
NHAc
OH
O
HO
O
OH
O
O
HO
HO
OHHO
O
HO
HO
OHHO
NH
HN
O
O
O
O
HO
NHAc
OH
O
O
HO
NHAc
OH
O
O
OH
O
OHO
OH
O
O
HO
HO
O
OH
O
HO
OOH
OHO
HO
OH
O
OHO
HO
OH
OH
HO
NH
HN
O
O
HO
O
O
HO
HO
OH
OH
O
HO
OOH
HO
O
HO
HO
OHOH
O
OH
O
OH
OH
O O
HO
OH
NHAc
O
O
HO2C
OH
AcHN
HO
OH
HO
O
O
HO
NHAc
OH
O
O
HO
NHAc
OH
O
HO O
OH
O
OHO
O
O
O
HO
O
NH
HN
O
O
O
O
OH
O
OH
OH
O
O
HO
OH
NHAc
O
HO2COH
AcHN
HO
OH
HO
OH
O
OH
O
OH
OH
O
O
HO
OH
NHAc
O
HO2COH
AcHN
HO
OH
HO
O
OH
O
OH
OH
O O
HO
OH
NHAc
O
CO2HOH
AcHN
HO
OH
HO
O
OH
O
OH
OH
O O
HO
OH
NHAc
O
HO2C
OH
AcHN
HO
OH
HO
O
OH
OH
OH
O O
HO
OH
NHAc
O
O
O
HO
NHAc
OH
O
O
HO
NHAc
OH
O
HO O
O
O
OHO
O
O
HO
NH
HN
O
O
HO
O
OH
OH
OH
O
O
HO
OH
NHAc
HO
OO
HO2C
HO
AcHN
HO
OH
HO O
OH
OH
OH
O O
HO
OH
NHAc
O
OO
HO2C
OH
AcHN
HO
OH
HO
O
OH
OH
OH
O
O
HO
OH
NHAc
O
OO
HO2COH
AcHN
HO
OH
HO
O
OH
OH
OH
O
O
HO
OH
NHAc
O
OHO
OH
O
OHO
HO
OH
O
OHO
HO
OH
OH
HO
OH
Hybrid 
Complex High mannose 
Core pentasaccharide 
22 
 
modification has been linked to several pathological states, including cancer, diabetes and 
Alzheimer's disease [34, 35]. 
One notable O-linked structure is the Gal-β(1-3)GalNAc sequence that has antigenic 
properties. Termination of O-linked glycans usually includes Gal, GlcNAc, GalNAc, fucose, 
or sialic acid. By far the most common modification of the core Gal-β(1-3)-GalNAc is mono-, 
di-, or trisialylation (Figure 1.3). A less common, but widely distributed O-linked 
hexasaccharide structure contains β(1-4)-linked Gal and β(1-6)-linked GlcNAc as well as 
sialic acid [33]. 
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Figure 1.3 Di- and Trisialylated O-linked Core. 
 
 
O-galactosylation is found on hydroxylysine residues of collagens, and the extent of this 
modification influences the three-dimensional structure of the protein, which is important to 
exert its biological function in tissue regeneration [36]. 
 
Proteins with epidermal growth factor (EGF) modules posses less common O-fucosylation 
and O-glucosylation repeats. O-fucosylation was first evident through the identification of 
Glcβ1-3Fucα-Thr, in human urine [33]. More interest grew when O-fucosylation was 
identified in human urokinase, and other clotting proteins such as tissue plasminogen 
activator and clotting factor VII. Initially fucose was considered to be a terminal sugar, so 
there was no inclination to search for glycosyltransferase enzyme that use fucose as an 
acceptor. However, clotting factor VII has a glycan structure Sia-α(2,6)-Gal-β(1,4)-GlcNAc-β-
(1,3)Fuc-α-, where the formation of GlcNAc-β-(1,3)Fuc-α- bond suggest that a transferase 
unique to this pathway is required [33]. Recently, new O-fucosylated patterns have been 
identified within thrombospondin type-1 repeats, suggesting a functional role in cell adhesion 
[37]. 
 
The Notch signaling pathway demonstrates the importance of O-fucosylation and O-
glucosylation for cell signaling systems in most multicellular organisms. The Notch protein is 
1 2 
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a transmembrane receptor protein where ligand proteins binding to the extracellular domain 
induce proteolytic cleavage and release of the intracellular domain. The cleaved intracellular 
domain migrates to the cell nucleus to alter gene expression [38]. The Notch 1 extracellular 
domain is composed primarily of small cysteine knot motifs called EGF-like repeats [39]. 
Each EGF-like repeat is composed of approximately 40 amino acids, and its structure is 
defined largely by six conserved cysteine residues. The EGF-like repeat can be modified by 
O-linked glycans at specific sites [40]. An O-glucose sugar may be added between the first 
and second conserved cysteines, and an O-fucose may be added between the second and 
third conserved cysteines. The addition of O-fucose by GDP-fucose and protein O-
fucosyltransferase 1 (POFUT1). POFUT is absolutely necessary for Notch function, and, 
without O-fucose, the Notch protein fails to function properly [39]. The O-fucose on Notch 
can be further modified by an N-acetylglucosaminyltransferase called fringe, followed by the 
addition of galactose by a galactosyltransferase, and sialic acid by a sialyltransferase. The 
addition of these sugars may inhibit or potentiate signaling through ligand proteins binding to 
the extracellular domain although the full mechanism is not completely understood [41]. 
 
O-mannosylation was discovered in yeast cells in the 1950‟s and only recently has been 
found among mammals, where it occurs especially in the brain, nerves, and skeletal muscles 
[33, 42]. Particular interest has been directed towards a tetrasaccharide derived from α-
dystroglycan (ADG), a component of the dystrophin-glycoprotein complex in skeletal muscle, 
where abnormal glycosylation is associated with neuromuscular diseases [42, 43]. ADG is a 
peripheral membrane protein that undergoes multiple and complex glycosylation steps to 
regulate its interaction with extracellular matrix proteins such as laminin, agrin and perlecan 
[44]. The mucin type O-glycans are clustered in a mucin-like domain near the N-terminus of 
mature ADG, which includes unique O-mannosyl glycans and sialic acid: Neu5Ac-α-2,3Galβ-
1,4GlcNAcβ-1,2Manα-1Ser/Thr [12]. Defects in glycosylation of the O-mannosyl glycans 
have been shown to cause muscular dystrophy [12]. Seven glycosyltransferases or 
glycosyltransferase-like genes, including POMT1, POMT2, POMGnT1, Fukutin, Fukutin-
related protein, LARGE, and LARGE2, have been found to be involved in ADG functional 
glycosylation [12]. In particular, overexpression of LARGE has restored dystroglycan 
glycosylation and laminin binding properties in primary cell cultures from patients affected by 
different genetically defined dystroglycanopathy variants [44]. LARGE displays 2 distinct 
structural domains homologous to UDP-glucose protein glucosyltransferase and β-3-N-
acetylglucosaminyltransferase (β3GnT1) [44]. It is β3GnT1 that plays a critical role in the 
synthesis of the laminin-binding glycans. Furthermore, several reports have shown that 
defects in ADG are associated with breast, colon, oral, and prostate carcinomas but only 
recently it has been demonstrated that reduced expression of β3GnT1 leads to diminished 
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synthesis of laminin-binding glycans, increased metastasis of cancer cells, and increased 
tumour formation [44]. 
 
 
 
Figure 1.4 The effect of ADG glycosylation on extracellular matrix proteins. (A) Interaction of 
intact ECM molecules such as laminin and fibronectin with integrin initiates kinase activation 
and promotes cancer cell migration and proliferation. (B) Up-regulation of β3GnT1 results in 
ADG playing an increased role in counteracting integrin-mediated signalling, resulting in a 
low migratory cell phenotype [44].  
 
In mammals, O-xylose is found as the first sugar residue of the tetrasaccharide GlcAβ1-
3Galβ1-3Galβ1-4Xylβ1-O-Ser, initiating the formation of the glycosaminoglycans (GAGs). 
These highly negatively charged molecules are primarily located on the surface of cells or in 
the extracellular matrix, where they act as lubricating fluids and provide passageways 
between cells, allowing for cell migration. GAGs are long unbranched polysaccharides 
containing repeating disaccharide units. The disaccharide units contain either of two 
modified sugars, N-acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), and an 
uronic acid such as glucuronate or iduronate [45, 46].  
 
 
Some important GAGs include: 
 Hyaluronates composed of D-glucuronate-β(1,3)-GlcNAc linkages; found in synovial 
fluid and the ECM of loose connective tissue [46]. 
 Dermatan sulphates composed of L-iduronate-α(1,3)-GalNAc-4-sulphate linkages; 
found in skin, blood vessels and heart valves [46]. 
(A) (B) 
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 Chondroitin 4- and 6-sulphates composed of D-glucuronate-β(1,3)-GalNAc-4- or 6-
sulphate linkages; found in cartilage, bone, heart valves and is the most abundant 
GAG [46]. 
 Heparin and heparan sulphates composed of iduronate-2-sulphate-α(1,4)-N-sulfo-D-
glucosamine-6-sulphate linkages. These sulphates are a component of intracellular 
granules of mast cells lining the arteries of the lungs, liver and skin [46]. 
 Keratan sulphates composed of galactose-β(1,4)GlcNAc-6-sulphate linkages and are  
found in cornea, bone and cartilage aggregated with chondroitin sulphates [46]. 
 
1.4 Glycosyltransferases 
 
Glycosyltransferases (GTs) are enzymes that catalyse the transfer of a monosaccharide unit 
from an activated sugar phosphate (known as the “glycosyl donor”) to an acceptor molecule, 
usually an alcohol. GTs usually transfer sugar molecules to the amino acid tyrosine, serine 
or threonine to give O-linked glycoproteins, or to asparagine to give N-linked glycoproteins. 
The commercial availability of GTs are limited and the nucleotide diphosphate-
monosaccharide donors are expensive. Despite this drawback, GTs still remains attractive in 
synthesising oligosaccharides over traditional chemical methods. The main advantages of 
GTs over chemical synthesis are the absence of protecting group chemistry and the ability of 
GTs to easily control regioselectivity and stereoselectivity.  
 
New methods to adapt the role of GTs have been investigated for potential biomedical 
applications [47-51]. For example, changing the glycosyl acceptor, the substrate to which a 
GT transfers its sugar molecule, allows the synthesis of a variety of oligosaccharides with 
different acceptor molecules. However this ultimately relies on the tolerance of the GTs to 
the glycosyl acceptor [52-57]. Less commonly GTs also catalysed reactions, where the 
glycosyl donor, a modified nucleotide diphosphate is used instead of its natural nucleotide 
diphosphate. This comprises of either a chemoenzymatic or a synthetic approach to produce 
a modified glycosyl donors where the modification is directly on the sugar which will be 
transferred by GTs. 
    
The reaction mechanism of GTs can either proceed with inversion or retention of 
configuration at the anomeric centre. The mechanism of inversion has been elucidated 
(Figure 1.5), but the mechanism by retention is still under debate. 
 
26 
 
O
O
NDP
O
H
R
OO
HO NDP
O
O
R
OHO
(HO)3
HO
HO
(HO)3
OHO
O
O
H
R
OO

O
NDPH
OO OO

 
Figure 1.5 Reaction mechanism of an inverting GT [57, 58].  
 
The two most widely accepted hypotheses that rationalise the retention of configuration 
involve either a double displacement dependent on acidic/basic residues on the enzyme 
(Figure 1.6) or through a direct attack of the aglycon with concomitant release of the 
nucleotide diphosphate (NDP) in a SNi mechanism. This involves an “internal return” 
intermediate (Figure 1.7) [57, 58].  
3 4 
5 
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Figure 1.6 Reaction mechanism of a retaining GT [57, 58]. 
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Figure 1.7 Proposed SNi mechanism of a retaining GT [57, 58]. 
 
 
1.5 Glycosidase and glycosynthase 
 
Glycosidases are enzymes which hydrolyse the glycosidic bonds between sugar molecules, 
and in so doing, they catalyse the reverse process to that of GTs. Withers et al. have shown 
that glycosynthase functionality can be conferred upon a subset of glycosidase enzymes by 
mutagenising the active site. He demonstrated that the mutagenised enzymes form 
glycoconjugates while losing the ability to hydrolyse the product [59].  
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Glycosynthases were originally formed from glycosidases by mutating the active site 
nucleophilic amino acid (usually an aspartate or glutamate) to a small non-nucleophilic 
amino acid (usually alanine or glycine) [60]. More modern approaches use directed evolution 
to screen for amino acid substitutions that enhance glycosynthase activity. 
 
Two discoveries led to the development of glycosynthase enzymes. The first was changing 
of the active site nucleophile of a glycosidase from a carboxylate to another amino acid 
prevented the formation of a hydrolysed product. The second discovery was that some 
glycosidase enzymes were able to catalyse the hydrolysis of glycosyl fluorides with inversion 
of configuration (Figure 1.8 A) [61, 62]. The enzymes underwent a transglycosidation 
reaction to form a disaccharide, which was then hydrolysed. The removal of the carboxylate 
group in glycosynthase prevents the formation of a covalent acyl enzyme intermediate. An 
activated glycosyl donor with a good anomeric-leaving group (often fluorine) is required. The 
leaving group is displaced by an alcohol of the acceptor sugar aided by the enzyme active 
site (Figure 1.8 B) [61, 62]. 
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Figure 1.8 Mechanism of glycosidase and glycosynthase enzymes. (A) Transglycosidation 
followed by hydrolysis with retention. (B) A glycosidic linkage is formed where a non- 
covalent enzyme intermediate is formed [61, 62]. 
1.6 Mannosyltransferase (Man T)  
Mannose is present in a wide range of glycoproteins and exhibits O-linkages to other sugars 
or to the hydroxyl groups of Ser or Thr residues of peptides [63]. Mannose forms C-linkages 
O
HO
HO
OH
OH
Enzyme
O O
H
O
H
Enzyme
OO
O
HO
HO
OH
OH
Enzyme
O O
Enzyme
OHO
OH
(A) 
(B) 
14 15 
16 
17 
18 
19 
29 
 
to Trp residues of protein chains and P-linkages through monophosphate units to other 
carbohydrates or polyisoprenoids (the dolichol lipid, through β linkage in humans) [64]. 
 
In eukaryotic organisms the occurrence of mannosylation in the N-glycosylation pathway is 
best understood. This is governed primarily by a class of enzymes called 
mannosyltransferases which catalyse the transfer of mannose from a donor to an acceptor 
molecule which is frequently another carbohydrate. There are two different types of glycosyl 
donors in which mannose is linked to, guanosine diphosphate (GDP) or dolichol-phosphate. 
Many ManTs are strongly discriminating regarding the nature of the glycosyl donor. However, 
changing the acceptor may be viable, for instance dolichol-phosphate mannose synthase 
transferred mannose to a dolichyl-phosphate (Dol-P) and synthetic Dol-P analogues 
containing fluorescent probes [65]. 
   
Many conserved eukaryotic ManT genes were originally identified in S. cerevisiae 
(asparagine-linked glycosylation (alg) genes), so it is not surprising that yeast nomenclature 
is mainly used. ManTs can be classified according to the pathway they are involved in (N-
glycosylation, O-glycosylation, or glycosylphosphatidylinositol (GPI) anchoring), the type of 
linkage formed (either α or β) and by position of the glycosidic bond. This can be shown by 
the common core N-linked glycoproteins where eight different ManTs are used respectively 
β-1,4(alg1p), -1,3(alg2p), -1,6(alg2p), -1,2(alg11p), -1,6(alg12p), -1,3(alg3p), -
1,2(alg9p) and dolichol-phosphate-mannose synthase (Dol-P-Man). Dol-P-Man is used to 
transfer mannose from GDP-Man to dolichol-P which in turn serves as a donor and transfers 
mannose to glycan-PP-dolichol. The exact pathway position and number of mannose 
introduced by these mannosyltransferase is shown (Figure 1.0) but can be summarised 
below: 
 
β-1,4-ManT: transfers mannose from GDP-man to dolichol-PP-GlcNAc2 at the cytoplasmic 
face of the ER membrane (Figure 1.9)[66]. 
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Figure 1.9 The structure of lipid-linked trisaccharide after the addition of mannose by β-1,4-
ManT. 
α-1,3-/α-1,6-ManT: adds one α-1,3- and one α-1,6-linked mannose to the trisaccharide-PP-
dolichol, at the cytosolic face of the ER membrane (Figure 1.10) [67]. 
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Figure 1.10 The structure of lipid-linked pentasacharide after the addition of mannose by α-
1,3-/α-1,6-ManT. 
 
α-1,2-ManT: uses GDP-mannose to add the next two mannose units to form the 
heptasaccharide-PP-dolichol, which is then flipped to the other side of the ER (Figure 1.11) 
[68]. 
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Figure 1.11 The structure of lipid-linked oligosaccharide after the addition of mannose by α-
1,2-ManT. 
 
 α-1,3-ManT: is the first ManT to add a mannose residue from the dolichol-P donor to the 
heptasaccharide-PP-dolichol at the lumenal face of the ER membrane in the N-glycosylation 
pathway [69] (Figure 1.12). 
 
 
 
 
 
                                                                                       
 
 
 
Figure 1.12 The structure of lipid-linked oligosaccharide after the addition of mannose by α-
1,3-ManT. 
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α-1,2-ManT: adds two mannose units to the growing oligosaccharide by using the dolichol-P-
man as a donor [70] (Figure 1.13). This protein has high homology with GPI-MT-I (PIG-Mp), 
GPI-MT-II(PIG-Vp), GPI-MT-III (PIG-Bp), and GPI-MT-IV (SMP3p) which sequentially adds 
the four mannose units to the GPI anchor [71]. They are all localised on the lumenal side of 
the ER membrane.  
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Figure 1.13 The structure of lipid-linked oligosaccharide after the addition of mannose by α-
1,2-ManT. 
 
α-1,6-ManT: adds another mannose to the lipid-linked oligosaccharide, and shares 
significant homology with α-1,2-ManT [72]. 
 
Dol-P-Man synthase : transfers mannose from GDP to dolichol-phosphate which in turn will 
serve as a donor in GPI anchoringand for O- and C-glycosylation pathways. The enzyme is 
a β-inverting transferase that is highly conserved among eukaryotes and in humans.  It 
forms a complex with two other membrane proteins Dpm2p and Dpm3p [73]. Another 
significant mannosyltransferase is protein O-mannosyl-transferase 1 which is encoded by 
the POMT1 gene in humans. It is a member of the dolichyl-phosphate-mannose-protein 
mannosyltransferases family. POMT1 and POMT2 both form a heterocomplex which O-
mannosylates α-dystroglycan in the ER, by using dolichol-P-man [74]. 
 
The catalytic transfer of mannose units onto acceptor substrates is not restricted to a single 
ManT enzyme, but despite this apparent redundancy of function the ManT‟s exhibit limited 
sequence homology. Christine and coworkers [75], compared unrelated families of yeast 
Golgi ManT‟s and showed a short motif containing two aspartate residues (DXD motif) 
conserved in both groups of proteins. Mutagenesis of one of the members of these families, 
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the α-1,3-ManT, showed that alteration of either of these aspartates eliminated all enzymatic 
activity [76]. It is further believed that this DXD motif is involved in binding a metal ion 
(usually magnesium), which is used to coordinate the phosphate of the glycosyl donor in the 
active site of the protein.   
 
Whilst the properties of a small number of ManTs have been well documented [76], the 
majority remain poorly characterised. For instance, only one eukaryotic ManT crystal 
structure has been reported to date, and online database entries show sequences of 
potential ManTs with unknown substrates [76]. Also, the ManT responsible for C-
mannosylation in humans has still not been identified. One of the reasons for this may be the 
difficulty in handling these proteins, as they are transmembrane proteins containing 
hydrophobic transmembrane domains which makes them difficult to isolate. Despite these 
difficulties, ManTs are attracting more interest in the scientific community for their 
involvement in diverse human disease states [77-84]. The interaction of mannose with its 
receptor on macrophages and endothelial cells is involved in the abnormal immunological 
response, which includes failed clearance of pathogens and autoimmune reactions [85]. The 
receptor is also involved in tumour proliferation, and in the uptake of vaccines and drugs. 
Great potential exists for ManTs as novel drug targets for treating or understanding some of 
these pathological conditions.   
 
So far, we have looked at the biosynthesis and role of glycoproteins in biology and 
concentrated on glycosyltransferases and, in particular, mannosyltransferases. Next we will 
look at the engineering of glycoproteins as drugs and the different methods currently 
employed.   
 
1.7 Glycoprotein drugs/engineering  
 
Glycoproteins play a key role in a variety of biological functions from cell communication to 
immune response and inflammation. The carbohydrate moiety has been found to be 
essential for correct folding, delivery, and solubility of many glycoproteins [23, 86]. The ability 
to harness these functions by engineering glycoproteins to be non-immunogenic for 
therapeutic use, at industrial scale and cost poses a huge challenge but is nevertheless 
highly desirable. To control glycosylation by manual or automated means presents a 
complex challenge compared to other biological processes such as nucleotide assembly. 
The number of monosaccharides and the possible ways of linking them together leads to an 
immense diversity in the glycan structure. 
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The production of glycoproteins can be divided into three major routes using biological, 
synthetic and semi-synthetic methods. Controlling the glycosylation of proteins by 
bioengineering yeast, bacteria, plant cells, insect cells, and mammalian cells have been 
investigated [87, 88]. The use of glycosylation enzymes to transfer sugars that can then be 
chemically modified is another approach. Total synthesis and enzyme protein ligation adds 
to the vast number of methods currently being used. 
 
More than 50% of human proteins are glycoproteins, which tend to be heterogeneously 
glycosylated [89]. This means that the sugars are attached at different sites along the protein 
(macroheterogeneity) and in different arrangements to form an array of glycan structures 
(microheterogeneity). Heterogeneous glycosylation is also found in bioactive natural 
products such as avermectin, antiparasitics, enediyne antibiotics, macrolides such as 
erythromycin and vancomycin, a natural glycopeptide antibiotic [89].  
 
The ability to control the type of glycosylation and produce homogeneous glycoproteins will 
allow researchers to relate glycan structures to biological activity and potentially tailor 
glycoprotein drugs to suit stability, uptake, immunogenicity and many other pharmacokinetic 
properties [89]. One example of an N-linked glycoprotein that has been studied extensively 
is the hormone erythropoietin (EPO) involved in the production of red blood cells 
(erythrocytes) [90]. Glycosylation of EPO is critical for its biological longevity and activity, but 
deducing the favoured glycosylation for optimum pharmacokinetic activity still poses a 
problem. EPO, like many other glycoproteins, is currently produced commercially in 
mammalian cells, which express it as a mixture of glycoforms. Hence controlling the 
glycosylation is beneficial to obtain biologically uniform molecules which are tailored for 
optimum therapeutic use. 
 
1.8 Commercial production of N-linked glycoproteins 
 
There are 140 therapeutic proteins approved in the US and Europe [91], with many more in 
clinical and preclinical trials. The therapeutic protein market can be divided into proteins 
which are non-glycosylated and those that are mostly N-glycosylated. Non-glycosylated 
proteins constitute for around 40% of the therapeutic market and are normally expressed in 
E. coli or S. cerevisiae [91]. The use of mammalian cell lines (for example baby hamster 
kidney [BHK] or Chinese hamster ovary cells [CHO]) is currently the expression system of 
choice for many approved therapeutic glycoproteins, including recombinant interferon-β, 
which is used in the treatment of multiple sclerosis and EPO, which is used to treat certain 
anaemias [92]. Although human type glycosylation is observed in different glycoforms, 
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culturing mammalian cells is a lengthy and very expensive process and handling mammalian 
cells can be difficult as they can be sensitive to environmental and process changes. So 
other expression systems may be attractive alternatives. 
 
1.9 Engineering bacteria to produce N-linked glycoproteins 
 
It was initially thought that expressing proteins in prokaryotic hosts such as E. coli did not 
glycosylate the protein. However, Wacker et al reported the presence of N-glycoproteins in 
the gram negative bacterium Campylobacter jejuni (C. jejuni) [93]. The glycan structure 
GalNAc-α4-GalNAc-α4-[Glcβ3-]GalNAc-α4-GalNAc-α4-GalNAc-α4-GalNAc-α-3-Bac-β-Asn 
(Bac = bacillosamine) was found to be vastly different to eukaryote glycan Glc3Man9GlcNAc2. 
Furthermore, the synthesis of Glc3Man9GlcNAc2 normally requires several enzymes and a 
“flippase” which are encoded by the pgl gene clusters. Studies have shown that the pglB 
gene was found in C. jejuni and researchers succeeded in reconstituting the C. jejuni 
glycosylation machinery in E. coli, by introducing the pgl gene cluster. The results showed 
that the bacteria N-glycosylation site is more specific than in eukaryotic systems, as the 
peptide acceptor sequence which pglB protein recognises is extended in bacteria: Asp/Gly-
Yaa-Asn-Xaa-Ser/Thr (Xaa and Yaa are not proline). However, in vitro assay of pglB protein 
showed that pglB can transfer N-glycans to completely folded proteins, which indicates that 
N-glycosylation apparently occurs without certain organelles such as ER which are not 
present in bacteria. Using pglB for the production of human type N-glycans is still at an early 
stage and further developments for the uptake of specific donor substrates, such as UDP-
GlcNAc and UDP-GalNAc or GlcNAc-α-3-Bac-undecaprenylpyrosphates will be a good 
starting point to engineer N-linked glycoproteins in bacteria. 
 
1.10 Engineering yeast to produce mammalian glycoproteins 
 
Due to low cost and ease of handling, yeast and bacteria are often favoured when 
manufacturing proteins and enzymes on an industrial scale [94, 95]. However, the use of 
yeast, while convenient, is not without a significant caveat: glycosylation conferred upon the 
recipient protein is of the high mannose type and is thus immunogenic to humans. 
 
The N-glycosylation pathways in humans and yeast is initiated in the ER, where the core 
oligosaccharide Glc3Man9GlcNAc2 is transferred onto the nascent polypeptide. In humans,  
glucosidase I, glucosidase II and ER-residing α-(1,2)-mannosidases trim the glycan to 
Man8GlcNAc2 for processing in the Golgi apparatus. The situation in yeast however is 
markedly different. Schizosaccharomyces pombe lacks ER α-(1,2)-mannosidases and 
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therefore transport glycoproteins containing Man9GlcNAc2 to the Golgi apparatus [92]. In S. 
cerevisiae, the Golgi apparatus contains enzymes α-(1,2), α-(1,3), and α-(1,6)-
mannosyltransferases which transfer mannose to the N-glycan. This results in the formation 
of hypermannosylated glycans, with terminal mannose residues that are immunogenic in 
humans, and are recognised for rapid clearance from the circulation by the mannose 
macrophage receptor. Hypermannosylation thereby presents a barrier to the use of yeast 
glycoproteins as therapeutics. Furthermore the yeast Golgi is devoid of GlcNAc transferases, 
and N-acetylneuraminic acid (sialic acid) transferase, which are present in humans (Figure 
1.14) [92]. If yeast is to be exploited to produce glycoproteins fit for therapeutic applications it 
must first be engineered or “humanised”. Humanisation strategies are not trivial, and 
frequently rely upon the elimination of endogenous hypermannosylation pathways and the 
introduction of non-native enzymes by genetic means. 
  
Recently, a company called GlycoFi has successfully generated human-like proteins from 
yeast [89]. Genetically engineering yeast, they produced a library of yeast strains that have 
been engineered to perform specific human glycosylation at high fidelity. They engineered 
yeast P. pastoris to secrete human glycoproteins with fully complex terminally sialylated N-
glycans. By the knockout of four genes to eliminate yeast-specific glycosylation, and 
introduction of 14 heterologous genes, allowed step wise replication of human glycosylation. 
The reported cell lines produced complex glycoproteins with greater than 90% terminal 
sialylation. The utility of these yeast strains were shown by the production of functional 
recombinant erythropoietin [95]. 
 
Of all of the expression systems specifically engineered to produce therapeutic glycoproteins 
for use in humans, yeast is the most advanced. Further work will need to concentrate on 
genetically incorporating specialised sugars to allow complex glycopeptide synthesis with a 
variety of glycans. 
 
36 
 
 
 
 
 
1.11 Engineering plant and insect cells to produce glycoproteins 
 
In contrast to yeast and bacteria, plant cells contain organelles capable of producing 
complex N-glycans. However, the presence of immunogenic fucose and xylose sugars 
render the associated glycoproteins unsuitable for use as therapeutic agents [89]. This 
apparent limitation was overcome by Stross and co-workers [89] who engineered plants to 
eliminate fucose and xylose and later developed a process to express galactosyltransferase 
in plants, which adds galactose to glycoproteins (this had never previously been achieved in 
plants [89]). Recently Steinkellner constructed a functional CMP-sialic acid biosynthesis 
pathway in Arabidopsis thaliana. The expression of key enzymes for mammalian N-
acetylneuraminic acid (Neu5Ac) biosynthesis was achieved. These enzymes UDP-N-
acetylglucosamine 2-epimerase / N-acetylmannosamine kinase, N-acetylneuraminic acid 
phosphate synthase, and CMP-N-acetylneuraminic acid synthetase resulted in the 
generation of Neu5Ac. Which was further converted to cytidine monophospho-N-
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 Figure 1.14  Major N-glycosylation pathways in humans and yeast.  
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acetylneuramic acid by co-expression of CMP-N-acetylneuraminic acid synthetase [96]. 
These results suggested that it is only a matter of time before the first fully humanised N-
linked-glycoprotein will be produced in genetically engineered plants. 
 
Genetically engineered insect cells are another method which has been used to produce 
glycoproteins. Betenbaugh and coworkers have humanised glycoproteins produced in insect 
cells by genetically engineering the cells to express metabolic enzymes and 
glycosyltransferases required to add GlcNAc, galactose, and sialic acid to insect glycans [97]. 
The main advantage of this system compared to mammalian systems is the ability to provide 
more recombinant glycoprotein in a biologically system that is less influenced by 
environmental changes. 
 
1.12 Total synthesis of glycoproteins and glycans 
 
So far we have looked some biological systems focussed upon genetically engineering cells 
to perform human-type glycosylation and with natural sugar-protein linkages. Engineering N-
linked glycopeptides can also be achieved synthetically by total synthesis or semi-
synthetically using a combination of biologically/chemically modified enzymes and proteins. 
Researchers believe that to chemically synthesise large proteins from the start is both costly 
and inefficient with only small quantities produced. Ligating two or more separate peptides 
together to create a full length protein can overcome this problem as synthesis of smaller 
peptides can be readily automated. Native chemical ligation (NCL) is rapidly becoming 
established as a robust method for the production of full-length proteins from peptide 
components [98]. NCL is the chemoselective coupling of two protein fragments, one 
containing a N-terminal cysteine residue and the other bearing a C-terminal thioester, where 
a native peptide (amide) bond is formed at the point of ligation [99]. There are many 
adaptions of NCL where development of thiol auxiliaries and sugar assisted ligation has 
overcome the limitation of the need for N-terminal cysteine residues [100,101] (Figure 1.15). 
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NCL is an attractive approach for the synthesis of N-linked glycoproteins, as it allows the 
construction of completely native structures by total chemical synthesis in aqueous solutions 
in the absence of protecting groups. This is particularly important for glycoproteins, as 
control can be exerted upon the position, number and type of oligosaccharides adorning the 
protein sequence. Additionally, controlling the synthesis of complex homogenous 
glycoproteins or chemically functionalising glycoproteins can be useful for therapeutic use 
and monitoring. Danishefsky and co-workers demonstrated the power of NCL by 
synthesising homogeneous EPO-like glycopeptides using cysteine-free ligations [102]. The 
method involved conjugating trifunctional glycopeptide using chemical ligation. Firstly the 
attachment of chitobiose and then exposing the glycopeptide to tris-carboxyethyl phosphine 
(TCEP), which reduced the disulphide bonds in both the acyl transfer donor and auxiliary-
linked acceptor. Following the O→S acyl shift, the thioester was formed (Figure 1.16) which 
participates in an NCL reaction. 
 
 
Figure 1.15 Sugar-assisted ligation (SAL). 
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Figure 1.16 Danishefsky's cysteine-free ligation. Reduction of the disulphide bond and an 
OS acyl shift regenerates the thioester, which undergoes auxiliary assisted NCL. 
 
The Kent laboratory further examined the kinetics of aryl and alkyl thioester participation in 
NCL reactions and found that aryl thioesters were more reactive, but were produced in situ 
with the addition of thiophenol to an alkyl thioester [103]. 
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27 
28 29 
30 
31 
32 
40 
 
 
Total chemical synthesis of glycans remains one of the oldest and most challenging 
strategies to produce glycans. Unverzagt and coworkers have pursued the total synthesis of 
complex oligosaccharides, including bisected N-glycans [104]. Their recent work showed a 
double regio- and stereoselective glycosylation strategy for the synthesis of N-glycans. They 
showed using a benzylidene acetal protected β-mannoside, the selective α-glycosylation at 
OH-3 of the 2,3-diol with GlcNβ1,2Man trichloroacetimidate donors [105]. In addition, this 
selectivity was increased with a phthalimido-protected donor. The total synthesis of glycans 
remains both laborious and time consuming due to its protecting group strategy. However it 
will always be very important, especially when complex homogenous glycoproteins will need 
to be synthesised with one point ligation to proteins.  
 
1.13 Semi-synthesis of glycoproteins 
 
Apart from the use of NCL to produce glycoproteins, glycoproteins produced by recombinant 
methods are easily accessible, and it is usually the glycan segment that is immunogenic to 
humans. Therefore to utilise the protein part and remodel the glycan in vitro, by semi-
synthetic means, could pose a good method to produced homogeneous glycoproteins. 
 
One approach in this semi-synthesis category involves isolation of a mixture of glycoforms of 
a single protein followed by exposure to a glycoside hydrolase, which mediates glycan 
degradation to the point of homogeneity. The uniformly glycosylated protein can then be 
remodelled in vitro using enzymes. An exo-glycoside hydrolase acts by sequential removal 
of non-reducing terminal monosaccharides, while an endo-glycoside hydrolyses the internal 
glycosidic bond of glycans [106,107]. A good example of an endo-glycoside hydrolase are 
endo-β-N-actylglucosaminidases (endo-NAGs), which hydrolyses the β(1-4) linkage of the 
N,N‟-diacetylchitobiose unit found in N-linked glycans. The resulting product by digestion 
with endo-NAGs will be free from microheterogeneity and further remodelling with enzymes 
such as glycosyltransferases may allow non immunogenic uniformly glycosylated proteins. 
Some endo-NAGs can also be used to catalyse transglycosylation of oligosaccharides from 
glycopeptides to βGlcNAc-Asn [107,108]. Two widely used endo-NAGs are bacterial enzyme 
Endo-A (Arthobacter) and the fungal enzyme Endo-M (Mucor hiemalis). These two endo-
enzymes have distinct substrate specificity. Endo-A is specific for high-mannose type N-
glycans, whereas Endo-M can act on N-glycans of the three major types (high-mannose type, 
hybrid type, and complex type), with preference to the complex type sugars. Furthermore, 
endo-NAGs can also use GlcNAc-based oxazolines as substrates for glycoprotein 
remodelling [107,108]. The nature of the glycan substrates that are transferred determines 
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whether endo-NAGs hydrolyse the product formed. For example disaccharide oxazoline, 
Glc-β-(1,4)-GlcNAc-oxazoline, was a substrate of Endo-M for transglycosylation but was not 
a substrate for Endo-A.  However low reaction rates with Endo-M were observed with only a 
5% yield due to hydrolysis of the product. When the substrate was extended to the 
trisaccharide Man-α-(1,3)-Glc-β-(1,4)-GlcNAc-oxazoline, it became an excellent substrate for 
Endo-M, and the transglycosylation proceeded with 91% yield without hydrolysis. 
 
 
 
Further developments of endoglycosidase-catalysed transglycosylation of triazole-linked 
glucose and N-acetylglucosamine-containing di-peptides and polypeptides were achieved 
using sugar oxazoline as donor substrates. Endo-A was effective in transglycosylation to 
both N- and C-linked Glc/GlcNAc-containing triazole derivatives [107-109]. 
   
These recent developments of endo-NAG-catalysed glycosyl transfer for sugar oxazolines 
will be imperative in the preparation of homogeneous N-linked glycoproteins. In fact a new 
method of producing homogeneous N-linked glycoproteins from eukaryotic cells has been 
demonstrated. This involves engineering the functional transfer of the C. jejuni glycosylation 
machinery in E. coil to express glycosylated proteins containing GlcNAc-Asn linkage. The N-
glycan is trimmed by α-N-acetylgalactosaminidase to give a GlcNAc-tagged glycoprotein.  
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Figure 1.17 The uses of endo-NAGs. 
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Finally, endoglycosidase-catalysed transglycosylation using pre-assembled N-glycan 
species as substrates gives rise to a pool of homogenous glycoproteins [110]. 
 
Many ligation methods have been developed to attach glycans to recombinant proteins. One 
method utilises the properties of selenium and sulphur compounds to ligate sugars to 
proteins through disulphide bonds [111]. Another method uses “click chemistry” (see below) 
by using the heterobifunctional adaptor 2-bromoacetyl propargylamide to ligated azido 
sugars and cysteine containing peptides. An unnatural azido amino acid azidohomoalanine 
(Aha) has also been incorporated into a protein where click chemistry with propargyl sugars 
ligates the sugars to the protein [112]. Further work will be required to test the durability of 
one point ligation of sugars to proteins and assess the toxicity of the chemical modification of 
the glycoprotein for human therapeutic use.   
 
1.14 Click chemistry 
 
In 2002 the groups of Meldal and Sharpless independently reported that catalytic amounts of 
copper (I) catalysed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) and improved its 
regioselectivity, yielding almost exclusively 1,4-substituted triazoles (Figure 1.18) [113, 114]. 
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Figure 1.18 Proposed mechanism for the Cu (I) catalysed 1,3-dipolar cycloaddition between 
a terminal alkyne and an azide (CuAAC). 
 
Nevertheless, the reaction is not flawless: the Cu (I) is thermodynamically unstable and is 
easily oxidised to Cu (II) or can disproportionate to Cu (II) and Cu (0), compromising the 
application of the reaction. For this reason, especially in aqueous environments, it is vital to 
add either anti-oxidant agents (e.g. ascorbic acid), or ligands typically Tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl] amine (TBTA) that can preserve the Cu (I) species [113]. Since the 
conditions have been optimised for biological applications, this reaction has been widely 
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used in the field of carbohydrates [115].The terminology click chemistry was introduced by 
Sharpless, although originally to indicate a general group of efficient reactions with broad 
scope, and that are particularly convenient, fast and reliable [116]. Further developments of 
click chemistry using ruthenium catalysed 1,3-dipolar azide-alkyne cycloaddition (RuAAC) 
gave the 1,5-triazole [117, 118]. Unlike CuAAC in which only terminal alkynes reacted, in 
RuAAC both, terminal and internal alkynes can participate in the reaction [117, 118]. This 
suggests that ruthenium acetylides are not involved in the catalytic cycle. 
 
 
Figure 1.19: Proposed mechanism for the Ru catalysed 1,3-dipolar cycloaddition between 
an alkyne and an azide. L= spectator ligand and X= Cl. 
The proposed mechanism (Figure 1.19) begins where the spectator ligands undergo a 
displacement reaction to produce an activated complex which is converted, via oxidative 
coupling of an alkyne and an azide to the ruthenium containing metallocycle (ruthenacycle) 
[117, 118]. A new C-N bond is formed between the less sterically-demanding and more 
electronegative carbon of the alkyne and the terminal nitrogen of the azide. The metallocycle 
intermediate then undergoes reductive elimination to produce the aromatic triazole product 
and regenerate the catalyst for further reaction cycles. 
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1.15 Project aim 
 
The overall aim of the project was to synthesise homogenous glycoproteins by three 
different methods. Initially the synthesis of propargyl glycosides of mannose, N-acetyl 
glucosamine, and N-acetyl lactosamine was investigated. These propargyl glycosides were 
used to remodel glycoproteins via click chemistry using the acetylene group of the 
glycosides and the azide group of the glycoprotein. 
 
Aim 1: The first method involved expressing the glycoprotein in Pichia pastoris in the 
presence of azido sugars, in an attempt to incorporate the azido sugars into the yeast glycan. 
The isolated azide containing glycoprotein was then remodelled using our propargyl 
glycosides to produce a “humanised” chemically homogenous molecule.  
 
Aim 2: The second method uses a novel chemoenzymatic strategy which is summarised 
below:  
 
 
                                                                      Step        The glycosylation of the   
                                                                                      expressed protein will be   
                                                                                      trimmed by subjecting the  
                                                                                      purified hyperglycosylated 
                                                                                      protein to glycosidase   
                                                                                      enzymes (α-1,2 mannosidases). 
 
 
                                                
                                                                         Step        We will next investigate the transfer  
                                                                                       of an unnatural azidosugar using α-                 
                                                                                       1,2 mannosyltransferase. We have   
                                                                                       synthesised GDP-azidosugars [119],  
                                                                                       and these will be used to transfer  
                                                                                       the azido sugar to the trimmed   
                                                                                       glycoprotein. 
 
                                                                         Step        Next the azide functionality of the  
                                                                                       transferred azidosugar will undergo  
                                                                                       click chemistry with a synthetic  
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                                                                                       propargyl glycoside of N- 
                                                                                       acetyllactosamine.  
 
                                                                         Step        Enzymatic transfer of sialic acid will  
                                                                                       finally complete the remodelling of  
                                                                                       the glycoprotein. 
 
 
                                                                               
 
                    
 
 
 
 
 
The resulting engineered glycoprotein containing a triazole linked N-acetyllactosamine and 
sialic acid may mimic human type glycosylation and therefore be less immunogenic to 
humans. The trimming of yeast glycans and the specific transfer of sugars will produce a 
homogeneous modified glycoprotein. 
 
Towards this aim a range of GDP-azidomannoses have been synthesised in our group 
where the key phosphate coupling of GTP to azidomannose-1-phosphate was performed 
enzymatically with GDP-mannose-pyrophosphorylase (Figure 1.20) [119]. The use of these 
GDP-azidomannose derivatives to transfer an azidomannose onto a yeast expressed and 
trimmed glycoprotein will be the basis of our remodelling technique. 
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Figure 1.20 Chemoenzymatic strategy 
of glycoprotein remodelling.                                 
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Figure 1.21 Synthesis of GDP-azidomannose. (The figure shows the synthesis of 6-
azidomannose but 2, 3, 4, and 6-azidomannose have been synthesised within our group). 
 
Aim 3: The third method involved chemically synthesising peptides using azidohomoalanine 
(Aha). Click chemistry with synthetic propargyl glycosides would allow further modification to 
the homogeneous glycopeptide analogues, which were tested for their compatibility with 
native chemical ligation. 
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                                         Chapter 2  
The synthesis of propargylic glycoside tools for protein 
remodelling 
 
To test our glycoprotein remodelling strategies we need to synthesise tools that would allow 
the introduction of sugars to our modified glycoprotein. The synthesis of propargylic 
glycosides such as propargyl N-acetyl-D-Iactosamine, propargyl mannose and propargyl N-
acetyl-D-glucosamine will provide useful tools for incorporation into the azide modified 
glycoproteins. As discussed in chapter one, click chemistry will be the method used to 
introduce the propargylic glycosides to the azide bearing glycopeptides. 
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Figure 2.0 The propargylic glycosides which will be synthesised in this chapter. 
 
2.1 Results 
 
2.2 The synthesis of propargyl N-acetyl-D-Iactosamine 
  
The synthesis of propargyl N-acetyl-D-Iactosamine has been demonstrated using ytterbium 
trifluoromethanesulfonate to introduce the propargyl group to a fully acetylated N-acetyl 
glucosamine [1] in the first instance.  A round of deprotection and selective protection of the 
6-hydroxy to form a glycosyl acceptor. Trichloroacetimidate activated galactose is used to 
form the glycosidic bond with the acceptor.  
 
We will explore this chemistry further by attempting to synthesise this disaccharide from 
simple starting materials. Commercially available glucosamine hydrochloride and galactose 
will be initially used. The propargyl group will be introduced at the end of the synthesis. The 
retro-synthesis of propargyl LacNAc that we will undertake is illustrated in Figure 2.1. 
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Figure 2.1 Proposed retro-synthesis of Propargyl LacNAc. 
 
Glucosamine hydrochloride 69 (Figure 2.2) was converted to the free base with sodium 
methoxide in methanol and protected with phthalic anhydride. Apart from neighbouring group 
participation, the phthalimide at C-2 can also facilitate selective glycosylation of the hydroxyl 
at C-4 rather than hydroxyl at C-3, by sterically hindering the hydroxyl at C-3. The hydroxyl 
groups of the phthalimide protected sugar were acetylated to produce the fully protected 
glycoside 71 (Figure 2.2). It is important to note that before acetylating the product, the 
partially protected phthalimide sugar should be completely dried under high vacuum to 
obtain higher yields of 71. Next the activation of the anomeric position with tin tetrachloride 
and treatment with thiophenol resulted in yields of up to 79% of the thiophenyl glycoside 72. 
Deprotection of the acetates and selective protection of the less hindered primary hydroxyl 
group at position 6, with the bulky silylating reagent TBDPSCI, gave the partially protected 
thiophenyl glycoside acceptor 68.  
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Figure 2.2 Synthetic route for the thiophenyl glycoside acceptor 68 [2]. 
 
The synthesis of the trichloroacetimidate donor was achieved from galactose 69, which was 
fully acetylated with acetic anhydride and perchloric acid to give a good yield (98%) of the 
peracetylated galactose 73 (Figure 2.12). This was then treated with benzylamine at 50 oC, 
to selectively deprotect the anomeric position to give the hemi- acetal 74 in 82% yield.  
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Figure 2.3 Synthetic route for the trichloroacetimidate donor 67 [3]. 
 
Next the anomeric trichloroacetimidate was produced by treatment of the hemi-acetal 74 
with trichloroacetonitrile and diaza(1, 3) bicyclo[5.4.0]undecane (DBU). It is important to note 
that depending on the type of base used either the α- or β trichloroacetimidate may be 
obtained. With a weak base such as potassium carbonate, mutarotation occurs faster than 
the nucleophilic attack onto trichloroacetonitrile by the anomeric hydroxyl, and so the β 
product is predominantly formed. However for our chemistry we used the strong base DBU, 
which quantitatively deprotonates the anomeric OH and the rate of nucleophlic attack is 
faster than the rate of mutarotation. This means the thermodynamically more stable α-
isomer 67 is formed (Figure  2.4).  
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Figure 2.4 Thermodynamically and kinetically controlled stereochemistry of 
trichloroacetimidates [4]. 
 
Next, the glycosidic linkage was formed with the activation of the trichloroacetimidate with  
TMS-OTf via neighbouring group participation (Figure 2.5). The SN1 type mechanism 
selectively forms a β- 1-4 linkage, where the 4-hydroxyl group is the favoured nucleophile. 
The reason for this is predominately due to the presence of the bulky phthalimide which 
sterically hinders the 3-hydroxyl group. This would favour the β-linkage with the more 
accessible 4-hydroxyl group. This type of regioselectivity has been shown to be used in 
different glycosyl donors such as thioglycosides for the synthesis of sialyl-Lewisx [5]. The 
protected thiophenyl disaccharide 66 was obtained in 84% yield. A series of selective 
deprotections with TBAF to remove the TBDPS protecting group, and ethylenediamine to 
remove the phthalimide produced the fully unprotected disaccharide which was acetylated 
with pyridine and acetic anhydride to give 75. The final step of this synthesis was to install 
the propargyl group. This was investigated with the use of propargyl alcohol and the 
thiophenyl glycoside 75 in the presence of a soft electrophile. Initially N-iodosuccinimide 
(NIS) was used with catalytic TfOH. The activation of the anomeric sulphide to form a 
sulphonium leaving group which then undergoes a SN1 type of pathway with neighbouring 
group participation was envisaged to afford the desired β-propargyl glycoside. However this 
final step was problematic since a mixture of starting thiophenyl glycoside and its hemi-
acetal 76 was mainly obtained. Mass Spectrometry analysis indicated that there were peaks 
representing the formation of oxazolines 77. 
β – trichloroacetimidate 
kinetically controlled 
α – trichloroacetimidate 
thermodynamically 
controlled 
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Figure 2.5 Towards the synthesis of propargyl LacNAc. 
 
Alternative soft electrophiles such as N-bromosuccinimide (NBS) and iodonium dicollidine 
perchlorate (IDCP) were investigated, both being unsuccessful. With unsuccessful 
introduction of the propargyl group we decided to convert the thiophenyl glycoside into the 
hemi-acetal 76 and then to the trichloroacetimidate. The hemi-acetal was formed in poor 
yield so this route was not feasible. Losing material during the later stages of the synthesis 
was very inefficient and time consuming. An alternative route to introduce the propargyl 
group before the glycosidic linkage was undertaken. Starting with the thio-glycoside 68, the 
3- and 4-hydroxyl groups were acetylated with acetic anhydride and pyridine to give the fully 
protected glycoside 79 (Figure 2.15). This was then treated with NBS and water in acetone 
to form the hemi-acetal 80. Furthermore the reaction with potassium carbonate and 
trichloroacetonitrile formed the kinetically controlled β-trichloroacetimidate 81. Next the 
propargyl group was introduced with the lewis acid; boron trifluoride diethyl etherate and 
propargyl alcohol. With the presence of neighbouring group participation an SN1 type 
mechanism operates to yield the propargyl sugar 82. Sodium methoxide and methanol was 
used to deprotect the 3- and 4-hydroxyl groups and to produce the new glycosyl acceptor 83 
(Figure 2.6).  
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Figure 2.6 Synthesis of building block 83. 
 
This same glycosyl acceptor was more simply produced from the fully protected glycoside 
71, directly installing the propargyl group with boron trifluoride diethyl etherate (Figure 2.7). 
This reaction was difficult to monitor by thin layer chromatography (TLC), as the Rf values 
were identical in all the solvent systems tested. Therefore the reaction was monitored by LC-
MS. The crude product was directly deprotected with sodium methoxide, then selective 
protection of the 6-hydroxy group with TBDPSCI to produce the glycosyl acceptor 83 (Figure 
2.7). 
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Figure 2.7 Improved synthesis of acceptor 83. 
 
The donor 67 was then used to selectively form the β-1,4 glycosidic linkage with acceptor 
83. The resulting fully protected propargyl N-acetyllactosamine 84 was deprotected with 
TBAF and ethylenediamine, and then acetylated to produce the fully acetylated propargyl N-
acetyllactosamine 85 (Figure 2.8).  
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Figure 2.8 The synthesis of peracetyl-propargyl LacNAc 85. 
 
The product was confirmed by NMR and LC-MS, which gave a single peak with the mass of 
the desired product (Figure 2.9). Note that the end product is fully acetylated; this is 
common throughout the synthesis, and allows simple handling and purification of 
intermediates and products. Zѐmplen deacetylation in sodium methoxide in methanol can 
conveniently free the hydroxyl groups. 
 
 
Figure 2.9 LC-MS trace of peracetyl-propargyl N-acetyl-lactosamine 85. 
 
 
2.3 The synthesis of propargyl N-acetyl-D-glucosamine 
 
Propargyl N-acetyl-D-glucosamine (propargyl GlcNAc) was produced by starting with fully 
protected glycoside 71, and directly installing the propargyl group with boron trifluoride 
diethyl etherate. The crude β-propargyl glycoside was deprotected with ethylenediamine and 
85 
59 
 
re-protected with acetic anhydride and pyridine to produce the desired propargyl 
peracetylated N-Acetyl-D-glucosamine 86 (Figure 2.10).  
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Figure 2.10 Synthesis of propargyl GlcNAc [2,4]. 
 
2.4 The synthesis of propargyl mannose 
 
The synthesis of propargyl mannose was achieved by starting with α-D-mannose, the sugar 
was fully acetylated and then selectively deprotected at the anomeric position with benzyl 
amine. The resulting hemi-acetal 88 was activated to the trichloroacetimidate 89 which 
underwent glycosidation with neighbouring group participation, to yield fully protected α-
propargyl mannose 90 (Figure 2.11). 
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Figure 2.11 Synthesis of propargyl mannose. 
 
 
2.5 Conclusion 
 
The synthesis of three sugars; propargyl N-acetyl-D-Iactosamine, propargyl N-acetyl-D-
glucosamine and propargyl α-D-mannoside was completed. We have synthesised fully 
acetylated propargyl LacNAc by two different routes, both routes producing the novel 
glycosidic acceptor 83. The route starting with the fully protected glycoside 71, and directly 
installing the propargyl group, is by far the best route as it requires fewer synthetic steps. 
Trying to install the propargyl group on to the thiophenyl disaccharide became problematic 
due to the formation of the hemi-acetal and oxazolines. Propargyl N-acetyl-D-glucosamine 
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has been synthesised from glucosamine hydrochloride and propargyl mannose from α-D-
mannose, both from readily available starting materials. These propargyl sugar derivatives 
will provide useful tools to incorporate into the azido-modified glycoproteins. 
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                                     Chapter 3 
 
The synthesis and metabolic incorporation of unnatural sugars into 
proteins 
 
With the synthesis of propargyl glycosides established, the next step was to incorporate the 
azide functionality into our glycoprotein so that we could perform click chemistry with the 
propargylic glycosides. There were three methods investigated when incorporating the azide 
functionality into our glycoprotein. This chapter will focus on the in vivo metabolic 
incorporation, where azidosugars will be incorporated during expression of our glycoprotein 
in yeast.  
 
Incorporating chemical handles in biological systems allows scientists to monitor and reveal 
novel biological functions. In particular, metabolic labelling of glycans enables their 
visualisation in cells and organisms as well as the enrichment of specific glycoprotein types 
for proteomic analysis [1]. However, it is important that the metabolic label does not interfere 
with or terminate the biological process that is being monitored. Azides and alkynes are 
good candidates for metabolic labelling, in that they are inert to biological modification but 
react specifically in chemical reactions with each other allowing them to be detected [2]. The 
detection of azides can be achieved by click chemistry (discussed in chapter 1) or by 
Staudinger ligation. 
 
3.1 The Staudinger ligation 
 
The Staudinger ligation (sometimes called the Bertozzi-Staudinger ligation) is an adaptation 
of the original Staudinger reaction discovered in 1919 by Staudinger and Meyer, who 
reported the formation of iminophosphoranes from azides and triaryl phosphines [3]. The 
reaction is conducted under mild conditions and is often quantitative. First, the phosphorus is 
believed to attack the azide to give a phosphazide; then, an intramolecular rearrangement 
via a four-membered ring transition state, yields an aza-ylide, with loss of nitrogen (Figure 
3.0). The iminophosphorane obtained offers a wide variety of uses in organic synthesis: not 
only can the highly nucleophilic nitrogen potentially react with a range of electrophiles, but 
also it is an amine precursor [3].  
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Figure 3.0 Mechanism of the Staudinger reaction [3]. 
 
In 2000, Saxon and Bertozzi [4] designed a variant of the original reaction (Figure 3.1). 
When an electrophillic trap, which is an ester, is introduced ortho to the phosphine, the aza-
ylide intermediate is captured by intramolecular cyclisation [5]. This process ultimately 
produces a stable amide bond. Furthermore if the phosphine is directly attached to a 
biological probe, then detection of azides by Staudinger ligation can be monitored via the 
probe.  
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Figure 3.1 Mechanism of the Bertozzi-Staudinger ligation [4 ,5]. 
 
One useful probe is the FLAG (Figure 3.2) which is selectively recognised by a specific 
antibody (α-FLAG) conjugated to horseradish peroxidase (HRP). The subsequent addition of 
the peroxidase substrate, together with a dye/chemoluminescent precursor, leads to a colour 
precipitate/light emission that serves for detection. 
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Figure 3.2 FLAG peptide phosphine probe [4,5]. 
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Another probe which can be useful is a biotin tag. Biotinylation of a Staudinger probe will 
allow detection of the biotin with anti-biotin antibodies or avidin/streptavidin tagged detectors 
like HRP or fluorescent dyes. Protein biotinylation can be via amine, thiol or aldehyde groups 
with sulfo-NHS biotin, EZ-Link biotin-HPDP (N-(6-(Biotinamido)hexyl)-3'-(2'-pyridyldithio)-
propionamide and biotin hydrazide repectively (Figure 3.3). 
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Figure 3.3 Biotin structures [5]. 
 
3.2 Metabolic labelling of glycans 
 
 
Figure 3.4 Different methods for labelling glycans in mammalian cells. Both methods begin 
with incubation of mammalian cells with azido sugar. These are hydrolysed and incorporated 
into the glycoprotein where different modes of detection are used. Mode one uses 
Staudinger ligation while mode two uses click chemistry. 
 
Bertozzi and co-workers first devised a method that involves metabolic labelling of glycans 
with a monosaccharide precursor that is functionalised with an azide group (Figure 3.4) [1]. 
Bertozzi synthesised five azido sugars, respectively; N-azidoacetylgalactosamine (GalNAz), 
N-azidoacetyl sialic acid (SiaNAz), N-azidoacetylmannosamine (ManNAz), N-
azidoacetylglucosamine (GlcNAz) and 6-azido fucose (6AzFuc). These sugar derivatives 
were incubated with mammalian cells and installed within cellular glycans by the biosynthetic 
machinery. With the successful incorporation of these azidosugars, they were poised to 
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react selectively with functionalised probes. Bertozzi showed that Staudinger ligation with 
phosphine-FLAG or phosphine-FLAG-His6 probe were successful for the identification of the 
incorporated azidosugars. Furthermore the Staudinger ligation was believed to be a better 
option for in vivo glycan labelling as it avoided the cytotoxcity of copper, which is associated 
with click chemistry. The result indicated that metabolic labelling is highly dependent on the 
cell type used. For instance, COS-7 [CV-1 (simian) in Origin, and carrying the SV40 genetic 
material] cells treated with SiaNAz and Ac4ManNAz constituted 5% of the total sialic acid. 
However, the same treatment in Jurkat and CHO cells, showed 20-40% of the total sialylic 
acid content labelled with SiaNAz and Ac4ManNAz [1]. 
 
As mentioned copper mediated click chemistry requires a toxic heavy metal catalyst, while 
the Staudinger ligation is limited by relatively slow kinetics but difluorinated cyclooctyne 
(DIFO) for ring strain-promoted cycloaddition, may overcome these problems. The rapid 
kinetics of DIFO to react with azides is demonstrated with the monitoring of cellular 
glycosylation of zebrafish embryos [7]. It has been found that the ring-strain promoted 1,3-
dipolar cycloaddition of (DIFO) with azides (Figure 3.5)  is a useful alternative to the 
Staudinger ligation [6]. 
F
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Figure 3.5 Ring-strain promoted 1,3-dipolar cycloaddition of difluorinated cyclooctyne with 
azide[6]. 
 
Wong and co-workers [7] used a slightly different approach to incorporate sugars in which 
alkynyl sugar analogues were used to label and visualise glycoconjugates in cancer cell 
lines. Alkynyl fucose and N-acetylmannosamine derivatives were synthesised and 
incorporated into fucosylated and sialylated glycans in several cancer cell lines [7]. 
Visualisation of the cell surface, intracellular and individual glycoproteins was achieved, with 
a biotin/fluroescein-conjugated streptavidin probe and on the cell surface with 3-azido-7-
hydoxycoumarin probe (Figure 3.6). 
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Figure 3.6 Alkynl sugar derivatives and their visualisation tools [7]. 
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We have seen a few examples where azides are used in biological systems for labelling and 
tagging. Such systems can be used to monitor in vivo animal modelling and allow potential 
methodology of glycan remodelling [8,7]. For our project azidosugars will be fed to Pichia 
pastoris at the same time as EPO expression is induced in the hope that the azido sugars 
will be incorporated into the expressed glycoprotein. 
 
3.3 Results  
 
3.4 The use of unnatural sugars and feeding experiments  
 
Prior to the metabolic incorporation of azidosugars, the synthesis of azidomannose must first 
be investigated. The synthesis of 6-azidomannose and 4-azidomannose will be performed 
and these sugars will be incubated with yeast expressing EPO. If the azidosugars have been 
incorporated then they will be detected with Staudinger ligation with a FLAG phosphine 
probe and itself be detected with anti-FLAG alkaline phosphatase and phosphatase 
substrate blue. If successful, the incorporated azido sugars can be used for further 
glycoprotein remodelling by click chemistry with synthetic propargyl glycosides following 
glycoprotein isolation. 
 
Introducing azido sugars into yeast glycans by feeding azidosugars to yeast expressing EPO 
will not allow complete control in which the azido sugars will be incorporated. The position 
and the type of glycosidic linkage that the azido sugars may form will be dependent on the 
glycoprotein biosynthesis. This may result in different glycosylation patterns and different 
glycan structure. Therefore if the unnatural sugars are incorporated, then the glycoprotein 
mass should be different to the wild type glycoprotein. Also the metabolic incorporation of 
unnatural sugars will not control the homogeneity of the expressed glycoprotein but will be a 
good starting point to see if these azido sugars can be tolerated by the natural cell 
machinery. 
 
In addition to synthesising 6- and 4-azidomannose, the synthesis of 6- and 4- thio mannose 
will also be undertaken. The thio sugars will also be incorporated into yeast expressed EPO 
and the glycosylation patterns will be examined. It is important to note that the Staudinger 
ligations cannot be performed on the thioacetate derivatives and we will only examine the 
glycosylation patterns by Western blot. If the thio sugars are incorporated it will potentially 
demonstrate another route to for glycoprotein remodelling using N-(propargyl)-
bromoacetamide and azido sugars (Figure 3.7).  
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Figure 3.7 The metabolic incorporation of the thiosugars will allow potential glycan 
remodelling with N-(propargyl)-bromoacetamide and azidosugars. 
 
All the unnatural sugar analogues will be synthesised in the fully acetylated form, as this 
modification is known to increase their cellular uptake [1, 3]. It is envisaged, that the acetate 
esters are subsequently hydrolysed in the cytosol to give the free hydroxyl sugars and the 
free thiol [1]. 
 
3.5 Synthesis of peracetyl-6-azidomannose 122. 
 
The preparation of the first azidosugar bearing an azide group at C-6 was based on the 
protocol described by Bertozzi [3]. Initially, p-toluenesulphonyl chloride selectively reacted 
with the primary alcohol function of α-methyl-D-mannopyranoside to yield 120 (Figure 3.8). 
Next 120 was treated with sodium azide in DMF, in order to substitute the tosyl group at 
carbon 6 leading to the formation of the azide 121. The remaining hydroxyl groups were then 
protected as acetate esters by a mixture of acetic anhydride and acetic acid in the presence 
of sulphuric acid as a catalyst. In the same reaction, an acetate group substituted the methyl 
glycoside at the anomeric position. The fully acetylated 6-azido-6-deoxy-α-D-
mannopyranose 122 was obtained in 72% yield over the two steps. 
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Figure 3.8 Synthesis of peracetyl-6-azidomannose [3]. 
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Fully acetylated 6-thioacetate-6-deoxy-α-D-mannopyranose (124) was produced in a similar 
manner to that of the azide derivative. Although thio-glycosides are commonly used to 
activate the anomeric position in carbohydrate chemistry, there is little research on the 
replacement of hydroxyl groups by thioacetates, primarily due to thioacetates being very 
reactive electrophiles [9]. However, in the published synthesis of 3- and 4-thio analogues of 
4-nitrophenyl 2-acetamido-2-deoxy-β-D-gluco- and galactopyranosides [10], thioacetates 
where used. The key step involved activation of the 4-hydroxyl with a triflate and 
displacement using potassium thioacetate. We will adopt this approach to install the 
thioaceate to the mannose derivatives. To introduce the thioacetate the aprotic solvent 
hexamethylphosphoramide (HMPA) was used. After successful introduction of the 
thioacetate at C-6, treatment with acetic anhydride and acetic acid in the presence of 
sulphuric acid produced the fully acetylated 6-thioacetate mannose 124 (Figure 3.9). 
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Figure 3.9 Synthesis of peracetyl-6-thioacetate-mannose. 
 
 
3.6 Synthesis of peracetyl-4-azidomannose 32. 
The synthesis of peracetylated 4-azidomannose was achieved from the cheap and readily 
available methyl-α-mannoside in seven steps (Figure 3.10): mannose was firstly protected 
by standard procedures to 125, leaving access to the hydroxyl at carbon-4; PCC oxidation, 
followed by stereoselective NaBH4 reduction inverted the configuration at C-4 to 126 in 90% 
yield. Triflation and substitution with sodium azide gave access to the fully protected 4-azido-
4-deoxymannose 127. Finally, subsequent stepwise deprotection and acetyl protection led to 
the desired azido monosaccharide 128 in 76% yield (Figure 3.10). 
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Figure  3.10 Synthetic route to peracetyl-4-azidomannose [11]. 
When we tried to reproduce the published method [11], we were pleased by the simplicity of 
the reaction procedures which indeed, when dry conditions were maintained, could be nicely 
followed by TLC to nearly quantitative yield in most cases. The only relatively low yielding 
step (for which Davis reported 64% yield), was the nucleophilic substitution by sodium azide. 
This was improved to 80% yield over two steps. Furthermore, we found that the deprotection 
steps with TBAF and 1,4-dioxane and subsequent protection with acetic anhydride and 
concentrated H2SO4 can all be performed without purification. This vastly improved the 
overall yield of the desired peracetylated 4-azidomannose. With the synthesis of the 
peracetylated 4-azidomannose completed, we repeated the same route for the synthesis of 
the thioacetate derivative. However, introducing the thioacetate at carbon-4 was problematic. 
Initially trying HMPA as the solvent and then changing to DMF both was unsucessful, as 
there was no sign of the desired product. 
With the synthesis of 4-, 6- azidomannose, and 6-thioacetate-mannose completed, we 
decided to perform the feeding experiments to see if any of these sugars would be 
incorporated into Pichia expressed EPO. 
3.7 Feeding experiments on Pichia expressed EPO. 
Wild type Pichia pastoris yeast was genetically engineered to express and secrete human 
erythropoietin following addition of methanol to the culture medium (Pichia expressing strain 
donated by Dr Jonathan Richardson). After inducing EPO expression, cultures were 
supplemented with either 4- or 6-azidomannose or 6-thioacetate-mannnose and further 
incubated to allow uptake and assimilation of unnatural sugars. After 48 hours, yeast were 
removed from the growth medium by centrifugation. The growth medium was then 
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Key: 
M: Pre –stained molecular weight markers 
1: Empty vector (-ve control) 
2: Picha induced with methanol 
3: Picha + 4-azidomannose (50 mM) 
4: Picha + 4-azidomannose (100 mM) 
5: Picha + 6-azidomannose (50 mM) 
6: Picha + 6-azidomannose (100 mM) 
7: Picha + 6-thioacetate-mannose (50 mM) 
8: Picha + 6-thioacetate-mannose (100 mM) 
 
 
 
 
 
concentrated and analysed by Westen blot using Anti-EPO monoclonal antibodies (Figure 
3.11). The results indicated that the presence of the azido- and thioacetate-sugars does not 
prevent EPO from being expressed or secreted. However, it appears that none of the 
unnatural sugars were been incorporated into the glycosylation that adorns the secreted 
EPO molecule. This was initially evident as there were no gross alterations in the banding 
pattern when compared with the cells cultured in the absence of the unnatural sugar. One 
reason why this may be that only a single unnatural sugar may had been incorporated and 
the sugar chain extended. Then perhaps Western blotting alone would not reveal the 
presence of a single azido group. If an azido group had been incorporated it could be 
detected by using the Staudinger ligation with a FLAG phosphine probe. 
 
 
 
 
 
 
Figure 3.11 Westen blot of EPO-expressing Pichia in the presence of different 
concentrations of unnatural sugars. 
 
The Staudinger ligation was performed on the secreted EPO samples that were incubated 
with 4- and 6-azidomannose. The membrane was probed with 250 mM FLAG-phosphine in 
phosphate buffered saline (PBS) for 3 hours and then with anti-FLAG alkaline phosphatase 
conjugate, alkaline phosphatase and phosphatase substrate blue (Figure 3.12). 
There was no signal from the Staudinger reaction product indicating that none of the azido 
sugars were incorporated. Further work will need to be carried out by repeating the feeding 
assays, together with a control for the antibody specificity. However, these preliminary 
results suggest that the transfer of these azidomannose derivatives were unsuccessful.    
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Figure 3.12 Western blot of expressed EPO in the presence of azidomannose. To examine 
the incorporation of azidosugars the membrane was treated with FLAG-phosphine, anti-
FLAG, alkaline phosphatase and phosphatase substrate blue. 
3.8 Conclusion. 
One explanation why the azidosugars may have not been incorporated into the expressed 
protein might be the position of the modification. Directly replacing a hydroxyl group with a 
chemical precursor such as an azide or thioacetate on a sugar, then feeding to yeast cells 
has not to date been investigated. In fact as we have seen, analogues like ManNAz, where 
the azide functionality is not directly replacing a hydroxyl group, are the only existing 
molecules that have been successfully incorporated metabolically. Ultimately the presence 
of free hydroxyl groups in mannose might be important for hydrogen bonding with the active 
site of the mannosyltransferase enzyme. Directly replacing the hydroxyl with an azide may 
prevent these intermolecular interactions from occurring and hence disable azidomannose 
transfer. Furthermore the unnatural mannose may not be able to compete with endogenous 
mannose production therefore in vitro methods will need to be investigated. 
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                                            Chapter 4 
Enzymatic assays to test the transfer of mannose and 
azidomannose 
 
With the unsuccessful incorporation of azidosugars by in vivo metabolic pathway, we next 
examined in vitro test conditions. The transfer of azidomannose from GDP-azidomannose to 
different acceptor substrates was investigated. This involved some proof of principle 
experiments, initially we sought to optimise the transfer of mannose from GDP-mannose to 
different substrates. Then we changed the donor to GDP-azidomannose and examined the 
transfer of azidomannose to the substrates. The synthesis of GDP-azidomannose analogues 
has already been established in our group [1]. However, the transfer of the azidomannose 
has not been investigated in detail. We will explore this further by trying to quantify the 
amount of α-1,2 mannosyltransferase required and develop a method for isolating the 
products. 
 
4.1 α-1,2-mannosyltransferase 
 
The commercial availability of mannosyltransferases (ManTs) is very limiting. Although there 
are many different types of ManTs, only one member of the family is commercially available 
this is the soluble fragment of Kre2p/Mnt1p, an α-1,2 mannosyltransferase from yeast S. 
cerevisiae. Wong and co-workers have shown that the use of the plasmid pManFLAG20 for 
protein expression in E. coli, will encode for the soluble fragment (amino acid 31-442) of 
Kre2p/Mnt1p α-1,2-mannosyltransferase [2, 3]. The pManFLAG expression vector has two 
N-terminal tags, an OmpA (outer membrane protein A) tag which is a peptide that directs the 
recombinant peptide to the periplasmic space. This is beneficial for purification, as very few 
proteins are present in this cellular compartment. The other tag is the immunogenic FLAG 
peptide which can be used for identification and purification of the recombinant protein. The 
soluble fragment 31-442 of Kre2p/Mnt1p pManFLAG20, shows catalytic activity, but does 
not encode for the full enzyme leaving out its transmembrane domain. Kre2p/Mnt1p is found 
in the golgi of S. cerevisiae, where it is used to sequentially add mannose units to the 
growing oligosaccharide chain. The natural substrates for Kre2p/Mnt1p have been 
unambiguously defined, as in vivo studies show that it is responsible for the addition of 
mannose to serine or thereonine-linked mannobiose units [3], while in vitro examples show 
that the N-linked glycans (Man15-30-GlcNAc) are natural substrates. Another example 
indicates P. pastoris expressed α-1,2,-ManT fragment, can transfer mannose from GDP-
mannose to a variety of substrates including methyl-α-1,2-mannobiose and methyl-α-1,-
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mannoside [4]. Wong and co-workers showed that the fragment Kre2p/Mnt1p expressed in E. 
coli was able to transfer mannose to a peptide linked mannose substrate but para-nitro 
phenyl substrate showed no relative activity (Figure 4.0)  
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Figure 4.0 Unnatural acceptors tested on the soluble fragment of Kre2p/Mnt1p expressed in 
E. coli and the relative activities are indicated in brackets [3, 5]. 
4.2 The crystal structure of α- 1,2-mannosyltransferase (Kre2p/Mnt1p) 
The crystal structure of Kre2p/Mnt1p is shown bellow (Figure 4.1). Its structure has two 
protein domains, each with an N-linked glycan attached. There are three disulphide bonds, a 
mixture of α/β folds, one Rossmann fold which is common to class-A glucosyltransferases. 
The cofactor magnesium is coordinated by a modified DXD motif and molecular modelling 
studies of glycosyltransferases suggest that the mannose donor is within distance for Van 
der Waals interactions with Ala 362, Trp 325, Met  223, and Cys 224. Hydrogen bonding is 
suggested with the oxygen of at Ser 326,  while the side-chain amine of Arg 245,  the 
carboxylic oxygen of Asp 361 nitrogen of Asn 327, all form a binding pocket in the active site 
of the enzyme. However it is only the Asp 361 which has been shown critical for activity by 
mutagensis [6]. There is little known about the interactions between the mannose donor and 
the enzyme.  
                                                     
 
 
 
Figure 4.1 Crystal structure of Kre2p/Mnt1p, displaying magnesium, and GDP-mannose in 
the catalytic site (PDB codes 1S4N, 1S4O, 1S4P) [6]. 
4.3 Modified nucleotide-sugars as glycosyl donors  
Modification of nucleotide-sugars are less commonly studied compared to the acceptor 
molecules. There is an instance where two thiopyranoside analogues of GDP-sugars were 
GDP-Mannose
Mg2+ 
129 130 
131 
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synthesised and tested for transfer [7]. The synthetic route to GDP-5-thio-D-mannose and 
GDP-5-thio-L-fucose included the phosphorylation of tetra-O-acetyl-5-thio-D-mannosyl 
bromide and tri-O-benzoyl-L-fucosyl bromide with silver dibenzyl phosphate. Then 
deprotection of the phosphate groups, and condensation of the deprotected phosphates with 
GMP-imidazolidate in the presence of MgCl2. These GDP-sugar analogues were found to be 
donor substrates for α-1,2-mannosyltransferase and α-1,3-fucosyltransferase, affording a 5-
thiomannose containing disaccharide (Figure 4.2) and a 5-thiofucose-containing 
trisaccharide [7]. 
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Figure 4.2 Unnatural GDP-5-S-mannose as a glycosyl donor [7]. 
The reaction of the tetramethylrhodamine (TMR)-labelled glycosyl acceptor was analysed by 
capillary electrophoresis and MALDI-TOF MS to reveal the corresponding product of the 
enzymatic 5-S-saccharide transfer [7]. The conditions for the transfer were not especially 
practical since the reactions were left for 44 days and high quantities of enzyme (280 mU) 
were used. This raises questions as to the efficiency and cost effectiveness of the reaction 
and furthermore illustrates the difficulty of trying to transfer unnatural sugars onto glycosyl 
acceptors. 
4.4 Results 
4.5 Initial transfer assays and testing 
GDP-mannose was initially used as a positive control for the transfer of mannose unit to its 
known acceptor; methyl-α-D-mannoside. The conditions employed were those developed by 
our group previously (S. Marchesan personal communication). However, the only difference 
was that the α-1,2-mannosyltransferase was expressed and purified previously whereas this 
study used the commercially available enzyme. Using the commercial enzyme would allow 
quantification (in millunits) of how much enzyme was added in each reaction. The assay 
consisted of ammonium formate buffer (50 mM) at pH 7.5, manganese chloride (10 mM), 
GDP-mannose (1 mM), methyl-α-D-mannoside (OMe) (10 mM) and various quantities of α-
1,2-mannosyltransferase (ManT). The assays were conducted for 24 hours at 30 oC, and 
then analysed by mass spectrometry. Unfortunately, there was no sign of the desired 
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product by ESI-MS, only that of the starting materials were shown. Changing the ratio of 
GDP-mannose and methyl-α-D-mannoside from 1:1 and 2:1, still indicated no formation of 
products (Table 1). 
 
Entry [GDP-man]/mM [Manα-OMe] /mM ManT/mU % Yield  
1 1 10 5 0 
2 1 10 10 0 
3 1 1 10 0 
4 2 1 10 0 
Table 1 Transfer assay of mannose from GDP-mannose to methyl-α-D-mannoside. All 
reactions conducted in ammonium formate buffer (50 mM) at pH 7.5, with MnCl2 (10 mM). 
Further literature searching revealed procedures where Triton X-100 had been added to 
assays as a source of detergent. Given these findings the assay was repeated in the 
presence of 0.1% v/v Triton X-100. A mini-extraction in an eppendorf tube was performed, 
with water and ethyl acetate to remove the Triton X-100. The extraction procedure was 
required otherwise Triton X-100 dominates the MS analysis. However, small peaks of the 
desired product were now visible. In attempting to further optimise this assay we next 
investigated different buffers, and the results showed that both ammonium formate and (4-
(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) buffers yielded encouraging 
results (Table 2). 
 
Entry [GDP-
man]/mM 
[Manα-OMe] /mM ManT/mU Buffer/50 mM pH 7.5 % Yield  
5 10 100 3 Tris buffer 0 
6 10 100 3 Ammonium formate 5 
7 10 100 3 HEPES 2 
8 10 100 3 Ammonium Acetate 0 
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Table 2 Transfer assays in different buffers. All reactions conducted at pH 7.5 with MnCl2 (10 
mM) and Triton X-100 (0.1%). Yields estimated by relative intensity of MS peak. 
Establishing that some transfer of mannose was achieved with these assays, we next 
investigated another substrate. We sought a substrate that with a UV chromophore so the 
reaction could be monitored and the product isolated by HPLC. To this end, benzyl-α-
mannopyranoside (OBn) was used instead of methyl-α-D-mannoside. Repeating the assays 
with the new acceptor in both HEPES and ammonium formate buffers, then extracting with 
DCM prior MS analysis, give no sign of the desired product. Furthermore, increasing the 
amount of enzyme from 3 mU to 18.3 mU showed no improvement in the results (Table 3). 
 
Entry [GDP-
man]/mM 
[Manα-OBn] /mM ManT/mU Buffer/50 mM pH 7.2 % Yield  
6 10 100 3 Ammonium acetate 0 
7 10 100 3 HEPES 0 
8 10 100 3 Ammonium formate 0 
9 10 100 18.3 Ammonium formate 0 
10 10 100 18.3 HEPES 0 
Table 3 Transfer assays with benzyl-α-mannopyranoside as the acceptor. All reactions 
conducted at pH 7.2 with MnCl2 (10 mM) and Triton X-100 (0.1%). 
Extensive literature searches revealed instances where a cocktail of phosphatase inhibitors 
were used to prevent breakdown of GDP-sugars [8]. We first decided to test the addition of 
phosphatase inhibitor (P5726, Sigma) with the methyl-α-D-mannoside substrate as we had 
already observed successful transfer previously. We found that the addition of phosphatase 
inhibitors greatly improved the rate of formation (Table 4) of the disaccharide product as 
observed by MS. While the MS analysis is not quantitative, there was an obvious 
improvement in the ionisation of the desired product. This can be seen by comparing the 
mass spectrum of the assay, with- and without phosphatase inhibitors (Figure 4.3 and 4.4). 
Note that a 10 fold excess of methyl-α-D-mannoside was used so this would be the 
predominant peak. Furthermore, looking at the reaction in ES –ve mode, it was apparent that 
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the GDP-mannose was abundantly present and did not degrade with the addition of 
phosphatase inhibitors. 
 
 
Entry [GDP-man]/mM [Manα-OMe] /mM ManT/mU Phosphatase 
inhibitors (4 µl) 
% Yield  
11 10 100 18.3 - 12 
12 10 100 18.3 + 35 
Table 4 Transfer assay conditions with- and without phosphatase inhibitors with methyl-α-D-
mannoside as the acceptor. All reactions conducted in ammonium formate (50 mM) at pH 
7.2 with MnCl2 (10 mM) and Triton X-100 (0.1%). 
 
Figure 4.3 MS of transfer assay without phosphatase inhibitors after 24 hours. 
 
Figure 4.4 MS of transfer assay with phosphatase inhibitors after 24 hours. 
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Establishing that there was some improvement with the assay we decided to perform the 
assay with benzyl-α-mannopyranoside acceptor (Table 5). Again, a successful transfer was 
observed as the desired product was produced ~15 minutes after addition of the reactants 
(Figure 4.5). 
 
Entry [GDP-man]/mM [Manα-OBn] /mM ManT/mU Phosphatase 
inhibitors (4 µl) 
% Yield  
13 10 100 18.3 + 40 
Table 5 Assay with benzyl-α-mannopyranoside with phosphatase inhibitors. The reaction 
was conducted in ammonium formate (50 mM) at pH 7.2 with MnCl2 (10 mM) and Triton X-
100 (0.1%). 
             
Figure 4.5 MS of the transfer of mannose from GDP-mannose to benzyl-α- 
mannopyranoside ~15 minutes after the addition of the reactant. 
Having demonstrated a successful transfer of mannose to benzyl-α-mannopyranoside the 
next step was to isolate the product in good yield for structural analysis. We increased the 
amount of donor; GDP-mannose and the acceptor; benzyl-α-mannopyranoside by 10 fold. 
The enzyme α-1,2-mannosyltransferase was increased by 5-fold and the reaction left to 
proceed for 48 hours at 30 oC, followed by a mini-extraction in an Eppendorf tube, with DCM. 
The aqueous phase was collected and purified by reverse phase HPLC using a C18 column 
at 245nm, 5-95% (water/acetonitrile) for 30 minutes (Figure 4.6). The purified disaccharide 
136 was lyophilised to afford a white foam (95% yield), which could be fully characterised 
using standard techniques such as MS (Figure 4.7), 1H and 13C NMR spectroscopy. 
135 136 
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Figure 4.6 LC trace of the reaction mixture containing the disaccharide 136. 
 
Figure 4.7 MS of the purified disaccharide 136. 
With a quantifiable transfer assay in place, the next step was to test the azido transfer from 
GDP-azidomannose derivatives to the benzyl acceptor. The GDP-azidomannose derivatives 
were donated by the previous student working on this project. We used the same successful 
transfer assay (entry 13) but replaced the GDP-mannose with GDP-azidomannose (Figure 
4.8). 
136
33 
The disaccharide product 136 
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mannopyranoside 
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Figure 4.8 Assay of GDP-4-azidomannose with benzyl mannose acceptor. 
The transfer of azido sugars onto the benzyl substrate was not observed. All four different 
GDP-azidomannose derivatives were tested; GDP 2-azido-, 3-azido-, 4-azido- and 6-
azidomannose. None were successful, and the control of GDP-mannose showed a positive 
result. To further check that the assay was working we added GDP-mannose in the same 
assay that contained GDP-azidomannose and again observed the successful transfer of 
mannose to benzyl mannose. 
These results suggest that the transfer of azidosugars was unsuccessful, although 
intriguingly the transfer of 4-azidomannose on to methyl-α-D-mannoside was observed 
previously (S. Marchesan personal communication). Previously the enzyme α-1,2-
mannosyltransferase was expressed and tested for transfer while our assays used the 
commercially available α-1,2-mannosyltransferase. Perhaps expressing and isolating the α-
1,2-mannosyltransferase may give a better indication whether there is a difference between 
the expressed and commercial enzyme. 
4.6 Expression of soluble Kre2p/Mnt1p in E. coli 
Wong and co-workers reported the successful expression of the recombinant soluble 
Kre2p/Mnt1p in E. coli by induction with low-levels of isopropyl β-D-1-thiogalactopyranoside 
IPTG (5 µM), and use of minimum medium enriched with 2% casaminoacids (M9-CA), at 30 
oC for 12 hours. The enzymatic tests were carried out on a partially purified protein batch, 
obtained after isolation of the periplasmic fraction by osmotic shock [2, 5].  
Soluble Man T was produced previously by our group (S. Marchesan personal 
communication) using a modified version to Wongs original procedure in which glycerol was 
used as a carbon source, and magnesium as a co-factor. Interestingly, and in contrast to the 
findings published by Wong [2, 5], the expressed Man T enzyme was not found in the 
periplasmic space of the cell, but appeared to be located in the cytoplasm.   
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Figure 4.9 Analysis of the periplasmic fraction by SDS PAGE. 
The purified enzyme was observed to transfer mannose from GDP-mannose to benzyl-α-
mannopyranoside. Having thus demonstrated the transfer of the natural sugar mannose 
(from GDP-mannose). The assay was performed with GDP-azidomannose molecules. Under 
all conditions tested the transfer of azido sugars was not observed. In an attempt to 
eliminate any batch specific anomalies associated with our protein preparation, the transfer 
assays were repeated using the commercially available Man T enzyme. An efficient transfer 
of mannose was observed, although definitive evidence for azidomannose transfer remained 
elusive.  
4.7 Conclusion 
The observations made in this study are in contrast to those reported previously (S. 
Marchesan personal communication), in which purified α-1,2-mannosyltransferase was 
observed to catalyse the transfer of 4-azidomannose to methyl-α-D-mannoside 
(demonstrated by MS analysis). One possible explanation for this may lie in the method of 
purification of Man T. We found the enzyme in the periplasmic space which was in contrast 
to the previous study but agreed with Wongs original protocol. This difference in purification 
may be linked to the amount of enzyme used in the transfer assays. Whilst (55 µL, 18.3 mU) 
of commercial enzyme and (55 µL, concentration unknown) of purified enzyme showed the 
transfer of mannose from GDP-mannose to benzyl-α-mannopyranoside in a 95% yield (for 
commercial). No azidomannose transfer was observed using either the commercial or 
purified enzyme. An unspecified amount (107.2 µL, concentration unknown) of enzyme was 
reportedly used in the study previously undertaken. This previous study successfully 
transferred 4-azidomannose and when we repeated the same procedure, albeit with our 
purified enzyme transfer was not observed. 
However, a continued analysis of Man T expression in 
this study demonstrated that Man T was present in the 
periplasmic space which agrees with Wongs original 
method and this was confimed by SDS PAGE analysis 
(Figure 4.9)  
83 
 
Given this observation, it may be reasonable to assume that the amount of enzyme used in 
the previous study may have been in vast excess compared with the amount used here, 
which may serve to explain the azido transfer observed previously or the enzyme used 
previously may have contained other proteins as there was no clear SDS PAGE data 
indicating the purity of the previously expressed enzyme.  
 
 
 
 
 
 
 
References: 
[1] S. Marchesan, D. Macmillan, Chem Commun. 2008, 36, 4321. 
[2] P. Wang, G. J. Shen, Y. F. Wang, Y. Ichikawa, C. H. Wong, J. Org. Chem. 1993, 58, 
3985. 
[3] H. A. D. Boer, L. J. Comstock, M. Vasser, Proceed. Natl. Acad. Sci. USA. 1983, 80, 21. 
[4] P. A. Romero, M. Lussier, A. M. Sdicu, H. Bussey, A. Herscovics, Biochem. J. 1997, 321, 
289. 
[5] G. F. Hermann, P. Wang, G. J. Shen, E. G. Sunceda, S. H. Khan, K. L. Matta, C. H. 
Wong, J. Org. Chem. 1994, 59, 6356. 
[6] Y. D. Lobsanov, P. A. Romero, B. Sleno, B. Yu, P. Yip, A. Herscovics, P. L. Howell,  J. 
Biol. Chem. 2004, 279, 17921. 
[7] O. Tsuruta, H. Yuasa, H. Hashimoto, K. Sujino, A. Otter, H. Li, M. M. Palcic, J. Org. 
Chem. 2003, 68. 6400. 
[8] C. Unverzagt, H. Kunz, J. C. Paulson, J. Am. Chem. Soc. 1990,112, 9309.  
 
 
 
 
 
84 
 
                                         Chapter 5 
Azidohomoalanine for glycoprotein remodelling  
5.1 Synthesis of tools to expand glycoprotein remodelling 
The third method to introduce azide groups to proteins was investigated in this study. This 
method introduced azide groups into fully synthetic peptides using the amino acid 
azidohomoalanine (Aha). Click chemistry with synthetic propargyl glycosides would allow 
further modification to the homogeneous glycopeptide analogues, which were tested for their 
compatibility with native chemical ligation. Although this synthetic method differs from the in 
vitro strategy of using GDP-azidosugars for glycoprotein remodelling, it nevertheless creates 
a homogeneous glycoprotein using click chemistry. 
Apart from incorporation of Aha into peptides we have also performed test reactions with our 
synthetic propargyl sugar analogues. Click chemistry of propargyl LacNAc to an azidosugar 
was performed and the resulting trisaccharide was enzymatically modified with 
sialyltransferase. These series of experiments validates the use of propargyl sugars for 
glycoprotein remodelling technique where chemical clicked sugars bearing a triazole can be 
tolerated enzymatically by sialyltransferase.  
In addition synthesis of potential tools that will help expand the use of our GDP-
azidomannose analogues where investigated in this chapter. The synthesis of Chitobiosyl 
azide would potentially act as a different substrate, for the transfer of azidosugars using the 
alternative enzyme β-1,4-mannosyltransferase. This may give us another route to explore 
our azidosugar transfer. Another tool that we have investigate is a peptide-linked mannose. 
The peptide will include a His6 tag, which will enable easy purification and isolation of the 
transferred azido product. Hopefully, these tools will be useful as intermediate molecules to 
test the transfer of azidosugars and further aid the ongoing research of the use GDP-
azidomannose for glycoprotein remodelling.  
5.2 Azidohomoalanine (Aha) in protein engineering 
The introduction of non-natural amino acids with a chemically unique group has numerous 
applications in protein engineering and functional studies. In 2002, Bertozzi demonstrated 
that a methionine surrogate, azidohomoalanine (Figure 5.0), is activated by the methionyl-
tRNA synthetase of E. coli and replaces methionine in proteins expressed in methionine-
depleted bacterial cultures [1]. Furthermore, proteins containing azidohomoalanine were 
selectively modified in the presence of other cellular proteins by means of Staudinger ligation 
85 
 
with triarylphosphine reagents [1]. In fact, a number of different azide–bearing amino acids 
were incorporated but Aha was by far the most translationally active azide-bearing analogue 
of methionine. The yield of purified Aha-substituted recombinant protein obtained in standard 
protein expression experiments was comparable to yields of wild-type, methionine-
substituted protein [1]. 
H2N
O
OH
N3  
Figure 5.0 Structure of L-azidohomoalanine (Aha)[1]. 
 
We will incorporate Aha into synthetic peptides and perform click chemistry with our 
propargyl glycosides. These synthetic propargyl glycosides will be tested for their 
acceptance of sialylic acid by sialyltransferase.     
5.3 Results 
5.4 Chitobiosyl azide synthesis 
The synthesis of chitobiosyl azide has already been published by Flitsch and co-workers [2]. 
We will replicate its synthesis and use it as a potential tool for our glycoprotein remodeling 
method. The anomeric azide can also be used to attach to a peptide via an N-(propargyl)-
bromoacetamide. This will produce a peptide-linked chitobiose (Figure 5.1).  
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Figure 5.1 The use of chitobiosyl azide as a peptide-linked precursor. The attached peptide 
tool 143 contains a His6 tag which would allow easy purification of the product, after testing 
of the potential azido transfer.   
The chitobiose-linked peptide would be a useful tool to investigate the transfer of our azido 
mannose by the alternative glycosyltransferase enzyme, α-1-4 mannosyltransferase. 
Chitobiosyl azide was synthesised via the glycosidic azide acceptor 149 and the 
trichloroacetimidate donor 151. 
The glycosidic azide acceptor was synthesised in a five-step process where readily available 
N-acetyl glucosamine reacted with acetyl chloride to produce the fully protected glycosyl 
chloride 145 (Figure 5.2). Next, sodium azide and tetrabutylammonium hydrogen sulphate 
(TBAHS) introduced the azide at the anomeric position, in a phase transfer catalysis reaction 
to produce the β-glycosyl azide 146. Hydroxyl deprotection and selective protection of the 
free 4- and 6-hydroxyl with p-anisaldehyde dimethylacetal, produced the p-
methoxybenzylidine protected azido glycoside 147. Further protection of 147 with acetic 
anhydride in pyridine yielded 148. Reductive regeoselective ring opening of 148 with sodium 
cyanoborohydride in the presence of trifluoroacetic acid resulted in the formation of the 
azide acceptor 149 (Figure 5.2).  
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Figure 5.2 Synthesis of the azide acceptor 149 [2]. 
 
The synthesis of glycosyl donor started with glucosamine hydrochloride which was 
converted to the free base with sodium methoxide and then the 2-amino group was 
protected, to produce the phthalimido sugar (Figure 5.3). It was found that drying the N-
phthalimido sugar overnight under high vacuum, before completing the protection with acetic 
anhydride and pyridine, resulted in a greater yield of the acetylated N-phthalimido sugar 71. 
  
Next, the activation of the anomeric position with tin tetrachloride and thiophenol resulted in 
yields of up to 79% of the thiophenyl glycoside 72. Selective deprotection of the anomeric 
position with N-bromosuccinimide (NBS) proved to be difficult. It was found that when 
monitoring the reaction by TLC, deprotection of not only the thioglycoside group, but also the 
acetyl groups, which was evident by the presence of four distinct spots when stained with p-
anisaldehyde dip. 
This could be controlled by recrystallising the NBS from boiling water and carefully 
optimising the reaction times. The optimum time of four hours, allowed a reasonable 
yield of the hemi-acetal product 150 and the starting thio-glycoside could be easily 
recovered by flash chromatography. The glycosyl donor was finally produced as the β-
trichloroacetimidate by reaction with trichloroacetonitrile with 150 in potassium 
carbonate to give 151 (Figure 5.3).  
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Figure 5.3 Synthesis of the trichloroacetimidate donor 151 [2]. 
 
Coupling of the trichloroacetimidate donor 151 to the azide acceptor 149 was a poor yielding 
step. It was vital that completely dry conditions were employed, where both the acceptor and 
the donor were dried under high vacuum for 16 hours before the reaction was performed. 
Activation of the anomeric trichloroacetimidate with a Lewis acid BF3,Et2O via SN1-type 
mechanism with neighboring group participation yielded the fully protected disaccharide 152 
in only 27% yield (Figure 5.4). The yield obtained was comparable to that reported [2], 
however by mass analysis it was apparent that a mixture of by-products were also formed. 
This included starting materials, the hemi-acetal form where the trichloroacetimidate donor 
was hydrolysed and a double N-phthalimido sugar disaccharide where the 
trichloroacetimidate donor reacted with the hemi-acetal by-product. 1H NMR analysis of 
these by-products was complicated and so further purification was required. 
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Figure 5.4 The glycosidic linkage between the trichloroacetimidate donor and the azide 
acceptor for the synthesis of chitobiosyl azide 152 [2]. 
Furthermore, we also tried to perform the β-1,4-glycosidic linkage using thioglycoside 72 as 
the donor. The use of thioglycosides has its advantages, as they are more chemically stable 
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than the trichloroacetimidates and will not react with the vast majority of nucleophiles unless 
specificlly activated with a soft electrophile. N-iodosuccinimide (NIS) is most frequently used 
along with a catalytic amount of trifluoromethanesulfonic acid (trific acid, TfOH). The 
activation of the anomeric sulphur occurs by the nucleophilic attack of the sulphur on NIS 
with the loss of succinimide. This forms the sulphonium leaving group and the azide 
acceptor is trapped via an SN1 type pathway. In a first attempt we used NBS in the presence 
of TfOH to form the β-1,4-glycosidic linkage using thioglycoside 72 and acceptor 149. 
However, no sign of the product was found, changing the soft electrophile to NIS, still 
resulted in gave a negative result, but only the loss of the p-methoxybenzyl protecting 
groups were observed.  The experiments discussed above demonstrated that the formation 
of a new glycosidic linkage between thioglycoside 72 and the azide 149 containing a p-
methoxybenzyl protecting group was unsuccessful. However, with the disaccharide 152 from 
the original methodology (Figure 5.4) the final deprotection steps with cerrium ammonium 
nitrate and hydrazine hydrate and then complete protection with acetic anhydride and 
pyridine were performed resulting in the fully protected chitobiosyl azide 153 (Figure 5.5).  
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Figure 5.5 Synthesis of chitobiosyl azide 153 [2]. 
 
5.5 The synthesis of mannose-linked peptide 
 
We envisaged that having another tool such as a mannose-linked peptide, would be useful 
to see the transfer of azidomannose onto a peptide precursor after the initial transfer of 
azidosugars have been rectified. A mannose containing an iodoacetimide group 154 was 
ligated to a cysteine residue of a His6 tag peptide 155 (Figure 5.6). The His6 tag would 
enable quick and easy purification after azido transfer using a nickel column.  
93  over 3 steps 
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Figure 5.6 Ligation of iodoacetamide mannose with the His6 tag. 
 
The peptide chosen contained a cysteine residue, which was required for the sugar ligation, 
two serine amino acids to allow some flexibility of the peptide, six histidine molecules and a 
glycine residue to contain the His6 tag and perhaps prevent terminal damage. Cysteine was 
loaded onto a rink amide resin manually, and the remaining peptide was synthesised in 
automated fashion. The rink amide resin was used due to its availability and its high loading 
capability also it is important to note that the rink amide resin is cleaved to give a C-terminal 
amide.  
 
The Kaiser test was performed to check efficiency of loading. The Kaiser test involves 
ninhydrin (2,2-Dihydroxyindane-1,3-dione) a chemical used to detect ammonia or primary 
and secondary amines. When reacting with these free amines, a deep blue or purple colour 
known as Ruhemann's purple is evolved [3]. After the first amino acid was coupled to the 
resin the Kaiser test showed a colorless/yellow. This indicated that the resin was fully 
coupled with the first amino acid as there were no free amines on the resin. 
Fluorenylmethyloxycarbonyl (Fmoc) deprotection and spectrophotometric methodology were 
used to calculate the level of first residue attachment. The actual loading of 0.225 mmol/g 
was comparable with the theoretical amount, which was 0.226 mmol/g. After automated 
synthesis of the remaining peptide, the purity of the peptide was examined by HPLC and 
MS, a distinct single peak at retention time: 11.06 minutes represented the His6 tagged 
peptide 155 (Figure 5.7). 
 
154 
155 
1 6 
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Figure 5.7 HPLC trace of His-tag peptide, performed with (5-95%) acetonitrile/water (0.1 % 
TFA), with C18 column (Luna C18 100A Size: 250 x 10.00 mm, 10 micron). 
  
Next with the iodoacetamide sugar (donated by Dr Derek Macmillan) 154 was ligated to the 
cysteine-terminated His6 peptide 155 in 50 mM ammonium formate buffer and purification by 
HPLC, resulted in a the mannose-linked peptide 156 as a white foam (Figure 5.6). MS 
showed the molecular ion as 1485.5, as well as 1509.76 (M+Na) and 744.45 (the 2+ ion). 
This peptide-linked mannose may be an important tool that will enable subsequent testing of 
azidosugar transfer. This tool will eventually be used to test the transfer of azidosugars, with 
both α-1,2 mannosyltransferase and β-1,4 mannosyltransferase enzymes. The His6 tag will 
be the main advantage of testing with this tool, as it will allow easy isolation of the product 
by nickel affinity chromatography. 
 
5.6 Click chemistry with propargyl LacNAc 
 
To test the final step of our glycoprotein remodeling technique we will need to demonstrate 
click chemistry of synthetic propagyl LacNAc to an azidosugar analogue and then test the 
resulting product, to see whether it is subsequently recognised by the enzyme 
sialyltransferase. These experiments would provide a good model for the final stages of our 
glycoprotein remodelling technique where a transferred azidosugar can be clicked with 
propagyl LacNAc and enzymatically modified.  
 
Click chemistry was performed between the fully protected propargyl LacNAc and the fully 
protected 4-azidomannose. Initially the reaction was performed in water/methanol/phosphate 
buffer (50 mM)/CI3CH (1:1:1:9), sodium ascorbate, and CuSO4.5H2O. However the reaction 
seemed to be very slow and only 15-20% yield was obtained after flash column 
chromatography. Cu(I) catalyses the formation of 1,2,3-triazoles from azides and alkynes. 
However it is thermodynamically unstable, resulting in easy oxidation to Cu(lI) and/or 
disproportionation to Cu(0) and Cu(ll) [14]. Tris-(benzyltriazolylmethyl)amine (TBTA), is a 
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stabilising ligand for Cu(l) developed by the Sharpless group [4]. TBTA protects Cu(l) from 
oxidation and disproportionation, while enhancing its catalytic activity. The ligand is a C3-
symmetric derivative, and is useful for azide-alkyne cycloaddition with upto 106-fold of rate 
acceleration [4].  
 
The synthesis of TBTA 160 was achieved by producing benzyl azide 158 from benzyl 
chloride 157 and then performing click chemistry with tripropargylamine 159 (Figure 5.8). 
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Figure 5.8 The synthesis of TBTA ligand 160 [4].   
 
The ligand was then used in the click reaction between propargyl LacNAc and 4-
azidomannose (Figure 5.9). The reaction proceeded for 5 hours and after flash column 
chromatography a 67% yield of the desired trisaccharide 161 was obtained (Figure 5.10).   
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Figure 5.9 Click chemistry between propargyl LacNAc and 4–azidomannose in the 
presence of TBTA. 
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 Figure 5.10 MS of the clicked trisaccharide product 161. 
 
The next step was to test the transfer of sialic acid onto our trisaccharide 161. Initially the 
transfer conditions were optimised on the natural substrate lactose, which is commercially 
available. The reaction mixture was adjusted to pH 7.1, prior to addition of CMP-sialic acid, 
α-2-6-sialyltransferase and lactose. The product α-2-6-sialyllactose 163 was purified by 
HPLC and MS showed the desired product.  
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Figure 5.11 The reaction conditions for the synthesis of α-2-6- sialylactose and the HPLC 
trace of the reaction mixture containing α-2-6-sialyllactose (RT: 6.324) Sphere Clone 5u SAX 
Size: 250 x 10.00 mm, 5 micron.  
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Deprotection of trisaccharide 161 was achieved with NaOMe in anhydrous MeOH and after 
neutralising with acetic acid and removal of solvent. The transfer of sialic acid was 
performed with our optimised conditions. After HPLC purification, the transfer of sialic acid 
was successful shown by MS analysis to form the tetrasaccharide product 164 (Figure 
5.12).  
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Figure 5.12 Sialic acid transfer to form the product 164. 
 
 
Figure 5.13 MS of tetrasaccharide 164.  
 
These results show that synthetic propargyl LacNAc can be “clicked “ onto an azido sugar 
and can be tolerated by the α-2,6-sialyltransferase for the transfer of sialic acid. Therefore 
these results give a good indication that the last stages of our overall remodelling technique, 
where glycoprotein incorporated azido sugars are clicked with propargyl LacNAc and 
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modified by sialyltransferase is a feasible process. 
 
5.7 Synthetic incorporation of azidohomoalanine for glycoprotein remodelling  
 
The introduction of azide groups into a fully synthetic peptide using the amino acid 
azidohomoalanine (Aha) was an alternative method we investigated for glycoprotein 
remodelling. Click chemistry with synthetic propargyl glycosides would allow further 
modification to homogeneous glycopeptide analogues which were tested for their 
compatibility with native chemical ligation. The glycoproteins CD52 and α-dystroglycan 
(ADG) were used as our model proteins. CD52 is a glycosylphosphatidylinositol (GPI)-
anchored cell surface antigen expressed on almost all human lymphocytes and sperm cells 
[15]. It is one of the smallest natural glycoproteins consisting of only twelve amino acids 
residues but carries a large complex- type N- glycan at the Asn-3 residue [5]. Our peptide 
was based on the sequence of CD52 with the following exceptions: Asn will be substituted 
with Aha to allow click chemistry with propargyl LacNAc and propargyl GlcNAc also, Asp-4 
will be replaced with Glu as Asp residues are known to be unstable during thioesterification. 
Furthermore, an extra Gly and Cys residue will be added to allow thioesterification to 
produce a thioester which can be used for native chemical ligation (Figure 5.14). 
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Figure 5.14 The synthetic route to produce a chemically modified peptide of CD52 
containing clicked sugars and terminal thioester.  
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ADG is an extra-cellular protein containing both N-linked and O-linked glycosylation sites 
and its defective glycosylation is associated with muscular dystrophy (Chapter 1). The 
mucin-like O-mannosylation domain in ADG spans from amino acid 316 to 489 [6]. Two 
similar peptide sequences, corresponding to residues 401–420 and 336–355, respectively, 
were shown to be strongly mannosylated by POMT, whereas other peptides from ADG and 
peptides of various mucin tandem repeat regions were poorly mannosylated [6]. Furthermore 
substitution of Ala residues for Ser or Thr residues have shown that Thr-414 of peptide 401–
420 and Thr-351 of peptide 336–355 were prominently modified by O-mannosylation [6]. 
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and Edman 
degradation analysis of the mannosylated peptide 401–420 indicated that Thr-414 was the 
residue that was most prominently modified by O-mannosylation [6]. With these results in 
mind the synthesis of peptide 401-420 was undertaken. The peptide was contructed from 
two fragments where Thr 404, 406 and 414 were replaced by Aha. The first fragment 
(peptide 401-409) contained an extra Cys residue could be thioesterified for native chemical 
ligation. The second fragment (peptide 410-420) replaced Tyr 410 with Cys facilitate native 
chemical ligation. These Aha bearing fragments will then undergo click chemistry with our 
propargyl mannose and then native chemical ligation to produce the chemical modified 
glycopeptide 401-420 of the mucin- like domain of ADG (Figure 5.15).  If successful then 
this chemically modified glycopeptide can be potentially used as test substrates for the 
transfer of mannose by POMT, to see if the enzyme can tolerate the unnatural triazole 
linkage. 
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Figure 5.15 The synthetic route to produce the chemically modified glycopeptide 401-420 of 
the mucin- like domain of ADG. Click chemistry, thioesterification and native chemical 
ligation methodologies are used to produce the modified peptide. 
 
The modified peptides 401-409 and 410-420 of ADG and CD52 peptide 59 were 
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synthesised in 0.01 mmol scale using the peptide synthesiser. Mass analysis showed the 
expected mass for all three peptides (168, 169 and 165) with the respective mass charge 
ratio values 1111.2, 1095.3 and 1359.1. With the correct sequence of peptides at hand, we 
performed click chemistry with our propargyl glycosides and then HPLC purification using 
C18 column (100Å Size: 250 x 10.00 mm, 10 micron). The resulting glycopeptides were 
examined using mass analysis (Table 6). 
Propargyl 
glycoside 
Azido-modified peptide 
(number) 
Expected mass of 
glycoprotein 
product m/z 
Mass 
Found m/z 
% yield 
GlcNAc CD52  (165) 1779.75 1778.50 15-20 
LacNAc CD52 (165) 2068.00 - - 
Mannose 401-409 ADG (168) 1911.07 1911.08 15-20 
Mannose       410-420 ADG  (169) 1495.61 1496.20 15-20 
  
Table 6 Mass analysis of click chemistry reactions between the azide bearing peptides 
CD52 165, ADG 401-409 168, and ADG 410-420 169 and fully acetylated propargyl 
glycosides. Click chemistry was performed in sodium ascorbate, Cu(II)SO4, (9:1:1) CHCl3: 
EtOH: 50 mM sodium phosphate.  
  
Click chemistry of propargyl GlcNAc to the modified CD52 peptide 165 was successful 
however, the same reaction with propargyl LacNAc was unsuccessful. This may be due to 
the time given for the reaction to proceed, perhaps repeating the reaction with the presence 
of TBTA stabilising ligand may improve the reaction. On the other hand the click reaction 
between propargyl mannose and peptides 168 and 169 were both successful showing not 
only the correct masses by mass analysis but also the plus two ions. 
 
The next step was the thioesterification of the modified glycopeptides 401-410 of ADG 168 
and the GlcNAc clicked CD52 peptide 166. The thioesterification reaction involves an N→S 
acyl shift with the terminal cystine residue, under acidic conditions to produce unstable 
thioester intermediate which reacts with MESNa to give a stable thioester (Figure 5.16) [7, 
8]. 
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Figure 5.16 Thioesterification reaction with MESNa [7]. 
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Initial results showed that modified glycopeptide 401-410 of ADG 168 did not undergo 
thioesterification. However, glycopeptide 166 underwent thioesterification and after HPLC 
purification, mass analysis showed the major product as the desired glycopeptide 167 
(Figure 5.17). 
 
 
O
AcO
AcO
NHAc
OAc
O
N
N
N
Gly-Gln-Aha-Glu-Thr-Ser-Gln-Thr-Ser-Ser-Pro-Ser-Gly-Cys
O
S
SO3H
Gly-Gln-Aha-Glu-Thr-Ser-Gln-Thr-Ser-Ser-Pro-Ser-Gly
10 % AcOH
10 % MESNa
0.5 % TCEP
60 oC, 48 hours
166
167
O
AcO
AcO
NHAc
OAc
O
N
N
N
 
 
Figure 5.17 Thioesterification of glycopeptide 166. *The reaction was also repeated in 1M 
sodium phosphate pH 5.8 without AcOH and also showed the product 167. Mass analysis 
showed the mass of 1801.8 m/z the calculated mass of 167 is 1801.5. 
The incorporation of azide groups into a fully synthetic peptide using the amino acid 
azidohomoalanine was successful. Click chemistry with synthetic propargyl glycosides of 
GlcNAc and mannose was also achieved. Thioesterification of modified peptide ADG 401-
410 was problematic showing no sign of the desired thioester product. However GlcNAc 
clicked CD52 peptide 166 was successful resulting in the desired thioester containing 
glycopeptide 167. This is the first time that an azidohomoalanine incorporated glycopeptide 
has tolerated our thioesterification procedure. Further work will need to test the compatibility 
of the thioester 167 with native chemical ligation. 
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5.8 Conclusion 
 
This project aimed to investigate and synthesise tools that would aid in a novel glycoprotein 
remodeling technique using GDP-azidomannose analogues. We have synthesised one of 
the key components, propargyl LacNAc and have shown that it can be chemically clicked to 
an azido sugar and enzymatically modified by α-2-6-sialyltransferase which we hope would 
suitably mimic terminal sugars found on N-linked glycoproteins. We have also used α-1,2-
mannosyltransferase to test the transfer of azidomannose from GDP-azidomannose, to 
different substrates. Although this was unsuccessful we have optimised the transfer reaction 
using GDP-mannose and developed a method to isolate the product using α-benzyl 
mannoside as the acceptor substrate. 
  
We have synthesised azido- and thioacetate-sugars and administered the sugars to yeast 
expressing EPO in an attempt to incorporate the synthetic sugars into yeast glycoprotein. 
Unfortunately, preliminary results show that the incorporation was unsuccessful. As an 
ongoing research for the use of GDP-azidomannose for glycoprotein remodeling, we have 
synthesised acceptor molecules including mannose linked His6 tagged peptide and 
chitobiosyl azide. These tools can potentially allow easy purification and further testing, to 
transfer azido mannose from GDP-azidomannose. 
  
One of the major reasons why we have not tried our glycoprotein remodeling technique on 
an actual glycoprotein is that the azido-transfer from GDP-azidomannose has been 
unsuccessful. One reason for this may be that GDP-azidomannose may be broken down to 
the nucleotide diphosphate. The nucleotide diphosphate GDP is known to inhibit the initial 
transfer of the sugar from its sugar nucleotide [9] and therefore may prevent our azido-
sugars from being transferred. 
  
A procedure to regenerate  the nucleotide sugar and remove nucleotide diphosphates may 
help push our unsuccessful azido-transfer reaction. This regeneration of nucleotide sugars 
can be seen in Figure 5.18. The cycle starts with the transfer of the mannose from the GDP-
mannose to the acceptor (O-methyl mannose). The by-product is a nucleotide diphosphate 
(GDP), which is known to inhibit the initial transfer of the sugar from its sugar nucleotide [9]. 
GDP is therefore recycled, by conversion to its corresponding nucleotide triphosphate (GTP) 
with phosphoenol pyruvate. The product GTP together with mannose-1-phosphate are 
substrates for the enzyme GDP-mannose-pyrophosphorylase (GDP-ManPP), which 
regenerates the sugar nucleotide GDP-mannose.  
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Figure 5.18 Regenerating the nucleotide sugar GDP mannose for mannose transfer [9]. 
 
A major by-product from the cycle is the inorganic diphosphates produced when forming the 
sugar nucleotide (GDP-mannose). These diphosphates can also potentially inhibit the cycle, 
but if broken down with inorganic phophatase to produce free phosphates, then they are 
rendered inactive. If this cycle becomes successful then we will apply the principle to our 
GDP-azidomannose derivatives.  
 
The purification of GDP-ManPP, an enzyme required for this regenerating cycle has been 
achieved (see experimental section). GDP-ManPP is only one component, within the 
regenerating cycle. The other components, such as phosphoenol pyruvate, inorganic 
pyrophosphatase and GDP mannose, are commercially available. While α-1,2-
mannosyltransferase has been expressed and is also commercially available. The only 
component missing to test the cycle is the mannose-one-phosphate. Further work will be 
required to test the cycle and apply it to our azido-mannose derivatives. 
  
During this project we have demonstrated the synthesis of propargyl glycosides and have 
successfully shown that these propargyl sugars can be ligated to azide bearing peptides 
using click chemistry. This can be seen with the synthesis of CD52 and ADG analogues 
which were modified using click chemistry. The modified CD52 peptide has also 
α-1,2-
Mannosyltransferase 
a nose-1-phosphate 
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successfully undergone thioesterification to produce a thioester which is poised for native 
chemical ligation. We have demonstrated that remodelling glycoproteins enzymatically 
using α-1,2 mannosyltransferase and GDP-azidomannose has been difficult but synthetic 
methods using Aha and propargyl glycosides to produce homogeneous glycopeptides 
analogues is less problematic.  
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Figure 5.19 Modified CD52 peptide 167 as a potential substrate for endo-NAGs.  
 
These synthetic homogeneous glycoprotein mimics may ultimately act as substrates for 
further methods of glycoprotein remodelling using enzymes such as endo-NAGs (Figure 
5.19) to ultimately produce homogeneous glycoproteins to suit therapeutic use.  
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                                                           Chapter 6  
                                       Experimental section  
6.1 Organic chemistry  
6.2 General techniques and reagents  
 
All solvents and reagents were standard laboratory grade purchased from Sigma Aldrich, 
Fisher or Acros and used as received unless otherwise stated. Where a solvent was 
described as dry it was purchased as anhydrous grade or from the University College 
London in-house anhydrous solvent system.  
6.3 Instrumentation 
 
1H NMR spectra were recorded at 250, 300, 400, or 500 MHz and 13C NMR spectra were 
recorded at 75, 100 or 125 MHz on a Bruker 250Y instrument. Chemical shifts (δ) are 
reported in ppm relative to Si(CH3)4 (δ=0) and coupling constants (J) in Hz, signals are sharp 
unless stated as broad (br), s: singlet, d: doublet, t: triplet, m: multiplet and q: quaternary. 
Residual protic solvent, CDCl3 (δH: 7.26, s) was used as the internal standard in 
1H-NMR 
spectra unless otherwise stated. Low resolution electrospray mass spectroscopy was carried 
out on a Micromass Quattro LC electrospray mass spectrometer with an applied voltage of 
35-50 V. High resolution electrospray ionisation (ESI) mass spectra were obtained at the 
mass spectrometry facility at University College London. UV spectroscopy was carried out in 
an 8543 UV/Vis spectrophotometer (Hewlett Packard) using disposable cuvettes. Infrared 
spectra were obtained using a Perkin-Elmer 1600. Paragon Series FT-IR spectrometer as 
liquid thin films. Peptides were synthesised on a rink amide resin (unless otherwise stated) 
using standard Fmoc chemistry with a peptide synthesiser (Applied Biosystems 433A).   
 
Analytical thin layer chromatography (TLC was carried performed using Merck aluminium 
backed plates coated with silica gel 60F254. Flash chromatography was carried out over 
Fisher silica gel 60 Å particle size 35-70 micron. Components were visualised using p-
anisaldehyde dip and UV light (254 nm). The HPLC was equipped with binary pump (P680 
HPLC pump Dionex), a semipreparative column (SAX, 10 µ, 100 A, 250 x 10 mm) or (carbon 
18), UV detector (UVD 170U/340U Dionex). 
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2-N-phthalimido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose [1]. 
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To a stirred solution of glucosamine hydrochloride (10.0 g, 46.3 mmol) and anhydrous 
methanol (75 ml), sodium methoxide (3.0 g, 46.3 mmol) was added. The reaction mixture 
was stirred for 10 minutes at room temperature and then filtered with suction. Phthalic 
anhydride (3.5 g, 23.0 mmol) was added to the filtrate and stirring was continued for a further 
20 minutes. A further portion of phthalic anhydride (3.5 g, 23.0 mmol) was then added 
followed by triethylamine (7.6 ml, 55.6 mmol). The reaction mixture was stirred at room 
temperature for 10 minutes and then at 50°C for 30 minutes. The resulting mixture 
(containing a thick white precipitate) was cooled for 1 hour in an ice bath and filtered with 
suction. The precipitate was washed with cold methanol (2 x 20 ml) and dried under high 
vacuum. The dry white solid was suspended in acetic anhydride (45 ml), cooled in an ice 
bath and pyridine (23 ml) was added carefully with stirring. The reaction mixture was stirred 
at room temperature for 16 hours and then poured into ice/water (200 ml) and extracted with 
chloroform (3 x 200 ml). The combined organic extracts were washed with 5% HCI (100 ml), 
saturated NaHCO3 (120 ml), water (120 ml) and brine (100 ml). The organic phase was then 
dried with (Na2SO4), filtered, and the solvent removed under vacuum to afford the crude 
product as an orange oil which was purified by flash column chromatography over silica 
(hexane/ ethyl acetate 1: 1 Rf 0.4) to afford 2-N-Phthalimido-2-deoxy-1,3,4,6-tetra-O-acetyl-
β-D-glucopyranoside (11.97 g, 54%) as a white foam. 1H NMR (300 MHz, CDCI3):δ ppm = 
7.68-7.75 (4H, m, ArH), 6.45 (1H, d, J = 7, H1), 5.80 (1H, dd, J = 8, H3), 5.13 (1H, dd, J = 8, 
H4), 4.38 (1 H, dd, J = 8, H2), 4.28 (1 H, dd. H6a), 4.05 (1 H, dd, H6b), 3.96 (1 H, m, H5), 
2.23 - 2.20 (12H, 4 x s, COCH3) 
13C NMR (62 MHz, CDCI3): δ (ppm) = 170.5, 170.0, 169.3, 
168.5 and 167.2 (qC), 134.4 (2 x ArCH), 131.1 (C), 123.7 ( 2 x ArCH), 89.6 (CH), 72.5 (CH), 
70.4 (CH), 68.1 (CH), 61.4 (CH2), 53.3 (CH), 20.6 (2 x OCH3), 20.4 (OCH3) and 20.3 
(COCH3) [1]. Found m/z (ESI): 500.30 (M+Na), C22H23NO11Na
+ requires m/z 500.40.  
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2-N-phthalimido-2-deoxy-3,4,6,-tri-O-acetyl-S-thiophenyl-β-D-glucopyranoside [1]. 
 
O
AcO
AcO
N
OAc
OAc
OO
O
AcO
AcO
N
SPh
OAc
OO
SH
SnCl4
2 3
79 %
 
 
A solution of the acetylated N-phthalimido sugar (10.0 g, 20.9 mmol) and tin tetrachloride 
(7.31 ml of a 1 M solution in DCM, 42.6 mmol) in anhydrous DCM (75.0 ml) under nitrogen 
was treated with thiophenol (3.06 g, 27.83 mmol). The reaction mixture was stirred at room 
temperature for 16 hours and then diluted with DCM (100 ml). The solution was washed with 
water (100 ml), saturated bicarbonate (100 ml), then water (100 ml). The organic phase was 
dried with MgSO4 and the solvent was removed under reduced pressure to afford the crude 
product, which was purified by flash chromatography over silica (ethyl acetate/petroleum 
ether 1: 1 Rf 0.4) to isolate a white solid (8.71 g, 79%) 
1H NMR (300 MHz, CDCl3):δ ppm = 
7.87-7.73 (4H, m, ArH), 7.41-7.24 (5H, m, ArH), 5.78 (1H, dd, J = 8, H3), 5.72 (1H, d, J = 8, 
H1), 5.13 (1H, dd, J = 8, H4), 4.34 (1H, dd, J = 8, H2), 4.27-4.17 (2H, m, H6b, H6b), 3.92-
3.86 (1 H, m, H5), 2.09, 2.21, and 1.82 (9H, 3 x S, COCH3). 
13C NMR (62 MHz, CDCI3):δ 
(ppm) = 170.5, 170.0, 169.3, 167.7, 166.8 ( 5 x qC), 134.3 ( 2 x ArCH), 123.6 (2 x ArCH), 
134.3 (ArCH), 133.1 (2 x ArCH), 130.8 (qC), 128.7 (2 x ArCH), 128.3 (ArCH), 123.6 (2 x 
ArCH) (5C, ArH), 82.9 (CH), 75.8 (CH), 71.5 (CH), 68.6 (CH), 62.1 (CH2), 53.4 (CH), 20.6, 
20.5 and 20.3 (3 x CH3) Found m/z (ESI): 551.01 (M+Na), C26H2SNO9Na
+ requires m/z 
550.53.  
 
2-N-phthalimido-2-deoxy-6-tert-butyl-diphenyl-silanyl- S-thiophenyl-β-D 
-glucopyranoside.  
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The fully protected thioglycoside (1.10 g, 2.08 mmol) was dissolved in methanol and a 0.5 M 
solution of NaOMe in MeOH was added until a pH of 10 was obtained. The reaction was 
stirred for 5 hours and monitored by TLC (1:1 EtOAc/hexane) then neutralised with acetic 
acid. The mixture was then concentrated and azeotroped with toluene, before being dried 
under high vacuum for 1 hour to yield the crude partial protected sugar (0.81 g, 1.99 mmol). 
Next this partially protected thioglycoside was dissolved in anhydrous DCM (30 ml), to which 
TBDPSCI (0.52 ml, 1.99 mmol), DIPEA (0.70 ml, 3.98 mmol), DMAP (24.0 mg, 0.19 mmol), 
was added, and the reaction stirred under nitrogen for 3.5 hours. The reaction was 
monitored by TLC (100%, EtOAc, Rf 0.3) to completion and diluted with (20 ml) DCM, 
washed with NaHCO3 (20 ml), and water (20 ml). The organic phase was dried with MgSO4, 
filtered and concentrated under reduced pressure to afford a yellow oil. The product was 
purified by flash chromatography over silica (100%, EtOAc, Rf 0.3) to afford the product as a 
yellow oil (0.96 g, 72%). 1H NMR (300 MHz, CDCI3): δ (ppm) = 7.73-7.17 (19H, m, 19 x ArH), 
5.64 (1H, d, J = 10, H1), 4.34 (1 H, dd, H3), 4.24 (1 H, dd, H4), 4.10 (2H, dd, H6a, H6b), 3.72 
(2H, m, H2, H5), 3.20 (1 H, s, OH), 2.80 (1 H, s, OH), 1.08 (12H, S, CH3 x 3). 
13C NMR (75 
MHz, CDCI3): δ (ppm) = 135.7, 134.8, 134.2, 133.1, 132.7,1 32.3, 131.6, 130.0, 129.0, 
128.9, 127.9, 127.8 (4 x NPht + 8 x ArH), 83.5,78.7,73.6,72.9,69.0,55.2, (C1-C6), 26.8 (3 x 
CH3), 19.2 (CCH3). MS (ESI): m/z 662.28 (M+Na), C36H37N06SSiNa
+ requires 662.82.  
 
1,2,3,4,6-penta-O-acetyl-α-D-galactopyranose [2]. 
O
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HO
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OH
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Ac2O, 0
oc
5 6
98%
 
To a 0°C solution of D-galactose (25.0 g, 0.13 mol) in acetic anhydride (223 ml), perchloric 
acid (0.1 ml) was added dropwise. The reaction mixture was stirred for 3 hours, and 
monitored by TLC to completion. The crude product was washed with chloroform (300 ml), 
brine (200 ml), NaHCO3 (200 ml) and water (200 ml). The organic phase was dried with 
MgSO4, filtered, and the solvent removed under reduced pressure to afford a brown oil (50.1 
g, 98%) that was used without further purification.1H NMR (300 MHz, CDCl3): δ (ppm) = 6.34 
(1 H, d, J = 2, H1), 5.41 (1 H, dd, H4), 5.33-5.29 (2H, m, H2, H3), 4.34-4.29 (1 H, m, H5), 
4.10-4.29 (2H, m, H6a, H6b), 2.19, 2.13, 1.99, 1.97,1.96, (15H, s x 5, COCH3 X 5). 
13C NMR 
(75 MHz, CDCI3): δ (ppm) = 170.3, 170.1, 169.9, 168.9, 166.4 (5 x RCOR), 89.7, 68.7, 67.4, 
Ac2O, 0 
oC 
69 73 
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67.3, 66.4, 61.2 (C1-C6), 20.1, 20.9, 20.6, 20.5, 20.5 (5 x COCH3). MS (ESI): m/z 413.15 
(M+Na), C16H22NaO11
+ requires 413.33. 
  
2,3,4,6-tetra-O-acetyl-D-galactose [2]. 
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The peracetylated galactoside (7.80 g, 20.00 mmol) was dissolved in anhydrous THF (120 
ml) under nitrogen at 50°C. Benzylamine (2.6 ml, 24.00 mmol) was added to the reaction 
mixture. The reaction was monitored by TLC (4:1 petroleum ether/ ethyl acetate) and when 
the reaction was almost complete the solvent was removed under reduced pressure and the 
resulting mixture purified by flash chromatography over silica (4/1 petroleum ether/ ethyl 
acetate, Rf 0.2) to afford a yellow oil (5.71 g, 82%).
1H NMR (300 MHz, CDCI3): δ (ppm) = 
6.34 (1H, d, J = 2, H1), 5.41 (1H, dd, H4), 5.20-5.07 (2H, m, H2, H3), 4.47-4.45 (1 H, m, H5), 
4.10-4.29 (2H, m, H6a, H6b), 2.15, 2.10, 2.06, 1.99, (12H, s x 4, COCH3 X 4). 
13C NMR (75 
MHz, CDCl3): δ (ppm) = 170.3, 170.1, 169.9, 166.4 (4 x RCOR), 89.7, 68.7, 67.4, 67.3, 66.4, 
61.2 (C1-C6), 20.1, 20.9, 20.6, 20.5 (4 x COCH3). MS (ESI): m/z 371.01 (M+Na), 
C14H20NaO10
+ requires 371.29. 
 
2,3,4,6-tetra-O-acetyl-α-D-O-galacopyranosyl trichloroacetimidate [2]. 
O
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A solution of the hemiacetal (3.66 g, 10.50 mmol) in anhydrous DCM (100 ml) was cooled to 
0°C. Trichloroacetonitrile (10.62 ml, 105 mmol) and DBU (1.57 ml, 10.50 mmol) were added 
to the mixture which was stirred 3 hours until TLC showed that the reaction was complete. 
The reaction mixture was concentrated under reduced pressure, and purified by flash 
chromatography over silica (1:1 petroleum ether/ ethyl acetate, Rf 0.5) to afford the product 
as a yellow oil (3.63 g, 68%).1H NMR (300 MHz, CDCI3): δ (ppm) = 8.67 (1H, s, NH) 6.34 
, 50 C 
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(1H, d, J = 3, H1), 5.53 (1H, dd, H4), 5.41-5.29 (2H, m, H2, H3), 4.43-4.38 (1H, m, H5), 
4.16-4.01 (2H, m, H6a, H6b), 2.06, 1.99, 1.98, 1.98 (12H, s x 4, COCH3 X 4).
13C NMR (75 
MHz, COCl3): δ (ppm) = 170.1 (4 x RCOR), 93.6, 69.0, 67.5, 67.4, 66.9, 61.3 (C1-C6), 20.6 
(4 x COCH3). MS (ESI): m/z 514.06 (M+Na), C16H2OCI3NNa010
+ requires 514.01.  
Disaccharide 66. 
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The trichloroacetimidate donor (0.92 g, 1.19 mmol) and the silylated acceptor (0.60 g, 0.94 
mmol) were dissolved in anhydrous DCM (20 ml), containing 4 Å molecular sieves at -20°C. 
A solution of 0.1 M TMS-OTF in anhydrous DCM (4.80 ml, 0.48 mmol) was added to the 
reaction mixture at -20°C and stirred at -20°C for 2 hours. The reaction was allowed to warm 
to room temperature then stirred at room temperature until TLC indicated that the reaction 
was complete. The reaction mixture was diluted with DCM (50 ml) and neutralised with solid 
NaHCO3, filtered, and solvent removed under reduced pressure. The crude product was 
purified by flash chromatography over silica (4:1 toluene / ethyl acetate, Rf 0.3) to afford the 
product as a white foam (0.77 g, 84%) 1H NMR (300 MHz, CDCI3): δ (ppm) = 8.14-7.18 
(19H, m, ArH), 5.69 (1H, d, J = 11, H1), 5.21 (1H, d, J = 3, H4), 5.18 (1H, dd, H2), 4.96 (1H, 
dd, H3), 4.74 (1H, d, J = 8, H1'), 4.42 (1H, dd, H3'), 4.12 (1H, dd, H2'), 4.12-3.87 (7H, m, 
H6a', H6b', H4', H6b, H6b, H5, H5'), 3.61 (1 H, d, OH), 2.16, 2.03, 2.01, 1.69, (12H, s, 
COCH3). 
13C NMR (100 MHz, CDCI3): δ (ppm) = 170.4, 170.0, 169.8, 169.0, 168.1, 197.4, (6 
x RCOR), 137.8, 135.9, 135.5, 134.0, 133.5, 132.6, 132.4, 132.1, 131.7,131.7,129.9, 129.8, 
129.0, 128.8, 128.2, 127.9, 127.7, 127.6, 125.2, 123.6, 123.2 (4 x NPht, 5 x SPh, 12 x ArH) 
101.1, 83.5, 80.4, 78.8, 71.2, 70.7, 70.5, 68.8, 66.8, 61.9, 61.1, 55.3, (C1-C6', C1-C6), 26.9 
(3 x CH3), 21.4, 20.5, 20.3, 20.2 (4 x COCH3), 19.3 (CCH3). MS (ESI): m/z (M+Na) 992.3202 
C50H55NO15SSiNa
+ requires 992.3197.  
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Peracetylated-N-acetyl-Lactosamine thioglycoside.  
 
 
 
 
 
A solution of the phthalimide protected disaccharide 66 (950 mg, 0.98 mmol), and acetic acid 
(0.59 ml, 9.18 mmol) was cooled at 0°C in THF (20 ml). A solution of 1 M TBAF in THF (1.14 
ml, 3.92 mmol) was added to the reaction mixture and stirred at room temperature for 15 
hours. The mixture was subsequently concentrated to a yellow oil. The oil was dissolved in 
n-BuOH and ethylendiamine (0.29 ml, 3.92 mmol) and the reaction stirred at 90°C under 
reflux for 15 hours. The resulting yellow solution was reduced to an oil and dissolved in (2:1) 
pyridine, acetic anhydride (90 ml) and stirred for 24 hours. The reaction was finally 
concentrated to give a brown oil and purified by flash chromatography over silica (100% 
EtOAc, Rf 0.4) to afford the product as a white foam (350 mg, 52%). 
1H NMR (400 MHz, 
CDCI3): δ (ppm) = 7.73-7.21 (5H, m, ArH), 5.74 (1 H, d, J = 10, NH), 5.21 (1 H, d, J = 4, H4), 
5.09-5.05 (2H, m, H2, H3'), 4.96 (1H, dd, H3), 4.63 (1H, d, J = 10, H1'), 4.49-4.47 (2H, m, 
H6a', H1), 4.14-4.06 (4H, m, H2', H6b', H6a, H6b), 3.89-3.83 (1H, m, H5), 3.73 (1H, dd, J = 9, 
H4'), 3.61 (1 H, m, H5'), 2.13, 2.08, 2.06, 2.04, 2.03, 1.98, 1.95 (21 H, S, COCH3). 
13C NMR 
(75 MHz, CDCl3): δ (ppm) = 170.9, 170.4, 170.3, 170.1, 170.1, 170.0, 169.3 (7 x RCOR), 
132.7, 132.3, 128.9, 128.7, 127.9 (5 x ArH), 101.1, 86.8, 77.2, 76.1, 74.2, 70.9, 70.7, 69.1, 
66.7, 62.4, 60.8, 52.9, (C1-C6', C1-C6), 23.3 (NHCOCH3) 20.6 (6 x COCH3). MS (ESI): m/z 
(M+Na) 750.2001 C32H41NO16SNa
+ requires 750.2044.  
 
Molecule 76. 
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The thiophenyl glycoside 75 (200 mg, 0.27 mmol) and N-bromosuccinimide (185 mg. 0.82 
mmol) were dissolved in acetone (20 ml) and water (1 ml). The mixture was stirred at room 
temperature for 3.5 hours and monitored by TLC (100% ethyl acetate, Rf 0.2). The reaction 
mixture was diluted with DCM (50 ml), and washed with water (20 ml), sodium thiosulphate 
(20 ml), and again with water (20 ml). The organic fraction was dried with MgSO4, filtered 
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and solvent removed under reduced pressure. The mixture was purified by flash 
chromatography over silica (100%, ethyl acetate, Rf 0.2) to afford a white foam (38 mg, 
20%).1H NMR (300 MHz, CDCI3): δ (ppm) = 6.63 (1 H, d, J = 10, NH), 5.31 (1 H, dd, H1 '), 
5.21 (1 H, d, J = 3, H4), 5.18 (1 H, dd, H2'), 4.97 (2H, m, H3. H2), 4.41 (2H, m, H1, OH), 4.08 
(5H, m, H6a', H6b', H6a, H6b, H2), 3.87 (1 H, dd, H4'), 3.76 (1 H, m, H5'), 2.14, 2.11, 2.07, 
2.06, 2.05, 2.00, 1.99 (21 H, s, COCH3). 13C NMR (75 MHz, CDCI3): δ (ppm) = 170.9, 170.4, 
170.3, 170.1, 170.1, 170.0, 169.3 (7 x RCOR), 101.1, 90.1, 77.2, 75.2, 71.2, 70.7, 70.9, 
69.0, 68.0, 66.8, 61.2, 52.9, (C1-C6', C1-C6), 23.0 (NHCOCH3) 20.6 (6 x COCH3). MS (ESI): 
m/z (M+Na) 658.1926 C26H37N017Na
+ requires 658.0.
3,4-di-O-acetyl-2-deoxy-2-N-phthaIimido-6-tert-butyl-diphenyIsilyl-β-S-thiophenyl-
glucopyranoside.  
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The partially protected sugar 4 (1.12 g, 1.75 mmol) was fully protected with (2/1 
pyridine/acetic anhydride 40 ml). The reaction mixture was stirred for 5 hours and 
concentrated under reduced pressure to afford a brown oil. The resulting oil was purified by 
flash chromatography over silica (3: 1 petroleum ether/ ethyl acetate, Rt 0.3) to afford a 
white foam (0.87 g, 70%). 1H NMR (300 MHz, CDCI3): δ (ppm) = 7.77-7.21 (19H, m, 19 x 
ArH), 5.83 (1H, dd, H3) 5.76 (1H, d, J = 11, H1), 5.21 (1H, dd, H4), 4.38 (1H, dd, H2), 3.82-
3.73 (3H, m, H5, H6a, H6b), 1.88, 1.83 (6H, s x 2, COCH3), 1.08 (12H, S, CH3 x 3). 
13C NMR 
(75 MHz, CDCI3): δ (ppm) = 171.2, 170.3, 169.3, 167.9 (4 x RCOR) 135.7, 135.7, 134.4, 
133.1, 133.0, 132.8, 131.6, 129.8, 129.0, 128.1, 127.8, 123.7 (4 x NPht + 8 x ArH), 83.1, 
79.0, 72.1,69.0,62.7, 53.7, (C1-C6), 26.7 (3 x CH3), 21.0, 20.5 (2 x COCH3), 19.2 (CCH3). 
MS (ESI): m/z 746.30 (M+Na), C40H41NO8SSiNa
+ requires 746.90.  
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3,4-di-O-acetyl-2-deoxy-2-N-phthaIimido-6-tert-butyl-diphenyIsilyl-β-D-
glucopyranose.  
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The thioglycoside 12 (700 mg, 0.95 mmol) and N-bromosuccinimide (516 mg, 2.90 mmol) 
were dissolved in acetone (20 ml) and water (20 ml). The reaction mixture was stirred at 
room temperature for 3 hours, then diluted with DCM (100 ml) and subsequently washed 
with water (100 ml), sodium thiosulphate (100 ml) and water (100 ml). The organic phase 
was dried with MgSO4, filtered, and the solvent removed under reduced pressure. The 
mixture was purified by flash chromatography over silica (1: 1 petroleum ether/ ethyl 
acetate, Rf 0.4) to afford a white foam (69% yield). 
1H NMR (300 MHz, CDCI3): δ (ppm) = 
7.83-7.38 (14H, m, 14 x ArH), 5.83 (1 H, dd, H3) 5.48 (1 H,br s, H1), 5.20 (1 H, dd, H4), 
4.24 (1 H, dd, H2), 3.82-3.71 (3H, m, H5, H6a, H6b), 3.16 (1 H, d, OH) 1.90, 1.85 (6H, s x 
2, COCH3), 1.07 (12H, S, CH3 x 3). 
13C NMR (75 MHz, CDCI3): δ (ppm) = 171.2, 170.3, 
169.3, 167.9 (4 x RCOR) 135.7, 135.7, 134.4, 133.1, 133.0, 132.8, 131.6, 129.8, 129.0, 
128.1, 127.8, 123.7 (4 x NPht + 8 x ArH), 83.1, 79.0, 72.1, 69.0, 62.7, 53.7, (C1-C6), 26.7 
(3 x CH3), 21.0, 20.5 (2 x COCH3), 19.2 (CCH3). MS (ESI): m/z 654.21(M+Na), 
C34H37NO9SiNa
+ requires 654.73.  
3,4-di-O-acetyl-2-deoxy-2-N-phthaIimido-6-tert-butyl-diphenyIsilyl-β-
trichloroacetimidate-glucopyranoside.  
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The hemi-acetal 13 (390 mg, 0.61 mmol) was dissolved in anhydrous DCM (10 ml), 
together with trichloroacetonitrile (892 mg, 6.10 mmol), and potassium carbonate (256 mg, 
1.85 mmol). The reaction was stirred under nitrogen for 5 hours, then filtered under suction 
and the solvent removed under reduced pressure. The reaction mixture was purified by 
flash chromatography over silica (3:1 petroleum ether/EtOAc, Rf 0.6) to afford a white foam 
(288 mg, 60%). 1H NMR (300 MHz, CDCI3): δ (ppm) = 8.56 (1 H, s, NH), 7.83-7.69 (4H, m, 
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4 x ArH), 7.68-7.36 (10H, m, 10 x ArH), 6.69 (1H, d, J = 9 , H1), 5.69 (1H, dd, H3), 5.42 (1 
H, dd, H4), 4.67 (1 H, dd, H2), 3.96-3.91 (1 H, m, H5) 3.84-3.76 (2H, m, H6a, H6b), 
1.96,1.91 (6H, s x 2, COCH3 X 2), 1.07 (9H, S, CH3 x 3). 
13C NMR (75 MHz, CDCI3): δ 
(ppm) = 170.3, 169.3, 167.9, 160.5 (4 x RCOR), 135.8, 135.7, 134.4, 133.2, 131.3, 129.7, 
129.6, 127.7, 127.6, 123.7 (6 x NPht + 4 x ArH), 93.4, 90.4, 75.6, 71.0, 98.7, 62.3, 53.8 
(C1-C6, C=NH), 26.7 (3 x CH3), 20.6, 20.5 (2 x COCH3), 19.25 (CCH3). MS (ESI): m/z 
799.21 (M+Na), C36H37CI3N2O9SiNa
+ requires 799.79.  
 
3,4-di-O-acetyl-2-deoxy-2-N-phthaIimido-6-tert-butyl-diphenyIsilyl-β-O-propargyl-
glycopyranoside. 
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A solution of the trichloroacetimidate sugar 14 (176 mg, 0.23 mmol), propargyl alcohol (12 
mg, 0.23 mmol) and activated 3 Å molecular sieves was stirred in anhydrous DCM (10 ml). 
The mixture was cooled to 0°C under nitrogen, and borontrifluoride diethyl etherate (7 µl, 
0.06 mmol) was added. The ice bath was removed and the reaction mixture stirred for 16 
hours. The reaction was monitored to completion by TLC (1/1 petroleum ether/ethyl acetate). 
The reaction was neutralised by dropwise addition of triethylamine, filtered and the solvent 
removed under reduced pressure. The product was purified by flash chromatography over 
silica (1:1 petroleum ether/EtOAc, Rf 0.5) to afford a yellow oil (172 mg, 98%). 
1H NMR (300 
MHz, CDCI3): δ (ppm) = 7.87-7.71 (4H, m, 4 x ArH), 7.70-7.38 (10H, m, 10 x ArH), 5.85 (1H, 
dd, H3), 5.58 (1H, d, J = 9, H1), 5.19 (1 H, dd, H4), 4.36-4.29 (3H, m, H2, CHz), 3.86-3.74 
(3H, m, H6a, H6b, H5), 2.31 (1 H, t, CH2CC-H), 1.92, 1,84 (6H, s x 2, COCH3 X 2) 1.07 (9H, 
s, CH3 x 3). 
13C NMR (75 MHz, CDCl3):δ (ppm) = 170.3, 169.4, 167.9, 163.5 (4 x RCOR), 
135.8, 135.6, 134.2, 133.3, 133.1, 131.5, 129.8, 127.8, 127.7, 123.6 (6 x NPht + 4 x ArH), 
95.7, 78.2, 75.4,74.7, 71.0, 69.3, 62.7 (C1-C6, -CH2CCH), 55.7 (-CH2CCH), 54.6 (CH), 26.7 
(3 x CH3), 20.6, 20.5 (2 x COCH3), 19.25 (CCH3). MS (ESI): m/z 692.21 (M+Na), 
C37H39NO9SiNa+ requires 692.22 
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2-N-phthaIimido-2-deoxy-6-tert-butyl-diphenyIsilyl-β-O-propargyl-glucopyranoside. 
O
HO
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O
OTBDPS
NaOMe
MeOH
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The fully protected sugar 15 (164 mg, 0.25 mmol) was dissolved in methanol (10 ml) and 
NaOMe (0.5 M in MeOH, 0.3 ml) was added. The reaction was monitored by TLC (1/1 
petroleum ether/EtOAc, Rf 0.3) to completion and diluted with DCM (20 ml), washed with 
NaHCO3 (10 ml), and water (10 ml). The organic phase was collected and dried with MgSO4, 
filtered and the solvent removed under reduced pressure to afford a white foam (140 mg, 
97%). 1H NMR (300 MHz, CDCI3): δ (ppm) = 7.85-7.70 (4H, m, 4 x ArH), 7.70-7.40 (10H, m, 
10 x ArH), 5.40 (1 H, d, J = 9, H1), 4.41 (1H, dd, H3), 4.23 (2H, s, CH2), 4.14 (1H, dd, H4), 
3.98-3.95 (2H, m, H2, H5), 3.71-3.61 (2H, m, H6a, H6b), 2.26 (1 H, s, CH2CC-H), 1.07 (9H, 
S, CH3 x 3). 
13C NMR (75 MHz, CDCI3): β (ppm) = 168.4, 163.5 (2 x RCOR), 135.7, 135.6, 
134.1, 132.7, 132.7, 131.8, 130.0, 127.9, 127.7, 123.4 (6 x NPht + 4 x ArH), 96.0, 78.5, 75.1, 
74.5, 74.0, 71.5, 64.8 (C1-C6, -CH2CCH), 56.1 (-CH2CCH), 55.6 (CH), 26.8 (3 x CH3), 19.2 
(CCH3). MS (ESI): m/z 608.25 (M+Na)+ , C33H35NO7SiNa
+ requires 608.71.  
2-N-phthaIimido-2-deoxy-6-tert-butyl-diphenyIsilyl-β-O-propargyl-
glucopyranoside.
 
 
The fully protected sugar 2 (1.00 g, 2.09 mmol), propargyl alcohol (0.12 g, 2.09 mmol) and 
activated 3 Å molecular sieves were stirred in anhydrous DCM (30 ml). The mixture was 
cooled to 0oC under nitrogen, and borontrifluoride diethyl etherate (64 µl, 0.52 mmol) was 
added. The ice bath was removed and the reaction mixture was stirred for 16 hours at room 
temperature. The reaction was monitored by HPLC, (C18 column) and MS. The reaction 
mixture was neutralised dropwise with triethylamine, and then filtered and solvent removed 
under reduced pressure. The crude mixture was dissolved in methanol (25 ml) and 0.5 M 
NaOMe in MeOH was added until pH 10 was obtained. The reaction was stirred for 16 hours 
and then neutralised with acetic acid.  The mixture was then concentrated under reduced 
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pressure, azeotroped with toluene, and dried under high vacuum for 1 hour. TBDPSCl (768 
µl, 2.91 mmol) DIPEA (0.50 g, 3.89 mmol), DMAP (0.02 g, 0.19 mmol), anhydrous DCM (10 
ml),  were added to the dried mixture under nitrogen. The reaction was stirred for 3.5 hours. 
The reaction was monitored by TLC (1:1 petroleum ether/EtOAc, Rf 0.3) to completion and 
diluted with DCM (20 ml), washed with NaHCO3 (10 ml), and water (10 ml). The organic 
phase was dried with MgSO4, filtered and the solvent removed under reduced pressure to 
afford a yellow oil. The oil was purified by flash chromatography over silica (1:1 petroleum 
ether/EtOAc, Rf 0.3) to afford the product a white foam (749 mg, 62%).
1H NMR (300 MHz, 
CDCl3:δ  (ppm) =  7.85-7.70 (4H, m, 4 x ArH), 7.70-7.40 (10H, m, 10 x ArH), 5.40 (1H, d, J = 
9, H1), 4.41 (1H, dd, H3), 4.23 (2H, s, CH2), 4.14 (1H, dd, H4), 3.98-3.95 (2H, m, H2, H5), 
3.71-3.61 (2H, m, H6a, H6b), 2.26 (1H, s, CH2CC-H), 1.07 (9H, S, CH3 x 3).
13C NMR (75 
MHz, CDCI3): δ (ppm) = 168.4, 163.5 (2 x RCOR), 135.7, 135.6, 134.1, 132.7, 132.7, 
131.8,130.0, 127.9, 127.7, 123.4 (6 x NPht + 4 x ArH), 96.0, 78.5, 75.1, 74.5, 74.0, 71.5, 
64.8 (7C, C1-C6, -CH2CCH), 56.1 (1 C, -CH2CCH), 55.6 (C1, CH), 26.8 (3C, CH3), 19.2 (1C, 
CCH3). MS (ESI): m/z 608.25 (M+Na), C33H35NO7SiNa
+ requires 608.71. 
 
 
Disaccharide 84. 
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The trichloroacetimidate 8 (3.02 g, 6.15 mmol) and the glycoside acceptor 16 (1.8 g, 3.07 
mmol) were dissolved in anhydrous DCM (100 ml), containing 4 Å molecular sieves at -20oC, 
under nitrogen. TMS-OTF (0.68 g, 3.07 mmol) was added to the  cooled reaction mixture at -
20°C and stirred at -20°C for 2 hours. The reaction was then stirred at room temperature 
until TLC indicated that the reaction was complete. The mixture was diluted with DCM (50 
ml) and neutralised with solid NaHCO3, filtered and the solvent removed under reduced 
pressure. The mixture was purified by flash chromatography over silica (4: 1 toluene / ethyl 
acetate, Rt 0.3) to afford the product as a white foam (1.60 g, 57%).
1H NMR (400 MHz, 
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CDCI3): δ (ppm) = 7.87-7.27 (14H, m, ArH), 5.46 (1 H, d, J = 9, H1), 5.37 (1 H, br s, H4), 5.20 
(1 H, t, H2), 4.97 (1 H, dd, H3), 4.73 (1 H, d, J = 8, H1'), 4.50 (1 H, dd, H3'), 4.30 (2H, s, 
CH2), 4.18 (1 H, dd, H2'), 4.00-3.83 (7H, m, H6a', H6b', H4', H6a, H6b, H5, H5'), 3.60 (1H, d, 
OH), 2.33 (1H, t, CH), 2.14, 2.04, 2.00, 1.72, (12H, s, COCH3), 1.12 (12H, S, CH3 x 3).
13C 
NMR (100 MHz, CDCI3): δ (ppm) = 170.5, 170.1, 170.0, 169.1 (4 x RCOR), 136.0, 135.6, 
134.0, 133.5, 132.6, 131.9, 130.0, 129.9, 127.9, 127.7 (6 x NPht + 4 x ArH) 101.3, 95.4, 
81.0, 78.3, 75.2, 75.0, 71.2, 70.8, 69.3, 68.7, 66.8, 61.7, 61.3, 56.0, 55.3 (C1-C6', C1-C6, 
CH2CCH), 26.9 (3 x CH3), 21.0, 20.5, 20.4, 20.3 (4 x COCH3), 19.4 (CCH3). MS (ESI): m/z 
(M+Na) 938.9961 C50H55NO15SSiNa
+ requires 938.9973. 
 
Peracetylated N-acetyl lactosamine β-O-propargyl-glycoside. 
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To a solution of the phthalimide protected disaccharide (827 mg, 0.90 mmol), in THF (20 ml) 
at 0°C , acetic acid (0.52 ml, 9.02 mmol) was added. A solution of 1 M tetrabutylammonium 
fluoride (TBAF) (1.05 ml, 3.61 mmol) in THF was added and the reaction mixture stirred at 
room temperature for 15 hours. The mixture was subsequently concentrated to a yellow oil. 
The oil was dissolved in n-BuOH and ethylenediamine (0.27 ml, 3.61 mmol) and the reaction 
stirred at 90°C under reflux for 15 hours. The resulting orange solution was reduced to an oil 
and dissolved in 2:1 pyridine/acetic anhydride (45 ml) and stirred for 24 hours. The reaction 
was finally concentrated to give an orange oil and purified by flash chromatography over 
silica (100%, EtOAc, Rt 3.2) to afford the product as an orange solid (300 mg, 50%). 
1H NMR 
(500 MHz, CDCI3): δ (ppm) = 5.74 (1 H, d, J = 10, NH), 5.34 (1 H, d, J = 3, H4), 5.12-5.05 
(2H, m, H2, H3'), 4.92 (1H, dd, H3), 4.67 (1H, d, J = 8, H1'), 4.50-4.48 (2H, m, H6a', H1), 
4.33 (2H, s, CH2), 4.13-4.05 (4H, m, H2', H6b', H6a, H6b), 3.92-3.84 (1 H, m, H5), 3.79 (1 H, 
d, J = 9, H4'), 3.64 (1 H, m, H5'), 2.44 (1 H, t, CCH), 2.13, 2.10, 2.06, 2.04, 2.03, 1.98, 1.97 
(21 H, s, COCH3) 
13C NMR (500 MHz, CDCl3): δ (ppm) = 170.8, 170.5, 170.4, 170.4, 170.2, 
170.1, 168.4 (7 x RCOR), 101.1, 98.4, 78.5, 75.7, 75.4, 72.9, 72.5, 70.9, 70.8, 69.2, 66.7, 
62.2, 60.9, 55.7, 53.0 (C1'-C6', C1-C6, -CH2CCH), 23.3 (NHCOCH3), 20.7 (6 x COCH3). MS 
(ESI): m/z 696.30 (M+Na), C29H39NO17Na
+ requires 696.60. 
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3,4,6-tri-O-acetyl-2-deoxy-2-N-acetyl-β-O-propargyl-glucopyranoside.. 
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2) NH2CH2CH2NH2, n-BuOH.
HO1) DCM, Bf3Et2O.
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19
 
The fully protected sugar (0.25 g, 0.53 mmol), propargyl alcohol (32 µl, 0.53 mmol) and 
activated 3 Å molecular sieves were stirred in anhydrous DCM (5 ml). The mixture was 
cooled to 0oC under nitrogen, and borontrifluoride diethyl etherate (64 µl, 0.53 mmol) was 
added. The ice bath was removed and the reaction mixture stirred for 16 hours at room 
temperature. The reaction mixture was monitored by LC-MS to completion and then diluted 
with DCM (10 ml), washed with water (10 ml), NaHCO3 (10 ml), NaCl (10 ml) and water (10 
ml). The organic phase was dried with MgSO4, filtered and the solvent removed under 
reduced pressure to afford a yellow oil. The oil was dissolved in n-BuOH (10 ml) and 
ethylenediamine (116 µl, 1.57 mmol) and the reaction stirred at 90oC under reflux for 16 
hours. The resulting orange solution was reduced to an oil and dissolved in 2:1 
pyrindine/acetic anhydride (30 ml) and stirred for 5 hours. The reaction mixture was diluted 
with ethyl acetate (40 ml), washed with water (30 ml), NaHCO3 (30 ml), NaCl (30 ml) and 
water (30 ml). The organic phase was dried with MgSO4, filtered and the solvent removed 
under reduced pressure to afford an orange oil. The oil was purified by flash 
chromatography over silica (100% EtOAc, Rf 0.4) to afford the product a white solid (80 mg, 
40% yield over 3 steps).1H NMR (300 MHz, CDCl3:δ  (ppm) =   5.62 (1H, d, J = 9, HN), 5.30 
(1H, dd, H3), 5.11 (2H, dd, H4), 4.86 (1H, d, J = 8, H1), 4.37 (2H, s, CH2), 4.29-4.24 (1H, dd, 
H6a), 4.15-4.11 (1H, dd, H6b), 3.99 (1H, dd, H2), 3.75-3.69 (1H, m, H5) 2.27 (1H, s, 
CH2CC-H), 2.08, 2.02, 2.02, 1.95 (12H, S, CH3 x 3).
13C NMR (75 MHz, CDCI3): δ (ppm) = 
170.9, 170.7 170.3, 169.4 (4 x RCOR), 98.3, 78.5, 75.4, 72.4, 72.0, 68.5, 61.9 (7C, C1-C6, -
CH2CCH), 55.9 (1C, -CH2CCH), 54.3 (C1, CH), 23.4, 20.7, 20.7, 20.6 (4C, CH3). MS (ESI): 
m/z 408.30 (M+Na), C17H23NO9Na
+ requires 408.36. 
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2,3,4,6-tetra-O-acetyl-α-D-mannopyranose [3]. 
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Mannose (3.0 g, 16.64 mmol) was dissolved in 1:1 acetic anhydride/acetone (50 ml) and 
cooled to 0°C. Concentrated H2SO4 (3.2 ml) was added dropwise over 30 minutes. The 
reaction was allowed to come to room temperature by removal of the ice bath and stirring 
was continued overnight. After 16 hours the reaction mixture was poured into ice cold water 
(250 ml) and the aqueous phase extracted with DCM (3 x 100 ml), washed with NaHCO3 
(200 ml), water (200 ml) and dried with MgSO4. The organic phase was then filtered, the 
solvent removed under reduced pressure and purified by flash chromatography over silica 
(1/1 petroleum ether/EtOAc, Rf 0.3) to afford the paracetylated mannose as a white foam 
(3.00 g, 70%). This was forwarded to the next step. The paracetylated sugar (3.00 g, 7.68 
mmol) in anhydrous THF (40 ml) was treated with benzyl amine (1.09 ml, 9.99 mmol) under 
nitrogen. The reaction mixture was warmed to 50°C and stirring was continued for 16 hours 
under nitrogen. The solvent was then removed under reduced pressure and the crude 
product purified by flash chromatography over silica (1: 1 hexane: diethyl ether) to afford a 
yellow oil (1.68 g, 67%),1H NMR (300 MHz, CDCl3): δ (ppm) = 6.17 (1 H, d, J = 4, H1), 5.82 
(1H, d, J = 9, OH), 5.24 (1H, dd, H3), 5.18 (1H, dd, H4), 4.50 (1H, dd, H2), 4.31-4.10 (3H, m, 
H6a, H6b, H5), 2.10, 2.03, 2.02, 1.96, (12H, s x 4, COCH3 X 4). 
13C NMR (75 MHz, CDCI3): 
δ (ppm) = 170.3, 170.1, 169.9, 168.9, 166.4 (5C, 5 x RCOR), 89.7, 68.7, 67.4, 67.3, 66.4, 
61.2 (6C, C1-C6), 20.1, 20.9, 20.6, 20.5, (4C, COCH3). MS (ESI): m/z 371.29 (M+Na), 
C14H20NaO1O
+ requires 371.29.  
 
2,3,4,6,-tetra-O-acetyl-1-trichloroacetimidate-α-D-mannopyranoside [3]. 
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To a solution of the hemi-acetal (1.6 g, 4.59 mmol) in anhydrous DCM containing 3 Å 
molecular sieves, anhydrous potassium carbonate (1.91 g, 13.7 mmol) and 
trichloroacetonitrile (4.65 ml, 45.96 mmol) was added. The reaction was stirred under 
nitrogen for 5 hours and filtered with suction. The solvent was removed under reduced 
pressure and purified by flash chromatography over silica (3/1 EtOAc/petroleum ether, Rt 
0.3) to afford a the product as a white foam (1.6 g, 77%). 1H NMR (300 MHz, CDCI3): δ 
(ppm) =  8.66 (1H, s, NH), 6.55 (1H, d, J = 4, H1), 5.52 (1H, d, J = 2, H4), 5.36 (1 H, dd, H3), 
5.23 (1 H, dd, H2), 4.38 (1 H, m, H5), 4.16-4.01 (2H, m, H6a, H6b), 2.13, 2.02, 2.00,1.98, 
(12H, s x 4, COCH3 x 4). 
13C NMR (75 MHz, CDCI3): δ (ppm) = 170.1 (4C, 4 x RCOR), 93.6, 
69.0, 67.5, 67.4, 66.9, 61.3 (C1-C6), 20.6, (4CH3, COCH3). MS (ESI): m/z 492.62 (M+Na), 
C16H20Cl3O10Na
+ requires 492.69.  
 
2,3,4,6-tetra-O-acetyl-α-O-propargyl-mannopyranoside [3]. 
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To a solution of the trichloroacetimidate (1.17 g, 3.50 mmol) in anhydrous DCM (10 ml) 
under nitrogen, powdered 4 Å molecular sieves and propargyl alcohol (0.20 ml, 350 mmol) 
were added. The resulting mixture was cooled to 0oc, and a solution of BF3.OEt2 (0.11 ml, 
0.87 mmol) in anhydrous DCM (1.6 ml) was added dropwise for 10 minutes. The stirring was 
continued at room temperature overnight. Then the reaction mixture was neutralised, by 
dropwise addition of Et3N, and the reaction filtered through celite. The filtrate was 
concentrated under reduced pressure and purified by flash chromatography over silica (1: 1 
ethyl acetate/ petroleum ether Rf:0.3) to afford the product as a white foam (1.3 g, 84%). 
1H 
NMR (500 MHz, CDCI3): δ (ppm) = 5.29 - 5.21 (3H, m, H4, H2, H3), 4.98 (1H, d, J = 2, H1), 
4.25- 4,21 (3H, m, CH2, H6a), 4.04 (1 H, dd, H6b), 4.96 (1 H, m, H5), 2.45 (1 H, t, CH), 2.09, 
2.04, 1.99, 1.92 (12H, s x 4, COCH3 x4). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 170.7, 170.0, 
169.9, 169.7 (4qC, 4 x RCOR), 96.3, 78.0, 76.1, 75.7, 69.3, 69.0, 98.7, 62.3, 55.0 (C1-C5, 
CH2 x 2, CH), 20.9, 20.8, 20.7, 20.7 (4CH3, COCH3). MS (ESI): mlz 409.22 (M+Na), 
C17H22NaO10+ requires 409.11. 
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6-O-Toluensulphonyl-α-methyl-D-mannopyranoside [4]. 
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A solution of the α-methyl-O-mannopyranoside (3.36 g, 17.3 mmol) in anhydrous pyridine 
(20.00 ml) was cooled to 0°C in an ice bath with stirring. A solution of p-toluenesulphonyl 
chloride (3.61 g, 19.0 mmol) in anhydrous pyridine (15.00 ml) was then added dropwise over 
30 minutes and stirring was continued at 0°C until the reaction was complete by TLC. The 
solvent was then removed under reduced pressure to afford a crude product, which was 
purified by flash chromatography over silica (15:2 DCM/MeOH) to afford 6-O-
toluensulphonyl-α-methyl-D-mannopyranoside (4.99 g, 85%) as a colourless oil. 1H NMR 
(300 MHz, CDCl3): δ (ppm) = 7.77 (2H, d, J = 9, 2 x ArH), 7.29 (2H, d, J = 8 Hz, 2 x ArH), 4.62 
(1H, br s, H1), 4.28 (2H, br s, H4, H5), 3.88 (1 H, br s, H2), 3.68 (3H, m, H3, CH2), 3.24 (3H, 
s, OCH3), and 2.38 (3H, S, CH3). 
13C NMR (63 MHz, CDCI3): δ (ppm) = 144.6 (qC, Ts), 132.3, 
129.6, 127.7 (3CH, Ts), 100.7 (CH, C1), 71.3, 70.1, 69.8, 69.6, 66.7, 54.5 (2CH, C2-C5), 
30.4 (OCH3), and 21.3 (CH3). MS (ESI): m/z 370.80 (M+Na), C18H20O8NSNa
+ requires 
371.40. 
 
 
1,2,3,4-tetra-O-acetyl-6-azido-6-deoxy-α-D-mannopyranoside [5]. 
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To a solution of anhydrous DMF (20 ml) and NaN3 (4.50 g, 69.0 mmol), was added to a 
solution of the tosylate (3.45 g, 9.90 mmol) in anhydrous DMF. The solvent had been dried 
over molecular sieves under nitrogen for 1 hour prior to use. The reaction was heated to 
100°C with stirring behind a blast shield and heating continued at 100°C for 6 hours. Upon 
cooling to room temperature, the colourless precipitate was removed by filtration through a 
plug of silica under suction and the solvent was evaporated under reduced presure. The 
solid was dissolved in DCM, filtered and evaporated under vacuum. The product was 
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119 120 
120 122 
121 
 
purified by flash chromatography over silica (15:2 DCM/MeOH) to afford 6-azido-6-deoxy-α-
methyl-D-mannopyranoside as a colourless syrup. This methyl glycoside (2.45 g, 11.00 
mmol) was dissolved in (1: 1 AC2O/AcOH) (206 ml) and cooled to 0°C. Concentrated H2SO4 
(2.20 ml) was added dropwise over 30 minutes, with stirring. The reaction was then allowed 
to come to room temperature by removal of the ice bath and stirring was continued 
overnight. After 26 hours the reaction mixture was poured into ice water (250 ml) and the 
aqueous phase was extracted with DCM (3 x 100 ml). The combined organic extracts were 
washed with cold water (200 ml), sat. aq. NaHCO3 (200 ml) and dried with MgSO4. The 
solvent was removed under reduced pressure to afford the crude product which was purified 
by flash chromatography over silica (60:40 pet.ether/EtOAc) to afford the peracetylated 
product 1,2,3,4-tetra-O-acetyl-6-azido-6-deoxy-α-D-mannopyranoside as a colourless oil 
(2.93 g, 72% over 2 steps).1H NMR (300 MHz, CDCI3): δ (ppm) = 6.04 (1 H, d, J = 2, H1), 
5.22-5.29 (2H, m, H3, H4), 5.23 (1 H, m, H2), 3.94 (1 H, m, H5), 3.36 (1 H, dd, H6a), 3.25 (1 
H, dd, H6b), 2.14, 2.13, 2.02, 1.99 (12H, s x 4, COCH3). 
13C NMR (75 MHz, CDCI3): δ (ppm) 
= 170.5, 169.6, 169.5, 168.0 (qC, 4 x COCH3), 90.6, 70.8, 70.2, 67.6, 62.9 (5CH, C1-C5), 
56.6 (CH2), 20.7 (4CH3, COCH3). MS (ESI): m/z 395.90 (M+Na), C14H19 N3O9Na
+ requires 
396.30.  
 
6-thioacetate-6-deoxy-α-methyl-D-mannopyranoside. 
 
O
HO
HO
OH
OTs
OMe
O
HO
HO
OH
SAc
OMe
KSAc, HMPA
24 27
58%
 
 
To a solution of HMPA (20.0 ml) and potassium thioacetate (0.98 g, 8.61 mmol), a solution 
of the tosylate (1.00 g, 2.87 mmol) was added at room temperature. The reaction was 
monitored by TLC (7:1 DCM/MeOH). The mixture was diluted with DCM (50 ml) washed with 
water (10 ml), HCl (10 ml) and water (10 ml), and dried with MgSO4. The organic phase was 
then filtered, concentrated under reduced pressure and purified by flash chromatography 
over silica (7:1, DCM/MeOH, Rf 0.3) to afford the product as a white foam (0.41 g, 58%).
1H 
NMR (300 MHz, CDCl3): δ (ppm) = 4.67 (1H, br s, H1), 3.94 (1H, br s, H2), 3.62-3.53 (2H, m, 
H4, H5), 3.32 (4H, m, H6a, OCH3), 3.19 (1H , dd, H6b), 2.38, (3H, S, CH3).
13C NMR (75 
MHz, CDCI3): δ (ppm) = 198.3 (1C, SCOR), 100.1, 77.2, 71.1, 70.5, 69.8, 55.0 (6C, C1-C6), 
31.0, 30.6 (2C, OCH3, SOCH3). MS (ESI): m/z 275.11 (M+Na), C9H16SNaO6
+ requires 
275.27. 
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1,2,3,4,-tetra-O-acetyl-6-thioacetate-6-deoxy-α-D-mannopyranoside. 
 
O
HO
HO
OH
SAc
OMe
O
AcO
AcO
OAc
SAc
OAc
Ac2O, AcOH, H2SO4
27 28
73%
 
 
The methyl glycoside (1.80 g, 7.14 mmol) was dissolved in 1:1 Ac2O/AcOH (20 ml) and 
cooled to 0oC. Concentrated H2SO4 (2.2 ml) was added dropwise over 30 minutes with 
stirring. The reaction was then allowed to come to room temperature by removal of the ice 
bath and stirring was continued overnight. After 26 hours the reaction mixture was poured 
into ice water (250 ml) and the aqueous phase was extracted with DCM (3 x 100 ml). The 
combined organic extracts were washed with cold water (200 ml), sat. aq. NaHCO3 (200 ml) 
and dried with MgSO4. The solvent was removed under reduced pressure to afford the crude 
product which was purified by flash chromatography over silica (1: 1 petroleum ether/EtOAc 
Rf: 0.2) to afford the peracetylated product as a yellow oil (2.12 g, 73%). 
1H NMR (300 MHz, 
CDCI3): δ (ppm) = 6.22 (1 H, d, J = 3, H1), 5.22 (3H, m, H2, H3, H4), 3.95 (1 H, m, H5), 3.19 
(1H, dd, H6a), 3.06 (1H, dd, H6b), 2.33, 2.17, 2.15, 2.11, 1.98, (15H, s x 5, ROCH3 X 5).
13C 
NMR (75 MHz, CDCI3): δ (ppm) = 194.8 (qC, SCOCH3) 170.0, 169.8, 169.8, 168.1, (4qC, 4 x 
COCH3), 90.5, 77.2, 71.8, 68.7, 68.4, 67.7 (5CH, CH2, C1C6), 30.4, 30.1, 20.8, 20.8, 20.6, 
(5CH3, ROCH3). MS (ESI): m/z 429.10 (M+Na), C16H22SNaO10
+ requires 429.08. 
Methyl 6-O-tert-butyl-diphenylsilyl-2,3-O-isopropylidene-α-D-mannopyranoside [6]. 
O
HO
HO
OH
OH
OMe
O
HO
O
O
OTBDBS
OMe
1) Ph2tBuSiCl
imidazole, DMF
2) Me2C(OMe)2
CSA, acetone
29
90%
23
 
Tert-butylchlorodiphenylsilane (10.43 g, 37.9 mmol) was added dropwise to a stirred solution 
of the methyl α-D-mannopyranoside (6.70 g, 34.5 mmol) and imidazole (5.17 g, 75.9 mmol) 
in DMF (140 ml) under nitrogen at room temperature. After 2 hours, TLC (1:9 
methanol/EtOAc) showed the loss of starting material (Rf 0.1) and the formation of a major 
product (Rf 0.6). The solvent was removed under reduced pressure and the residue 
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dissolved in chloroform (100 ml), and washed with HCI 0.1 M (100 ml), then water (100 ml). 
The aqueous fractions were re-extracted with chloroform (2 x 30 ml). The organic fractions 
were combined, dried over MgSO4, filtered, and the solvent was removed under reduced 
pressure. The residue (12.0 g, 27.8 mmol) was dissolved in a solution of (1:9 2,2-
dimethoxypropane in acetone) (125 ml) and the resulting solution adjusted to pH 4 using 
camphorsulfonic acid. The reaction solution was stirred under nitrogen at room temperature. 
After 2 hours, TLC (1:3 hexane/EtOAc) showed the loss of starting material and the 
formation of a major product. The solution was neutralised using aqueous ammonia solution 
and the solvent removed under reduced pressure, the residue dissolved in chloroform (100 
ml), and washed with water (2 x 100 ml). The aqueous fractions were re-extracted with 
chloroform (2 x 30 ml). The organic fractions were combined, dried over MgSO4, filtered, and 
the solvent was removed under reduced pressure. The residue was purified by flash 
chromatography (1:3 hexane/EtOAc) to give the desired product (11.5 g, 90%) as a 
colourless oil. 1H NMR (300 MHz, CDCI3): δ (ppm) = 7.69 (4H, m, ArH), 7.26 (6H, m, ArH), 
4.88 (1 H, s, H1), 4.10 (2H, m, H2, H3), 3.89 (2H, m, H6a, H6b), 3.78 (1 H, m, H4), 3.59 (1 
H, m, H5), 3.34 (3H, s, OCH3), 2.75 (1 H, d, J = 4, OH), 1.51, 1.35 (6H, s x 2, CH3), 1.07 
(9H, s, CH3). 
13C NMR (75 MHz, CDCI3): δ (ppm) = 135.7, 135.6, 134.8, 133.1, 133.0, 129.9, 
127.8,127.8 (CH, Ar), 109.5 (qC, C(CH3)2), 98.3, 78.2, 75.3, 70.6, 69.5 (5CH, C1-C5), 64.7 
(CH2), 54.9 (OCH3), 27.9 (CH3, C(CH3)), 26.8 (3CH3, SiC(CH3)), 26.1 (CH3, C(CH3)), and 
19.2 (qC, SiC(CH3h). MS (ESI): m/z 495.5 (M+Na), C26H36O6SiNa
+ requires 495.6. 
 
Methyl 6-O-tert-butyl-diphenyl-silyl-2,3-O-isopropylidene-α-talopyranoside [6]. 
O
HO
O
O
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O
O
OTBDBS
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1) PCC, DCM
2) NaBH4
EtOH/H2O
29
30
89%
 
The methyl α-O-mannopyranoside (3.88 g, 8.21 mmol), powdered dried molecular sieves 
(5.61 g) and pyridinium chlorochromate (5.42 g, 25.2 mmol) were stirred in anhydrous DCM 
(27.00 ml) under nitrogen at room temperature for 5 hours. At this point TLC (1:2 
ether/hexane) showed complete conversion of the starting material (Rf 0.3) to a single 
product (Rf 0.5). The reaction mixture was triturated with ether (50 ml), then filtered through 
a plug of silica topped with celite (ether eluant). The solvent was removed under reduced 
pressure, the residue dissolved in (9:1 EtOH/water), and cooled to 0oC. Sodium borohydride 
(570 mg) was added and the solution allowed to warm slowly to room temperature. After 3 
hours TLC (1:3 EtOAc/hexane) showed the formation of a single product (Rf 0.4) and the 
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complete consumption of the starting material (Rf 0.5). The reaction was quenched with 
ammonium chloride until effervescence ceased. The solvent was removed under reduced 
pressure and the residue dissolved in chloroform (40 ml), and washed with water (2 x 40 ml). 
The organic fraction was dried over MgSO4, filtered, and the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (1:3 EtOAc/hexane) to 
give the desired product (3.47 g, 90%) as a colourless oil. 1H NMR (300 MHz, CDCl3): δ 
(ppm) = 7.72 (4H, m, Ar), 7.37 (6H, m, Ar), 5.08 (1H, d, H1), 4.21 (1H, dd, H3), 4.08 (1H, dd, 
H2), 3.95 (1H, dd, J = 7, H6a), 3.94 (1H, dd, J = 7, H6b) 3.84 (2H, m, H4, H5), 3.41 (3H, s, 
OCH3), 2.36 (1 H, d, J = 7, OH), 1.59, 1.36, (6H, s, 2 x C(CH3)), and 1.10 (9H, S, SiC(CH3)). 
13C NMR (75 MHz, CDCI3): δ (ppm) = 135.7 (CH, Ar), 135.6 (CH, Ar), 134.9 (qC, Ar), 129.8 
(CH, Ar), 127.8 (CH, Ar), 109.4 (qC, C(CH3h), 98.5, 73.8, 72.8 ,69.5, 64.1 (5CH, C1-C5), 
63.4 (CH2), 54.0 (OCH3), 26.9 (3CH3,SiC(CH3)), 25.9, 25.2 (2CH3, C(CH3)2, and 19.2 (qC, 
SiC(CH3)3. MS (ESI): m/z 495.5 (M+Na), C26H36O6SiNa
+ requires 495.6.  
Methyl 4-azido-6-O-tert-butyl-diphenyl-silyl-4-deoxy-2,3-O-isopropylidene-α-D-  
mannopyranoside [6].  
 
O
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O
O
OTBDBS
OMe
ON3
O
O
OTBDBS
OMe
1) Tf2O, Pyr, DCM
2) NaN3, DMF
30
31
80%
The methyl-α-D-mannopyranoside (3.94 g, 8.32 mmol) was dissolved in anhydrous DCM (80 
ml) under nitrogen. Pyridine (2.7 ml, 33.28 mmol) was added and the solution was stirred at 
– 35°C for 30 minutes. Triflic anhydride (1.62 ml, 9.65 mmol) was added dropwise with 
stirring and the mixture allowed to reach -10°C. After 2 hours TLC (1:3 ether/hexane) 
showed complete conversion of the starting material (Rf 0.4) to a single product (Rf 0.5). 
Methanol (1 ml) was added to quench the reaction and the resulting solution warmed to 
room temperature. The solution was washed with water (100 ml), pH 7 PBS solution (100 
ml), and the aqueous layer re-extracted with chloroform (30 ml x 2). The organic fractions 
were combined, dried with MgSO4, filtered, and the solvent was evaporated under reduced 
pressure. The residue was dissolved in DMF (31 ml) under nitrogen and sodium azide (2.16 
g, 33.28 mmol) was added. The resulting mixture was heated at 90°C for 3 hours with 
stirring. The mixture was then allowed to cool down to room temperature, filtered through a 
plug of silica (DCM as eluant), and the solvent was removed under reduced pressure. The 
residue was dissolved in chloroform (100 ml), washed with distilled water (100 ml x 2), and 
the aqueous layers were re-extracted with chloroform (30 ml x 2). The organic fractions were 
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combined, dried with MgSO4, filtered and the solvent removed under reduced pressure. The 
crude product was purified by flash chromatography (1:3 ethyl acetate/hexane, Rf 0.6)  to 
give the desired product (3.30 g, 80%) as a colourless oil. 1H NMR (300 MHz, CDCI3): δ 
(ppm)= 7.79-7.72 (4H, m, Ar), 7.46-7.93 (6H, m, Ar), 5.01 (1 H, d, H1), 4.21 (1 H, dd, J = 8, J 
= 5, H3), 4.19 (1 H, dd, J = 5, H2), 3.88 (2H, m, H6a, H6b), 3.75 (1H, dd, J = 11, J = 9, H4), 
3.41 (1 H, m, H5) 3.36 (3H, s, OCH3), 1.60, 1.41 (6H, s, C(CH3)2), and 1.12 (9H, s, 
SiC(CH3)3). 
13C NMR (75 MHz, CDCl3): δ (ppm) = 135.9, 135.7 (CH x 2, Ar), 133.4, 133.2 
(2x qC, Ar), 129.7, 129.7 127.8, 127.7 (4CH, Ar), 110.0 (qC, C(CH3)2), 98.2, 76.7, 75.0, 68.9, 
(CH, C1, C2, C3, C5), 63.3 (CH2), 60.7 (CH, C4), 54.9 (OCH3), 28.2 (2CH3, C(CH3)2), 26.8 
(3CH3, SiC(CH3)3), and 19.4 (qC, SiC(CH3)3). MS (ESI): m/z 520.23 (M+Na), 
C26H35N3O5SiNa
+ requires 520.22. 
 
1,2,3,6-tetra-O-acetyl-4-azido-4-deoxy-α-D-Mannopyranoside [6]. 
 
ON3
O
O
OTBDBS
OMe
ON3
AcO
OAcAcO
OAc
1) Bu4NF/THF
2) TFA H2O/dioxane
3) Ac2O, AcOH H2SO4
31
76%
32
 
 
The methyl α-D-mannopyranoside 31 (1.12 g, 2.25 mmol) was dissolved in anhydrous THF 
(12.5 ml) under nitrogen. A 10 M solution of tetrabutylammonium fluoride (TBAF) in THF was 
slowly added (4.4 ml), and stirring was continued under nitrogen. After 1 hour TLC (3:1 
ether/hexane) showed complete conversion of the starting material (Rf 0.5) to a single 
product (Rf 0.1). The solvent was evaporated under reduced pressure. The residue was 
dissolved in chloroform (20 ml), washed with distilled water (20 ml x 2), and the aqueous 
layers were re-extracted with chloroform (10 ml x 2). The organic fractions were combined, 
dried with MgSO4, filtered and the solvent was evaporated under reduced pressure. The 
crude product (750 mg, 2.90 mmol) was dissolved in 0.3 ml 1,4-dioxane and aqueous TFA 
(1:1 TFA/water, 10.00 ml), and stirring was continued at room temperature. After 1 hour TLC 
(3:1 ether/hexane) showed complete conversion of the starting material (Rf 0.1) to a single 
product (Rf ~0). The solvent was co-evaporated with toluene (5 ml x 2) to dryness under 
reduced pressure. The residue was dissolved in acetic anhydride (16.50 ml), and the 
solution was cooled down to 0°C. Concentrated H2SO4 (0.50 ml) was added dropwise and 
the reaction was allowed to come to room temperature by removal of the ice bath. Stirring 
was continued overnight. The reaction mixture was then diluted with chloroform (10.00 ml), 
cooled to 0°C with an ice bath, and neutralised with sat. aq. NaHCO3 which was slowly 
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added. The organic layer was washed with distilled water (20 ml x 2), dried MgSO4 and 
concentrated under reduced pressure. The resulting mixture was purified by flash 
chromatography over silica (3:2 petroleum ether/EtOAc, Rf 0.3) to afford a pale yellow oil 
(820 mg, 76% over three steps). 1H NMR (500 MHz, CDCI3): δ (ppm) = 6.09 (1H, d, J = 1.9 
Hz, H1), 5.19 (1H, dd, H3), 5.16 (1H, dd, H2), 4.28 (1H, dd,
H6a), 4.23 (1 H, dd, H6b), 3.84 (1 H, dd, H4), 3.75 (1 H, m, H5), 2.10, 2.08, 2.05, and 2.02 
(12H, S, COCH3). 
13C NMR (75 MHz, CDCI3): δ (ppm) = 170.5, 169.6, 169.5, 168.0 (4qC, 
COCH3), 90.6, 70.8, 70.2, 67.5 (3 CH, C1, C2, C3, C5), 62.9 (CH2), 56.6 (CH, C4), 20.7 
(4CH3, COCH3). (ESI): m/z 396.10 (M+Na), C14H19 N309Na
+ requires 396.10. 
 
Molecule 136.
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ManT 18.3 mU, MnCl2 (10 mM), 
phosphatase inhibitors (4 µl),
ammonium formate (50 mM),
pH 7.2, Triton-X (0.1%).
95 %
33
GDP-mannose
 
To a 1.5 ml Eppendorf tube, GDP-mannose (3.2 mg, 100 mM), mannose α-benzyl glycoside 
(1000 mM), α-1,2 mannosyltransferase (91.5 mU), ammonium formate buffer (50 mM) at pH 
7.2, Triton X-100 (0.1%), MnCI2 (10 mM) and phosphatase inhibitors (20 µl) were  added to 
make up a total volume of 500 µl. The reaction mixture was shaken at 30oC for 48 hours then 
diluted with water (200 µl) and extracted with DCM (100 µl). The aqueous phase was 
collected and purified by reverse phase HPLC using C18 column at 254nm (RT: 17.9, 
gradient 5-95% (water/acetonitrile) over 30 minutes). The purified disaccharide was 
Iyophilised to give the product as a white foam (2 mg, 95%, Rf 0.6, 12:12:4 
MeOH:CHCl3:H2O). 
1H NMR (500 MHz, D2O): δ (ppm) = 7.32 (5H, m, ArH), 5.07 (1, s, H1 
'),4.91 (1H, s, H1), 4.32 (1H, d, J = 12, CH2), 3.98 (1H, dd, H2), 3.88 (1H, dd, H2'), 3.81 (1H, 
dd, H3'), 3.78 (2H, dd, H6a, H6b), 3.73 (1H, dd, H3), 3.68 (2H, dd, H6a, H6b), 3.65-3.51 (4H, 
m, H4', H5', H4, H5). 13C NMR (125.77 MHz, D2O): δ (ppm) = 134.0, 129.2, 129.0, 128.8, 
170.1 (6 x ArH), 100.6, 100.3, 73.2, 73.3, 70.9, 70.8, 70.4, 70.3, 69.7, 67.2, 67.1, 64.5, 61.2, 
(C1-C6, C1'-C6', CH2) MS (ESI): m/z (M+Na) 455.1526, C19H2SO11Na
+ requires 455.1529.  
 
Man  18.3 mU, MnCl2 (10 mM), 
Pho tase inhibitors (20 µl), 
Am oniu  formate (50 mM), 
pH 7.2, Triton X-100 (0.1%) 
                    95% 
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2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-D-glucopyranoside chloride  [1]. 
 
O
HO
HO
NHAc
OH
HO
41 %
AcCl O
AcO
AcO
NHAc
OH
AcO
34  
 
N-acetyl glucosamine (10.10 g, 43.25 mmol) was added to acetyl chloride (20 ml) with 
stirring and the mixture stirred overnight at room temperature. The mixture was then diluted 
with DCM (80 ml) and poured into ice-water (40 ml) with stirring. The organic layer was 
added to saturated sodium bicarbonate solution and ice (80 ml) with stirring until neutral (gas 
evolution stops). The organic phase was extracted, dried over MgSO4 and evaporated to 
give a yellow oil. The crude product was purified by column chromatography on silica (ethyl 
acetate 100% Rf 0.2) to afford the desired product (6.70 g, 41%). 1H NMR (300 MHz, 
CDCI3):δ ppm = 6.19 (1H, d, J = 3, H1), 5.77 (1 H, d, J = 9, NH), 5.35-5.19 (2H, m, H3, H4), 
4.54 (1 H, m. H2), 4.23 (2H, m, H6a, H5), 4.10 (1 H, dd, H6b), 2.24-1.98 (12H, 3s, 4 x CH3). 
Found m/z (ESI): 365.9. C14H21NO8CI requires m/z 366.1. 
 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl azide [1]. 
 
O
AcO
AcO
NHAc
OH
AcO
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NaN3. TBAHS, DCM, 
Sat aq. NaHCO3
35  
 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-O-glucopyranosyl chloride (6.54 g, 17.66 mmol), 
sodium azide (3.61 g, 55.55 mmol) and tetrabutylammonium hydrogen sulphate (6.14 g, 
18.08 mmol) were dissolved in DCM (70 ml). Saturated sodium bicarbonate was then added 
and the reaction mixture stirred vigorously for 1.5 hours. The reaction mixture was then 
diluted with ethyl acetate (120 ml) and extracted a further two times with ethyl acetate (100 
ml), brine (100 ml) and water (100 ml), then dried over MgSO4 and the solvent removed 
under reduced pressure to give 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl 
azide as a white solid (6.21 g, 95%).1H NMR (300 MHz, CDCI3):δ ppm = 5.57 (1 H, d, J = 9, 
NH), 5.24 (1 H, d, J = 9, H3), 5.10 (1 H, dd, H4), 4.76 (1 H, d, H1), 4.26 (1 H, dd. H6a), 4.18 
(1 H, dd, H6b), 3.90 (1 H, dd, H2), 3.80 (1 H, m, H5), 2.08-1.98 (12H, 4 x s, 4 X CH3). Found 
m/z (ESI): 395.10 (M+Na), C14H21N4O8Na
+ requires m/z 395.11. 
 
41% 
% 
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2-Acetamido-2-deoxy-3-O-acetyl-4-6-O-p-methoxybenzylidene-β-D-glucopyranosyl 
azide [1]. 
O
AcO
AcO
NHAc
N3
AcO
OO
AcO
NHAc
N3
OPMP
1) NaOMe, MeOH
2)
OMe
MeO
MeO
DMF, TsOH
35
37
51% over 3 steps
3) Ac2O, pyr
 
2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl azide 35 (5.01 g, 13.44 mmol) 
was dissolved in anhydrous MeOH (25 ml) and sodium methoxide (300 µl of 0.5 M solution 
in MeOH) was added and the reaction mixture was stirred for 2 hours at room temperature. 
The reaction mixture was the neutralised by the addition of acetic acid (10 µl  and then 
concentrated under reduced pressure to afford 2-acetamido-2-deoxy-3,4,6-tri-O-hydroxy-β-
D-glucopyranosyl azide as a crude pale yellow foam (3.19, 96%), The crude was forwarded 
on to the next step without further analysis and purification. Found m/z (ESI): 246.00 
(M+Na), C6H14N4O5 requires 246.22. The crude azide was dissolved in anhydrous DMF (20 
ml) and p-anisaldehyde dimethyacetal (5.64 g, 30.96 mmol) and p-tosic acid (0.46 g, 2,42 
mmol) were added. After stirring for 1.5 hours at 50°C the reaction mixture was 
concentrated under reduced pressure and the residue poured into a cold mixture of 
saturated sodium bicarbonate (50 ml) and DCM (50 ml). The mixture was cooled to 4°C for 
10 minutes and the remaining precipitate was filtered off and then crystallised with ethyl 
acetate. The solid was dried under vacuum to afford the crude 2-acetamido-2-deoxy-4,6-O-
p-methoxybenzylidene-β-D-glucopyranosyl azide as a white solid. Found mlz (ESI): 407.40 
(M+Na), C17H22N4O6Na
+ requires 407.38. The crude was forwarded on to the next step 
without further analysis and purification. Due to its very poor solubility the crude acetal (3.11 
g, 8.53 mmol) was dissolved in pyridine (30 ml) and acetic anhydride (15 ml) was added. 
The mixture was stirred for 24 hours at room temperature then concentrated under vacuum. 
DCM (150 ml) was then added and the organic phase was washed with water (20 ml), sat. 
aq. NaHCO3 (20 ml) and water (20 ml). The organic layer was dried with Na2SO4 and the 
solvent removed under vacuum and crystallised from ethyl acetate to afford 2-acetamido-2-
deoxy-4,6-O-p-methoxybenzylidene-β-D-glucopyranosyl azide as a white solid (2.76 g, 51% 
over three steps). 1H NMR (300 MHz, CDCI3): δ ppm = 7.35 (2H, d, J = 8.7, ArH), 6.89 (2H,d, 
J = 9, ArH), 5.68 (1 H, d, J = 9, NH), 5.47 (1 H, s. ArCH), 5.24 (1H, dd, H3), 4.57 (1H, d, J = 
9.2, H1), 4.37 (1H, dd. H6a), 4.11 (1H, dd, H2), 3.80 (3H, s, OCH3), 3.80 - 3.55 (3H, m, H6a, 
H4, H5), 2.08 (3H, s, CH3), 1.92 (3H, s, CH3) Found mlz (ESI): 387.10 (M+Na), 
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C14H21N4O8Na
+ requires mlz 387.12 
 
2-Acetamido-2-deoxy-3-O-acetyl-6-O-p-methoxybenzyl-β-D-glucopyranosyl azide [1]. 
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Trifluoroacetic acid (5.73 g, 50.25 mmol) in anhydrous DMF (30 ml) was cooled to 0oC and 
added dropwise to a mixture of p-methoxybenzylidene acetal (2.01 g, 4.90 mmol), sodium 
cyanoborohydride (1.66 g, 26.40 mmol) and 4 Å molecular sieves in anhydrous DMF (40 ml) 
at 0°C. After the addition was complete, the ice bath was removed and the reaction mixture 
stirred at room temperature for 16 hours. The reaction mixture was then filtered with suction 
and the filtrate poured into ice cold sat. aq. NaHCO3. The mixture was extracted with DCM 
(6 x 60 ml), and the organic layers combined and washed with sat. aq. NaHCO3 (80 ml). The 
organic layer was dried with MgSO4 and the solvent removed under reduced pressure. The 
crude product was purified by flash chromatography over silica (100% etheyl acetate) and 2-
acetamido-2-deoxy-3-O-acetyl-6-O-p-methoxybenzyl-β-D-glucopyranosyl azide was isolated 
as a white solid (0.90 g, 45%) 1H NMR (300 MHz, CDCI3):δ ppm = 7.25 (2H, d, J = 8.6, ArH), 
6.88 (2H, d, J = 9, ArH), 6.05 (1 H, d, J = 9, NH), 5.08 (1H, dd, H3), 4.57 (1H, d, J = 9, H1), 
4.55 (2H, d. CH2), 3.94 (1H, m, H2), 3.76 (3H, s, OCH3), 3.71-3.69 (3H, m, H6a, H6b, H4), 
3.60 (1 H, m, H5), 2.16 (3H, s, CH3), 1.96 (3H, s, CH3) Found m/z (ESI): 389.53 (M+Na), 
C14H21N4O8Na
+ requires m/z 389.14.  
 
2-Phthalimido-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranose [1]. 
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The thiophenyl glycoside 3 (4.5 g, 8.54 mmol) and N-iodosuccinimide (3.19 g, 14.2 mmol) 
was dissolved in acetone (20 ml) and water (2 ml). The mixture was stirred for 3.5 hours  at 
room temperature, then diluted with DCM (100 ml) and washed with water (100 ml), 
saturated sodium thiosulphate (100 ml) and again with water (100 ml). The organic layer was 
dried over Na2SO4 and the solvent removed under reduced pressure to afford the hemi-
50% 
148 149 
72 150 
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acetal as a crude yellow oil. The product was purified by flash chromatography over silica 
(ethyl acete/ petroleum ether 1: 1) to afford a white solid (50%).1H NMR (300 MHz, CDCl3):δ 
ppm = 7.87-7.81 (4H, m, ArH), 5.82 (1 H, d, H1), 5.60 (1 H, dd, H2), 5.16 (1 H, dd, H4), 4.30-
4.11 (3H, m, H2, H6b, H6b), 3.96-3.90 (1 H, m, H5), 2.12, 2.03, and 1.82 (9H, 3 x s, COCH3) 
Found m/z (ESI): 458.30 (M+Na), C20H21NO10Na
+ requires m/z 438.37. 
 
O-(2-phthalimido-2-deoxy-3,4,6-tri-O-acetyl-β-D-gIucopyranosyl)-
trichloroacetimidate[1].  
 
O
AcO
AcO
NPht
O
OAc
CCl3
NH
Cl3CCN, K2CO3
DCM.
40
75 %
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A solution of hemi-acetal 39 (0.7 g, 1.61 mmol) and trichloroacetimidate (3.3 ml, 16.07 
mmol) in anhydrous DCM containing 3 Å molecular sieves was added to a solution of 
potassium carbonate (0.64 g, 4.82 mmol). The reaction mixture was stirred under nitrogen at 
room temperature for 5 hours, filtered with suction and the solvent removed under reduced 
pressure. The product was purified by flash chromatography over silica (3: 1 ethyl acetate/ 
petroleum ether, Rf 0.3) and was isolated as a white solid (0.71 g, 75%). 
1H NMR (300 MHz, 
CDCl3): δ ppm = 7.87-7.73 (4H, m, ArH), 6.64 (1H, d, J = 9, H1), 5.95 (1 H, dd, J = 9, H3), 
5.32 (1 H, dd, J = 10, H4), 4.64 (1 H, dd, J = 9, H2), 4.43 (1 H, dd, H6b), 4.09 (1 H, dd, H6a) 
4.06 (1 H, m, H5), 2.17, 2.05, and 1.87 (9H, 3 x s, COCH3) Found m/z (ESI): 601.07 
(M+Na), C22H21C13N2O10Na
+ requires m/z 601.01.  
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2-N-Phthalimido-2-deoxy-3,4,6-tri-O-acetyl-β-D-gIucopyranosyl-(1-4)-2-acetamido-2-
deoxy-3-O-acetyl-6-O-p-methoxybenzyl-β-D-gIucopyranosyl azide [1].  
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A solution of the azide 149 (0.28 g, 0.71 mmol), trichloroacetimidate 151 (0.40 g, 0.71 mmol) 
and 3 Å molecular sieves in anhydrous DCM (10 ml) was cooled down to 0°C in an ice bath, 
under nitrogen. Borontrifluoride diethyletherate (20.0 µl, 0.18 mmol) was added. The 
reaction was stirred for 16 hours and further borontrifluoride diethyletherate (20.0 µI, 0.18 
mmol) was added. After 4 hours the reaction was diluted with DCM (50 ml) and filtered with 
suction. The filtrate was washed with sat. aq. NaHCO3 (25 ml) and water (25 ml). The 
organic phase was dried over sodium sulphate, the drying agent was filtered off and the 
solvent was removed under reduced pressure. The resulting white solid was purified by flash 
chromatography over slica (100% ethyl acetate, Rf 0.36) and the product was isolated as a 
white solid (0.16 g, 28%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 7.94-7.69 (4H, m, ArH), 
7.18 (2H, d, ArH), 6.83 (2H, d, ArH), 6.16 (1 H, d, J = 10, NH), 5.71 (1 H, dd, H3), 5.39 (1 H, 
d, J = 8, H1), 5.09 (1 H, dd, H4), 4.99 (1 H, dd. H3) 4.39-4.32 (3H, m, Hi, CH2OPMB), 4.15-
3.99 (3H, m, 3 x CH), 3,79 (3H, s, OCH3), 3.61-3.29 (4H, m, 4 x CH), 2.07, 2.02, 1.97, 1.93 
and 1.79 (H15, 5 x s, ROCH3). 
13C NMR (100 MHz, CDCl3): δ (ppm) = 171.2, 170.3, 169.9, 
169.3, 158.9 (qC x 5), 134.5 (ArCH), 1.9 (qC), 129.8 (qC), 129.3 (2 x ArCH(PMB)), 123.6 
(ArCH), 113.7 (2 x ArCH(PMB)), 97.1 (CH), 88.6 (CH), 76.6 (CH), 73.1 (CH), 72.7(CH), 72.5 
(OCH2Ar), 71.7(CH), 70.5 (CH), 68.4 (CH), 66.9 (CH2OPMB), 61.5 (CH2), 55.3 (OCH3), 54.9 
(CH), 53.4 (CH), 23.2, 20.8, 20.7, 20.6 and 20.4 (5C CH3). MS (ESI): m/z 848.70 (M+Na), 
C38H43N5O16Na
+ requires 848.76,  
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2-Acetamido-2-deoxy-3 ,4, 6-tri-O-acetyl-β-D-gIucopyranosyl-( 1→4 )-2-acetamido-2-
deoxy-3, 6-di -O-acetyl-β-D-gIucopyranosylazide [1]. 
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1)CAN, MeCN/H2O 9:1
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41 42
93 % over 3 steps
 
  
The phthalimide protected disaccharide 41 (134 mg, 0.19 mmol), was dissolved in a solution 
of (1:9 acetonitrile/water) (1 ml). Ceric ammonium nitrate (212 mg,  0.38 mmol) was added 
and the reaction mixture was stirred at room temperature for 3 hours until TLC showed that 
the reaction was complete. The mixture was diluted with DCM (25 ml) and washed with sat. 
aq. NaHCO3 (10 ml). The organic phase was dried over MgSO4 and the solvent removed 
under reduced pressure to produce a yellow gum which was purified by flash 
chromatography over silica (100% EtOAc, Rf 0.3) to afford a white foam. The white foam 
was dissolved in anhydrous NaOMe in MeOH (0.5 M, 30 µl) and the reaction was stirred for 
4 hours. The reaction was then neutralised with acetic acid (3 µl) and the solvent removed 
under reduced pressure. The residue was dissolved in ethanol (200 µl) and hydrazine 
hydrate (92 µl, 1.90 mmol) was added and the reaction monitored by TLC to completion. The 
resulting fully deprotected sugar was suspended in pyridine, acetic anhydride (2:1) total of (6 
ml) and the mixture stirred for 16 hours. The solvent was removed under reduced pressure 
and the mixture was dissolved in DCM (50 ml), washed with 2 M HCl (25 ml), saturated 
sodium bicarbonate (25 ml) and water (25 ml). The organic phase was dried over sodium 
sulphate, the drying agent was filtered off and the solvent was removed under reduced 
pressure. The resulting yellow oil was purified by flash chromatography over slica (95: 1 
ethyl acetate/MeOH, Rf 0.2) and the product was isolated as a white solid (107 mg, 93%), 
1H 
(400 MHz; CDCl3): δ (ppm) = 6.24 (1H, d, J = 9, NH), 6.49 (1H, d, J = 10, NH), 5.23-5.02 
(3H, m, 3 x CH), 460-4.55 (2H, m, 2 x CH), 4.41-4.36 (2H, m, 2 x CH), 3.86-3.84 (1H, m, 
CH), 3.75-3.64 (3H, m, 3 x CH), 2.17-1.94 (14H, m, 7 x CH3). 
13C NMR (100 MHz, CDCl3): δ 
(ppm) = 171.2, 171.0, 170.8, 170.6, 170.6, 170.5, 169.4 (7qC, COCH3), 101.3, 88.6, 75.7, 
75.0, 72.4, 72.4, 71.9, 68.0, 54.7, 53.1 (10CH, C1 -C5), 62.1, 61.7 (2CH2), 20.7 (7CH3, 
ROCH3). Found mlz (ESI): 682.58 (M+Na) C26H37N5015Na
+ requires 682.59. Ir δ max = 
2112.1 (N3). 
 
 
 
1) CAN, MeCN/H2O 9:1 
2) a e, e , 2 2 
3) Ac2 / Pyridine 
93% over 3 steps 
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Molecule 156. 
 
The His6-tag peptide 155 (16.10 mg, 0.014 mmol) was measured into a 2.5 ml Eppendoff 
tube and 50 mM NH4HCO2 (2 ml) was added. The iodoacetamide sugar 156 (7.2 mg, 0.016 
mmol) was added and the reaction mixture was shaken at 780 rpm for 2 hours. The reaction 
mixture was monitored by MS, and after 1 hour the mixture was concentrated under reduced 
pressure. The mixture was Iyophilised and placed under high vacuum for 2 days. HPLC was 
performed with (5-95%) acetonitrile/water (0.1% TFA), with C18 column (Luna 10µ C18 
100A Size: 250 x 10.00 mm, 10 micron). The sample was dissolved in 100 µl of water prior 
to injection, the product eluted at 13.10 RT at 280 nm, while the iodoacetamide sugar eluted 
at 14.64 RT. The product was lyophilised and placed under high vacuum for 1 day to a yield 
a white foam (10.8 mg, 53%). MS (ESI): m/z 1486.82 (M+H), C6,H80N24019S
+ requires 
1485.50. 
 
Benzyl azide. 
 
Cl N3
TBAHS, NaN3
DCM/NaHCO3
79%
51 52  
To a solution of benzyl chloride (1.80 ml, 15.80 mmol), TBAHS (5.36 g, 15.80 mmol) and 
sodium azide (3.08 g, 47.48 mmol) in DCM (40 ml) and NaHCO3 (40 ml) was added. The 
resulting biphasic solution was stirred vigorously at room temperature for 16 hours. Ethyl 
acetate (100 ml) was added and the organic layer was separated, washed with sat. aq. 
NaHCO3 (2 x 40 ml) and NaCI (2 x 10 ml). The organic phase was dried over MgSO4 and 
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the solvent removed under reduced pressure to produce a yellow oil that was used without 
further purification (1.65 g, 79%).1H NMR (300 MHz, CDCI3): δ ppm = 7.44 (5H, m, ArH), 
4.35 (2H, s ,CH2), Found m/z (ESI): 157.50 (M+Na). C7H7N3Na
+ requires m/z 156.48. Ir δ 
max = 2096-1 (N3).  
 
Tris((1-benzyl-1-H-1,2,3-triazol-4-yl)methyl)amine [7]. 
N3
N
N
N
N
N
N
NN
N N
N
Bn
Bn
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2-6-lutidine,
Cu(MeCN)4PF6,
MeCN
86%
52
54
53
 
 
Tripropargylamine (0.23 g, 1.67 mmol) was dissolved in acetonitrile (4 ml). Benzyl azide 
(1.00 g, 7.51 mmol), 2-6-lutidine (0.18 g, 1.68 mmol) was added together with 
Cu(MeCN)4PF6 (0.02 g). Upon addition of the salt the reaction was cooled in an ice bath. 
The brown solution was stirred for 3 days. A pale white precipitate formed which was filtered 
off and washed with cold acetonitrile. This crude product (0.7 g) was recrystalised from hot 
1:1 tert-butyl alcohol/water (30 ml). After filtration and washing with water (2 x 10 ml), the 
pale pink solid was dried under high vacuum overnight (86%). 1H NMR (300 MHz, CDCI3) δ 
ppm = 7.68 (3H, s, 3 x NCH=C), 7.36-7.27 (15h, m, 3 x Bn), 5.50 (6H, s, 3 x BnCH2N), 3.72 
(6H, s, CCH2N). MS (ESI): m/z 532.69 (M+), C30H31N10
+ requires 531.63. 
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Molecule 161.  
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In a 1.5 ml Eppendorf tube propargyl LacNAc 85 (20 mg, 0.03 mmol) and peracetylated 4-
azidomannose 128 (22 mg, 0.06 mmol) were added to a solution of 
water/methanol/phosphate buffer (50 mM)/CI3CH (1: 1: 1 :9). Sodium ascorbate (5.8 mg, 
0.03 mmol), TBTA (1 mg) and CuSO4.5H2O (1 mg) was added to the reaction mixture and 
the reaction was stirred for 5 hours at 30oC. Next the mixture was diluted with CI3CH (5 ml) 
and washed with water (2 ml). The organic phase was collected and the solvent removed 
under reduced pressure. The crude product was purified by flash chromatography over silica 
(1:1 ethyl acetate/petroleum ether, then 10% methanol) to afford the product as a white 
foam (21 mg, 67%).1H NMR (500 MHz, CDCI3): δ (ppm) =  7.73 (1H, br s, CHN), 6.18 (1H, S, 
H1"), 6.10 (1H, d, J = 8, H1'), 5.74 (1H, d, J = 10, NH), 5.34 (2H, dd, H4, H2"), 5.08 (1H, dd, 
H3"), 4.91 (5H, m, H2, H3, H3", CH2), 4.56 (1H, br s, H1), 4.49 (5H, m, H4", H3, H6a', H6a", 
H6b"), 4.05 (5H, m, H2', H6b',H6a, H6b, H5"), 3.82 (2H, m, H5, H4'), 3.82 (1H, br s, H5'), 
2.22, 2.15, 2.13, 2.13, 2.08, 2.05, 2.04, 1.99, 1.98, 1.89, 1.85 (33H, s x 11, COCH3). 
13C 
NMR (500 MHz, CDCI3): δ (ppm) = 171.0, 170.6 170.5, 170.4, 170.3, 170.3, 170.2, 169.5, 
169.5, 169.2, 168.1 (11 x RCOR), 144.8, 125.1, 101.1, 99.9, 90.7, 77.1, 75.6, 72.9, 72.5, 
70.9, 70.8, 69.1 ,68.1, 67.5, 66.7, 62.4, 62.3, 62.2, 60.8, 56.7, 53.0 (C1-C6', C1-C6, C1-C6", 
-CH2CCHN), 23.3 (NHCOCH3), 23.3 (NHCOCH3), 20.7 (6 x COCH3). MS (ESI): m/z 
1069.2939 (M+Na), C43H58NO26Na
+ requires 1069.3232. 
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Molecule 164. 
 
O
OH
OH
O
O
HO
NHAc
HOO
OH
HO
OH
O
AcHN
HO
OH
HO
O
N N
N
O
AcO
OAcAcO
OAc
O
O
AcO
NHAc
AcOO
AcO
AcO
OAc
OAc
O
N N
N
O
AcO
OAcAcO
OAc
55
58
1) NaOMe, MeOH
2) Sodium Cacodylate (0.2 M)
MnCl2 (30 mM)
Bovine Serum albumin (2 mg)
CMP-Sialic acid
-2-6-Sialyltransfersae (30 mU)
Phosphatase inhibitors.
 
 
The trisaccharide 161 (21 mg) was deprotected with (0.5 M) NaOMe in anhydrous MeOH. 
The reaction was then neutralised with acetic acid and the solvent removed under reduced 
pressure. The residue was dissolved in a total of 1 ml buffer solution at pH 7.1 containing 
sodium cacodylate (0.2 M), manganese chloride tetrahydrate (30 mM), Bovine Serum 
albumin (2 mg), phosphatase inhibitors (10 µl, Sigma Aldrich P5726), CMP-sialic acid (10 
mg), and α-2-6-sialyltransferase (30 mU). The reaction mixture was shaken for 70 hours at 
37 °C. Next the mixture was diluted with water, and ion exchange HPLC using a Sax column 
(5 µ, 100 A, 250 x 10 mm) was performed (0.6 M ammonium formate / water) gradient 10 
minutes at 10%. UV at 254nm was measured and the fractions containing the product 
(retention time 7.395 minutes) were collected and lyophilised before analysis by MS. MS 
(ESI): m/z 916.3194 (M-), (C34H54 N5024
-) requires 916.3159. 
 
6.4 Aha modified peptides and click chemistry 
 
Cys-Val-Glu-Pro-Aha-Ala-Val-Ala-Thr-Pro-ProIle-Arg-Pro-Aha-Met-Aha-Ile-Pro-Gly-Cys
N3N3 N3
Modified peptide 401-409 of ADG Modified peptide 410-420 of ADG
62
63
Gly-Gln-Aha-Glu-Thr-Ser-Gln-Thr-Ser-Ser-Pro-Ser-Gly-Cys
N3
Modifed peptide sequence of CD52
59
 
  
The modified peptides 401-409 (168), 410-420 (169) of ADG and CD52 peptide (165) were 
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165 
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synthesised on 0.01 mmol scale using the peptide synthesiser on a preloaded Fmoc-
Cys(Trt)-NovaSyn-TGT resin (Merck Biosciences). Peptide elongation employed ten 
equivalents of each amino acid, HBTU/HOBt as coupling reagents and N,N-
diisopropylethylamine as base. Fmoc-Aha-OH (Chiralix) was incorporated manually with five 
equivalents at 2 hours.  Following the synthesis a small amount of the resin was cleaved 
with trifluoroacetic acid: ethanedithiol: water (95: 2.5: 2.5 = 4.0 ml) for 5 hours. The resin 
filtered off and the filtrate poured into cold diethyl ether (20 ml), to produce a white solid. The 
ether layer was decanted and the white solid lyophilised. Mass analysis showed the correct 
mass for all three peptides. The calculated mass of peptides 168, 169 and 165 were 1110.3, 
1095.2, and 1394.4. The respective mass charge ratio values found where 1111.2, 1095.3 
and 1395.1. 
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Click chemistry was performed between the azide bearing peptides and the propargyl 
glycosides. The general conditions for click chemistry were: 1 equivalent (eq) resin bound 
peptide, 5 eq propargyl glycoside, 5 eq  sodium ascorbate,  Cu (II) SO4 (1 mg), (9:1:1) CHCl3 
EtOH: 50 mM sodium phosphate pH 7.0 in a total volume of 1.1 ml. The reactions were 
shaken overnight at 40oC and after cleavage from the resin the resulting glycopeptides were 
purified by HPLC using C18 column (100Å Size: 250 x 10.00 mm, 10 micron) (5-50% 
acetonitrile 45 minutes). The resulting glycopeptides were examined by mass analysis. The 
calculated mass of modified glycopeptides 166, 170, and 171 were 1911.07, 1779.75, and 
1495.61. The respective mass charge ratio values found were 1911.08, 1780.50, and 
1496.20 in 15-20% yield. 
Thioesterification of the modified glycopeptides 170 and 166 was performed in 2.5 ml 
Eppendoff tubes each containing (0.8 ml) 6 M guanidine hydrochloride, (0.1 ml) AcOH 10% 
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(w/v), (0.1g) MESNa 10% (w/v), (5 mg) TCEP 0.5% (w/v) at 60oC for 48 hours. After HPLC 
purification using C18 column (100Å Size: 250 x 10.00 mm, 10 micron) (5-50% acetonitrile 
45 minutes) mass analysis showed successful thioesterification of glycopeptide 166 to form 
167. The calculated mass of 167: 1801.5 m/z, mass found 1801.8 m/z. 
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6.5 Molecular biology.  
 
6.6 Instruments and general techniques. 
 
Centrifugation of small samples in Eppendorf tubes was carried out at maximum speed in an 
Eppendorf centrifuge 5410. Larger samples (up to 50 ml) were centrifuged in an Eppendorf 
5410R. Large scale (15 ml - 0.3 L) samples were centrifuged in a Beckmann Avanti J-25 
centrifuge. Sonication was performed using a Sanyo Soniprep 150 at 50% of maximum 
power. Cells were sonicated on ice for 15 periods of 30 seconds separated by 30 second 
intervals.  
Protein electrophoresis was carried out using Bio-Rad Mini-PROTEAN III vertical gel 
electrophoresis apparatus. Polyacrylamide resolving gels were run for approximately 1 hour 
at 200 V. SDS PAGE gels were stained (0.1% (w/v) Coomassie blue R-250, 40% (v/v) 
MeOH, 10% v/v AcOH) for 1 hour and destained with several washings of 40% (v/v) MeOH, 
10% (v/v) AcOH.  
Media, glassware, and equipment were sterilised by autoclaving at 121oC for 15 minutes in 
an Astell autoclave. Plates were prepared and media inoculated either on ethanol swabbed 
surfaces or in a Class II environmental cabinet. Ampicillin antibiotic stock solutions were 
stored at -20°C and were used at a concentration of 100 µg/ml. Shake flask fermentations 
were carried out in a New Brunswick Scientific INNOVA 4000 incubator shaker (37°C, 250 
rpm). Large scale fermentations (10 L) were carried out in a New Brunswick Scientific 
BioFlow 1000 fermenter at 37°C, stirred at 250 rpm with an air flow of 2 L min-1. 
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6.7 Growth Media. 
 
Luria-Bertani (L.B) medium. Per litre: Bacto Tryptone (10.5 g), Bacto yeast extract 
(5 g), NaCI (10 g). Adjust pH to 7.5 with NaOH. Autoclave.  
 
Minimal salts (M9) medium. Dissolve 5.64 g of 5 x M9 salts (Sigma-Aldrich) in 500 
ml of deionised water. Autoclave.  
 
6.8 ManT expression [10]. 
XL-1 Blue cells transformed with pManFlag20 was donated by Dr Derek Macmillan. A single 
transformed colony was used to seed 10 ml of fresh L.B medium containing ampicillin (100 
µg/ml). The culture was incubated at 37°C overnight with shaking at 250 rpm. The overnight 
culture was then centrifuged (3000 rpm, 4°C, 15 min), the supernatant was discarded, and 
the cell pellet was resuspended in 10 ml of fresh M9-CA modified medium (M9 salts with 20 
g/I casamino acids, 0.4 % glycerol, 2 mM MgSO4) containing ampicillin (100 µg/ml). This 
was cultured as above until A600=0.5, then in two large conical flasks, 5 ml of the culture was 
resuspended in 500 ml fresh M9-CA medium containing ampicillin (100 µg/ml). This was 
cultured at 37oC at 250 rpm until A600=0.5, then protein expression was induced with 5 µM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 30°C for 12 hours. Cells were harvested by 
centrifugation at 8000 rpm (10,000 x g) at 4°C for 15 minutes. The pellet could then be 
stored at – 20°C prior to purification.  
6.9 ManT purification. 
The cell pellet from 1 L culture was thawed on ice and resuspended in 20 ml of ice-cold 20 
% sucrose, 10 mM tris-HCl pH 7.6, containing 2 mM phenylmethylsulphonyl fluoride (PMSF), 
0.4 ml of 0.5 M ethylenediaminetetraacetic acid (EDTA) was slowly added. Cells were 
incubated on ice for 30 minutes, and then collected by centrifugation at 8000 rpm for 20 
minutes. The supernatant was removed and the pellet resuspended in 20 ml cold distilled 
water. The suspension was incubated for 30 minutes on ice and then centrifugation at 8000 
rpm. The supernatant was dialysed against 0.1 M ammonium formate, pH 7.5, and then 
concentrated to 1 ml using a Vivaspin centrifugal concentrator (MWCO 10 kDa).  
6.10 Western Blot Buffers. 
 
Western blot transfer buffer: 192 mM glycine, 25 mM Tis-HCl and 20% methanol in a total 
volume on 100 ml. 
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Blocking solution: 16 mM disodium hydrogen orthophosphate, 4 mM sodium di hydrogen 
orthophosphate, 100 mM NaCl, 0.1% tween.  
 
6.11 Western Blot. 
 
A membrane and filter paper was cut to the same dimensions of the SDS-PAGE. The filter 
paper, membrane and fiber pads were soaked in transfer buffer for 1 hour prior to the 
preparation of the gel sandwich. In the trans-blot assembly cell the gel sandwich was 
performed by adding the pre-wetted fiber pad onto the cassette, followed by a sheet of filter 
paper then the equilibrated gel. Next the pre-wetted membrane was placed on the gel and 
then the sandwich was completed by adding a piece of filter paper on the membrane 
followed by the last fiber pad. The cassette was carefully closed, making sure that the gel, 
filter paper sandwich was undisturbed and placed into the cassette tank. The tank was filled 
with transfer buffer and the transfer blot was run. 
 
6.12 Preparation of a cell-free extract of His10-GDPMP (CFE) [10]. 
 
His10-GDPMP protein expression pellet was donated by Dr Derek Macmillan. 
A pellet derived from a 1 L induced culture was thawed on ice and resuspended in 35 ml 
binding buffer (5 mM imidazole, 500 mM NaCI, 20 mM Tris-HCI, pH 8) containing 10 mM 
PMSF. The cells were sonicated on ice for 15 periods of 30 seconds separated by 30 
seconds intervals. Triton X-100 was added to a final concentration of 0.1% (v/v) and the 
resulting solution was rocked on ice for 10 minutes. The cells were then sonicated again on 
ice for 15 periods of 30 seconds separated by 30 second intervals. Inclusion bodies and 
cellular debris were collected by centrifugation at 10,000 rpm for 15 minutes at 4°C. The 
resulting pellet was discarded and the CFE was stored at -20°C prior to affinity 
chromatography.  
 
6.13 Affinity chromatography of His10-GDPMP. 
 
His10-GDPMP was purified from the CFE under non-denaturing conditions using Ni
2+ 
immobilised on metal chelation resin as described in the manufacturer's instructions (Sigma-
Aldrich). The column (2.5 ml bed volume) was charged with 7 ml aqueous NiSO4 and 
equilibrated with 12.5 ml binding buffer. Extracts were applied to the column and allowed to 
drain by gravity flow. Unbound proteins were washed with binding buffer containing 1 mM 
PMSF, and then wash buffer (50 mM imidazole, 500 mM NaCI, 20 mM Tris-HCI, 1 mM 
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PMSF, pH 7.8) until A280 < 0.1. The target protein was then eluted in 1.5 ml fractions using 
eluting buffer (500 mM imidazole, 500 mM NaCI, 20 mM Tris-HCI, pH 7) until A280 < 0.1. The 
fractions were then analysed by SDS PAGE. The fractions containing the desired protein 
were combined, exchanged 3 times against fresh buffer (50 mM Tris pH 7.6), and 
concentrated to a final volume of 1 ml using a Vivaspin (MWCO 30 kDa) concentrator, which 
was previously passivated with 5% Tween 20 according to the manufacturer‟s instructions.  
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